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Apoptosis is a physiological form of cell death. It is a 
highly evolutionarily conserved process that is non-
inflammatory or anti-inflammatory in nature. This anti-
inflammatory nature of apoptosis is evident by the fact 
that neutrophils are histologically absent from sites 
where homeostatic apoptosis rates are high. The rapid 
phagocytosis of apoptotic cells as a means to prevent the 
release of noxious inflammatory compounds also accounts 
for the anti-inflammatory environment of such sites. 
However, the mechanisms that enable mononuclear phagocytes 
to migrate to sites where homeostatic apoptosis rates are 
high, and not granulocytes, the professional phagocytes 
that accumulate at sites of inflammation, have not been 
determined yet. Using Burkitt’s lymphoma (BL) as a model 
of apoptosis, the aim of this thesis was to identify the 
regulatory mechanisms or factors underlying the non-
phlogistic features of sites where homeostatic apoptosis 
rates are high and in particular, those preventing the 
recruitment of neutrophils -a major granulocyte subclass- 
to these sites. 
BL is a highly aggressive B cell lymphoma that is mainly 
characterised by a high rate of apoptosis. By carrying out 
a series of in vitro chemotaxis assays and biochemical 
approaches, it was found in this thesis that BL cells 
actively inhibit neutrophil migration by releasing factors 
that were identified to be lactoferrin, a 80 kDa iron-
binding glycoprotein with anti-bacterial and anti-
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inflammatory properties. It was further demonstrated that 
lactoferrin selectively inhibited migration of 
granulocytes (both neutrophils and eosinophils) but not 
mononuclear phagocytes and this effect was irrespective of 
its iron saturation status and the chemoattractant used. 
Also, lactoferrin potently inhibited neutrophil migration, 
as assessed by thioglycollate-induced in vivo model of 
mouse peritonitis. This anti-inflammatory function of 
lactoferrin was attributed to its effect on granulocyte 
signalling pathways that regulate cell adhesion and 
motility. Finally, it was demonstrated that in cell types 
of diverse lineages, induction of apoptosis results in de 
novo synthesis and secretion of lactoferrin. In subsequent 
proliferation assays determining the in vitro growth of a 
number of BL cell types, it was demonstrated that 
lactoferrin is an essential component of BL cells and 
promotes their proliferation, as its antibody-mediated 
neutralisation or shRNA-mediated expression knockdown, 
reduced BL cell growth. 
Together, the results of this thesis identified 
lactoferrin as one of the few characterised anti-
inflammatory components of the apoptosis milieu that 
negatively regulate granulocyte migration. This effect may 
provide opportunities for broad therapeutic interventions 
concerning the use of lactoferrin in chronic inflammatory 
conditions characterised by aberrant neutrophil influx as 
well as atopic allergic disorders, such as asthma. 
Moreover, based on the tumour-supporting role of 
lactoferrin described in this study, targeting its 
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expression in tumours could lead to tumour regression and 






Apoptosis is the most renowned physiological process of 
cell death. It is a tightly regulated and evolutionarily 
conserved process that was first described in 1972 by 
Kerr, Wyllie and Currie (Kerr et al., 1972). Its term 
derives from the Greek words α•ό (from) and •τώσις (fall). 
Apoptosis is an active process that is expressed by 
profound alterations in the genetic component of the cell 
that lead to self-destruction. The importance of apoptosis 
is fundamental: firstly, it acts as a homeostatic 
mechanism to regulate the cell number in all tissues in a 
living organism (Majno and Joris, 1995). Secondly, it is 
implicated in organ and digit ontogenesis during embryonic 
development and later on in life in situations, such as 
the fashioning of the limbs, the involution of 
phylogenetic vestiges and the formation of interdigital 
clefts. In fact, the regression of ductus arteriosus after 
birth was the first typical apoptotic phenomenon described 
by Aristotle. Thirdly, apoptosis is involved in hormone-
dependent atrophy, as first described by Wyllie in rats, 
during which a massive number of apoptotic cells appeared 
in the adrenal cortex following a reduction in 
adrenocorticotrophic hormone (ACTH) blood concentration 
(Kerr et al., 1972). Apoptosis also plays a major role in 
cell turnover, as evidenced by the editing of exons and 
dendrites during brain development (low turnover rate), 
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the disposal of the outer segments in the eye retina, the 
disposal of circulating granulocytes (high turnover) as 
well as of gut epithelia (intermediate tissue turnover 
rate).  
In pathological situations, apoptosis is implicated in 
many conditions, including stroke, myopathies, 
neurodegenerative conditions and malignant neoplasms. In 
the latter case, apoptosis is going on continuously in 
growing neoplasms and is affected or even exacerbated by 
therapeutic conditions engendered by chemotherapeutic 
agents, hypoxia and ionising radiation (Kerr et al., 1994; 
Kerr et al., 1972; Thompson, 1995). Of pivotal importance 
is also the role of apoptosis in immunity (Ekert and Vaux, 
1997; Marsden and Strasser, 2003). The poorly understood 
apoptotic process in the germinal centres of lymphoid 
follicles has given rise to the notion that apoptosis is 
necessary for the proper functioning of the immune system. 
Indeed, apoptosis is necessary for the development of T 
and B lymphocytes, as cells not positively selected 
following V(D)J recombination (for B cells) or MHC 
recognition (for T cells) die by apoptosis. Apoptosis 
eliminates the self-reactive population by clonal deletion 
and this is particularly important to prevent autoimmune 
conditions. Also, cytotoxic T cell killing is mediated by 
an active apoptotic process. In this way, defects in the 
apoptosis program or inappropriate activation of apoptotic 
cell-death pathways could lead to autoimmune situations, 




As a process, apoptosis is discerned into three phases: 
induction/initiation phase, effector phase and 
degradation. In the initiation phase, the cell receives 
the apoptosis-inducing stimuli, during the effector phase 
the apoptotic machinery is activated, while during the 
last (degradation) phase, the cell enters a non-reversible 
route of disintegration and any associated changes in cell 
morphology become visible (Leist and Nicotera, 1997; Majno 
and Joris, 1995; Susin et al., 1997; Yang and Korsmeyer, 
1996). The duration of the apoptotic process is estimated 
between 12 and 24 hours. However, it is highly dependant 
on the apoptotic stimulus and the affected cell type in 
every tissue. 
Morphological Detection of Apoptosis 
The first morphological description of apoptosis was 
described by Flemming in 1885 as cells with “ill-defined 
nucleus containing several small, heavily stained lumps 
and a pale, homogeneous cytoplasm containing what appeared 
to be fine fat droplets ”  (Flemming, 1885). This 
description came in accordance to what Kerr, Wyllie and 
Currie later described as apoptotic bodies, i.e. “small, 
roughly spherical or ovoid cytoplasmic fragments some of 
which contain pyknotic remnants of nuclei ” (Kerr et al., 
1972). They proceeded further to divide apoptosis into two 
separate processes: (i) the formation of apoptotic bodies 
followed by (ii) their phagocytosis by other cells.  
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Subsequent electron microscopy analyses revealed that the 
morphological transformation of cells undergoing apoptosis 
involves the condensation of chromatin to delineated 
granular masses beneath the nuclear envelope, cell 
shrinking, convolution of the cellular outlines and 
finally nuclear fragmentation (Kerr et al., 1994; Majno 
and Joris, 1995; Yang and Korsmeyer, 1996). The formed 
apoptotic bodies containing the nuclear remnants are 
rapidly removed by neighbouring macrophages. What is 
surprising is that during this process, the cell membrane 
that encases the apoptotic fragments remains intact 
retaining its integrity. Also, the lysosomes remain 
unaffected and their enzymes are not released to the 
surrounding tissue, enhancing in this way the role of 
apoptosis in tissue homeostasis, as it involves extensive 
cell deletion with restricted tissue disruption. Moreover, 
there is no inflammation and thus apoptotic cells could be 
described as cellular graves, in which nuclear remnants 
are disposed of in a non-inflammatory manner. Also, as it 
has been described since 1972, “ the process is economical 
in terms of re-utilisation of cell components ”.  
Despite the extensive involvement of apoptosis in both 
normal and malignant tissues, the rate of apoptosis varies 
depending on cell type (Kerr et al., 1972). To determine 
apoptosis rate in a tissue section, traditional techniques 
are employed that are based on the characteristic 
morphological features of apoptotic cells. However, more 
refined techniques have been undertaken for tissue studies 
and involve the radioactive or non-radioactive labelling 
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of free ends of DNA (in situ 3’-end labelling method) or 
the TUNEL (terminal deoxytransferase-mediated dUTP nick-
end labelling) in which terminal transferase adds labeled 
nucleotides into the 3’ end of DNA (Ansari et al., 1993; 
Wijsman et al., 1993). Also, other recent techniques 
include the immunohistochemical detection of apoptosis-
associated proteins, such as active caspase-3 in tissue 
sections. However, these techniques bear some limitations 
varying among research groups. This point is particularly 
important in the measurement of apoptotic index point to 
tumour tissues as the presence of resident apoptotic 
immune cells (e.g. macrophages, lymphocytes) might be 




Much of our knowledge about the molecular mechanisms of 
apoptosis arises from the nematode Caenorhabditis elegans 
(Hengartner and Horvitz, 1994; Leist and Nicotera, 1997). 
In this nematode, 131 somatic cells die through apoptosis 
out of the 1090 somatic cells that are formed during adult 
development. The 11 identified C.elegans genes that are 
involved in the cell death process include CED3 and CED4 
that positively regulate apoptosis, whereas CED9 is anti-
apoptotic. As apoptosis is a highly conserved process, 
these C.elegans genes have homologous partners in mammals. 
The C.elegans CED9 is highly homologous to the mammalian 
anti-apoptotic oncogene BCL2, as BCL2 can partially 
substitute for CED9 in C.elegans to prevent apoptosis, 
whereas CED3 is homologous to cysteine proteases caspases 
and CED4 has high homology to apoptosis activating factor-
1 (Apaf-1), which is involved in cytochrome c dependent 
activation of caspase-3. Genetic studies indicate that 
CED4 acts upstream of CED3 and downstream of CED9 
(Hengartner and Horvitz, 1994). 
Based on C.elegans, we now come to our current knowledge 
of apoptosis in mammals. Indeed, the apoptotic machinery 
can be activated by many different stimuli. Such stimuli 
involve DNA damage or radiation, serum withdrawal, TNF-α, 
1,25-dihydroxyvitamin D3 (Haimovitz-Friedman et al., 1994; 
Hannun, 1996) as well as the withdrawal of a growth factor 
or hormone, as for example, in the case of the withdrawal 
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of a nerve growth factor from neuronal cells pathways, in 
which a p38 mitogen-activated protein kinase pathway was 
activated to induce apoptosis (Kummer et al., 1997). 
Apoptosis can even be initiated by changes in the cellular 
membrane that result to the formation of cell surface 
receptors, known as death receptors, which trigger 
apoptotic pathways. In this way, there are two main routes 
that have been described to induce apoptosis: the 
intrinsic pathway (mitochondrial-mediated apoptosis) and 
the extrinsic pathway that involves the activation of 
death receptors (Figure 1). Both pathways result in the 
activation of caspases; however, other caspase-independent 
types of apoptosis have been noted (Green and Kroemer, 
2004; Wolf and Green, 1999). 
The role of caspases 
The family of caspases involves at least 14 aspartate-
specific cysteine proteases that play a key effector role 
in the apoptotic process (Barge et al., 1997; Harvey et 
al., 1997). They normally exist in cells as inactive 
proenzymes, which are proteolytically cleaved into 10 and 
20 kDa subunits that constitute the active enzyme by 
heterodimerisation and association into tetramers. Each 
active caspase tetramer includes two heterodimers of a 
large and a small subunit. Caspase activation follows a 
distinct mode, in which caspases-2, -8, -9 and -10 
(initiator caspases) trigger the apoptotic cascade and 
activate caspases -3, -6 and -7 (effector caspases) 
(Philchenkov, 2004; Wolf and Green, 1999).  
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The activity of caspases is responsible for the 
morphological changes that take place during apoptosis, as 
they act by disrupting the nuclear membrane, cleave 
cytoskeletal proteins, disrupt cell-cell contact and 
induce DNA fragmentation (Brancolini et al., 1997). 
Indeed, caspases cleave cytoskeletal proteins such as 
actin, fodrin, gelsolin as well as nuclear lamins and DNA 
repair enzymes such as poly-ADP-ribose-polymerase (PARP) 
(Kothakota et al., 1997; Lazebnik et al., 1994; Lazebnik 
et al., 1995). The activity of caspases is also linked to 
the activation of caspase-activated DNase (CAD) that 
triggers DNA fragmentation. Under normal conditions, the 
activity of CAD is inhibited by forming a complex with the 
Inhibitor of CAD (ICAD), which is cleaved by caspase-3 
upon induction of apoptosis (Sakahira et al., 1998). Other 
regulators of caspase activity involve the members of the 
Inhibitor of Apoptosis Protein (IAP) family, which include 
Apollon/BRUCE, c-IAP1, c-IAP2, Livin, Survivin, NAIP, ILP-
2 and XIAP (X-linked IAP (Liston et al., 2003).  
Mitochondrial‐mediated apoptosis 
Mitochondrial-mediated apoptosis is elicited by the 
permeabilisation of the outer membrane of the 
mitochondrion and the subsequent formation of a 
permeability transition (PT) pore (Green and Kroemer, 
2004; Hotchkiss et al., 2009). The opening of the PT pore 
induces uncoupling of the oxidative phosphorylation 
process and entry of water to the mitochondrial matrix. 
This results in a consequent swelling of the mitochondrial 
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space and rupture of the outer mitochondrial membrane that 
is followed by the release of apoptosis-inducing proteins, 
such as apoptosis-inducing factor (AIF), cytochrome c and 
endonuclease G (Churbanova and Sevrioukova, 2008; van Loo 
et al., 2001). 
Cytochrome c binds to apoptosis protease activating 
factor-1 (Apaf-1), forming an “apoptosome ” that in turn 
activates pro-caspase-9 that further activates pro-
caspase-3. Apoptosis-inhibiting proteins like Bcl-2 and 
Bcl-xL counteract this apoptosis-inducing effect by 
binding to Apaf-1 (Zou et al., 1997; Zou et al., 1999). 
AIF is released from mitochondria into the cytoplasm and 
in combination with one or more factors, such as 
cyclophilin A, translocates to the nucleus. In the 
nucleus, AIF induces DNA fragmentation and chromatin 
condensation, as part of an endonuclease complex (Seiler 
et al., 2008; Susin et al., 1999; Wang et al., 2002; Ye et 
al., 2002). It should be noted that if the soluble 57 kDa 
fragment of AIF does not enter the nucleus, then apoptosis 
cannot be induced (Norberg et al., 2010; Zhu et al., 
2007). Other apoptosis-inducing proteins that are released 
upon mitochondrial permeabilisation involve Omi/HtrA2 
(high temperature requirement A2) and Smac/DIABLO (second 
mitochondria-derived activator of caspases/direct IAP-
associated binding protein with low pI) that promote 
caspase activation by acting as IAP antagonists (Du et 
al., 2000; Suzuki et al., 2001).  
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Mitochondrial-mediated apoptosis is also induced following 
p53 activation by pro-apoptotic stimuli. Normally, the 
transcriptional activity of p53 is inhibited by human 
double minute-2 (HDM-2); however, once p53 becomes 
activated, its interaction with HDM-2 becomes disrupted 
and the activated p53 induces the expression of Apaf-1 and 
Bcl-2 family members (Brooks and Gu, 2003; Hofseth et al., 
2004). Moreover, it has been recently described that p53, 
bcl-2 family proteins and reactive oxygen species are all 
factors contributing to the permeabilisation of the 
lysosomal membrane. In fact, lysosomal membrane 
permeabilisation occurs following apoptosis induction; 
however, depending on the type of inducing agent, 
permeabilisation of the lysosomal membrane can stimulate 
the release of cathepsin early in apoptosis or can occur 
late in apoptosis, amplifying in this way the death signal 
(Johansson et al., 2010).  
The Bcl‐2 family 
Another group of proteins that play a key role during 
mitochondrial-mediated apoptosis is the Bcl-2 family of 
proteins; however, its activity is independent of the 
formation of the PT pore (Green and Kroemer, 2004; Reed, 
1994). Members of the Bcl-2 family of proteins include 
both death-promoting proteins (Bax, Bak, Bad, Bid, 
Bik/nbk, Bcl-XS, Bim/bod, Blk and Hrk/dp5) and death-
inhibiting ones (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, Bfl-1, Brag-
1, A1, Boo) (Cheung et al., 2005; Hockenbery, 1994; Reed, 
1994). They act upstream of caspases and their activity is 
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competitive. For example, in apoptotic conditions, there 
is an excess of Bax and thus, Bax homodimers that allow 
apoptosis to take place are formed. By contrast, in an 
excess of an anti-apoptotic molecule, like Bcl-2, there 
are Bax/Bcl-2 heterodimers formed to lead to an inhibition 
of apoptosis. Moreover, there could be heterodimers formed 
between two apoptosis-inhibitory proteins, e.g. Bcl-2/Bcl-
xL that allow the release of an apoptotic protein, e.g. 
Bad, something that would trigger apoptosis (Kroemer, 
1997). For apoptosis induction, the apoptosis-promoting 
proteins (Bax, Bad etc) act by forming pores and 
functioning as ion channels in mitochondrial membranes 
that form calcium fluxes and by stimulating the release of 
the above mentioned apoptosis-promoting agents. 
The role of Bcl-2. Bcl-2 is best known as an anti-
apoptotic protein. Some characteristic examples involve 
its activity in inhibiting the glucorticoid-mediated 
apoptosis in lymphoid cells as well as oestrogen-
stimulated apoptosis in breast cancer cells (Almawi et 
al., 2004; Huang and Cidlowski, 2002; Song et al., 2005). 
However, its activity is also linked to its oncogenic 
role, especially in the context of haematopoietic and 
lymphoid malignancies (Vaux et al., 1988).  
Indeed, the oncogenic activity of Bcl-2 accounts back in 
1985, when the cloning of the breakpoint of t(14;18) 
chromosomal translocations in non-Hodgkin’s lymphomas 
resulted to the identification of a juxtaposed BCL2 gene 
under the control of the IgH enhancer. That position of 
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the BCL2 gene accounted for its dysregulated expression 
(Bakhshi et al., 1985; Tsujimoto et al., 1985). A year 
later, in 1986, the identification of the amino acid 
sequence of Bcl-2 and its high homology to Epstein Barr 
Virus (EBV) and several other Herpes-family viruses 
provided a first clue to the possible oncogenic properties 
of Bcl-2 (Cleary et al., 1986). This was supported by 
subsequent observations that BCL2 gene rearrangements were 
linked to poor prognosis in large-cell non-Hodgkin’s 
lymphoma (Armitage et al., 1988; Yunis et al., 1989). The 
involvement of Bcl-2 in oncogenesis was confirmed in 1992, 
when the BCL2 gene was found to be hypomethylated in the 
majority of chronic lymphocytic leukemias (CLLs) (Jonveaux 
et al., 1992; Tanaka et al., 1992). Also, BCL2 gene 
amplification was noted in non-Hodgkin’s lymphomas 
(Wessendorf et al., 2003). Importantly, it was until 
recently, in 2005, when it was revealed that specific 
endogenous microRNAs account for the suppression of BCL2 
gene expression in normal B cells and deletions or 
mutations in these microRNAs account for the majority of 
CLLs (Cimmino et al., 2005). In summary, it is evident 
that apart from its anti-apoptotic role, Bcl-2 has also an 
oncogenic potential, linking in this way, apoptosis and 
malignancy (Vaux et al., 1988).  
Death receptor mediated‐apoptosis 
Death receptor mediated-apoptosis involves the activity of 
cell surface receptors that induce apoptosis upon ligand 
binding (Ashkenazi and Dixit, 1998; Hotchkiss et al., 
20 
 
2009). Such receptors, that are all members of the TNF 
superfamily, include Fas (CD95; Apo1), TNFR1 (p55; CD120), 
TRAMP (DR3; Apo3; WSL-1; LARD), TRAIL-R1 (DR4), TRAIL-R2 
(DR5, Apo2, TRICK2, KILLER) and others. Their ligands 
involve FasL (for Fas), TNF and lymphotoxin α (for TNFR1), 
Apo3L (for TRAMP) and Apo2L for TRAILR1 and TRAILR2 
(Bodmer et al., 1997; Dhein et al., 1995; MacFarlane et 
al., 1997).  
Upon ligand binding, the intracellular death domain of 
each receptor interacts via the TNFR-associated death 
domain (TRADD) to the Fas-associated death domain (FADD). 
FADD then forms the death-inducing signalling complex 
(DISC) by interacting with procaspase-8. Caspase-8 becomes 
activated, which in turn induces the activation of other 
effector caspases (Ashkenazi and Dixit, 1998; Pan et al., 
1997; Tartaglia et al., 1993; Thorburn, 2004).  
The apoptosis-promoting activity of death receptors is 
regulated by the family of decoy receptors (DCR), which 
involves DCR1, DCR2, DCR3 and osteoprotegerin, which 
interact with TRAIL and FasL to inhibit their activity. 
Cellular FLICE-like inhibitory protein (c-FLIP) is also an 
antagonist of apoptosis due to its interaction with FADD 
(Ashkenazi and Dixit, 1998; Irmler et al., 1997).  
In summary, the apoptotic programme can be either 
mitochondrial- or death receptor-mediated and caspase-
dependent or independent. The role of the members of the 
Bcl-2 family in the apoptotic process should be emphasised 
as they were demonstrated to actively regulate induction 
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of apoptosis. In particular, Bcl-2 acts by both 
suppressing apoptosis and by exerting an oncogenic effect, 
as mutations in the BCL2 gene can result in lymphoma and 







Apoptosis is triggered via two major pathways: An 
intrinsic (mitochondrial-mediated) pathway that is 
controlled by bcl-2 family of proteins and an extrinsic 
(death-receptor-mediated) pathway. Both pathways result to 
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the cleavage and activation of pro-caspase 3 to an active 
caspase 3 that induces apoptosis.  
The Immunosuppressive Nature of Apoptosis 
Apoptosis is an anti-inflammatory form of cell death. 
Apart from histological evidence that neutrophils are 
absent from sites where homeostatic apoptosis rates are 
high, the anti-inflammatory nature of apoptosis is mostly 
due to the rapid phagocytosis of apoptotic cells to 
prevent the release of noxious inflammatory compounds and 
due to subsequent alterations in the type of cytokines 
(from proinflammatory to anti-inflammatory) secreted from 
resident immune cells (Savill et al., 1993; Vaux, 1993). 
Indeed, failed or delayed clearance of apoptotic cells can 
have detrimental inflammatory consequences including the 
development of autoimmune pathologies.  
The immunosuppressive environment of the sites where 
homeostatic apoptosis rates are high is greatly influenced 
by signals that attract monocytes to such sites in order 
to promote phagocytosis. These chemoattraction signals 
play a major role in the initiation of the resolution 
phase of inflammation and most of them were found to be 
released from late or post-apoptotic cells. These include 
lysophosphatidylcholine (LPC), platelet activating factor 
(PAF), monocyte chemotactic protein-1 (MCP-1), complement 
C1q, fractalkine and microparticles, which are membrane 
vesicles with high levels of oxidised lipids that act as a 
rich source of chemoattractants (Kadl et al., 2004; Lauber 
24 
 
et al., 2003; Martinez et al., 2005; Nagaosa et al., 2003; 
Riches et al., 1990). Also, the anti-inflammatory 
environment of the sites where homeostatic apoptosis rates 
are high can be greatly influenced by released anti-
inflammatory cytokines, such as IL-10 (Poon et al., 2010; 
Voll et al., 1997). 
This anti-inflammatory response arises independently of 
the apoptosis stimulus, as evidenced by apoptosis 
induction following bacterial LPS, ultraviolet light, γ-
rays or deprivation of a growth factor. In all cases, it 
results in diminished IFN-γ levels and reduced inflammation 
(Mosmann, 1994; Paul and Seder, 1994). However, 
experimentally, changes in the incubation time of 
monocytes along with apoptotic cells have been shown to 
result in changes in the secreted cytokine expression 
pattern. Moreover, repeated exposure to the apoptotic 
material during tumourigenesis or viral infection results 
in impairments in the elicited immune responses, proving 
in this way that apoptosis is a tightly-regulated 
mechanism in terms of the molecules involved and of the 
association times (Hanayama et al., 2004; Kang et al., 
1994; Meunier et al., 1995). Moreover, heat-shock proteins 
are stress-inducing proteins, which although have been 
described to maintain thermotolerance, can induce 
apoptosis in severe stress conditions. In parallel, their 
role is immunomodulatory, as their expression induces the 
synthesis and release of various pro-inflammatory 
cytokines (Yokota and Fujii, 2010). 
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In general terms, all the above-mentioned mechanisms 
constitute an integral homeostatic process for the anti-
inflammatory resolution of an apoptotic event. This anti-
inflammatory response distinguishes apoptosis from 
necrosis. Necrosis has been described as a vaguely 
regulated, passive form of cell death (Kerr et al., 1994; 
Majno and Joris, 1995). It is a type of cell death that is 
dictated by external injurious agents and not arising as 
part of a physiological cellular response. Indeed, there 
are many differences between apoptosis and necrosis that 
highlight the perfection in terms of the control of cell 
death that is observed in apoptotic tissues. Unlike 
apoptosis, necrosis is an inflammatory form of cell death 
that comprises large groups of cells in the same area, 
while apoptotic cells can be very few and scattered in a 
tissue (Leist et al., 1997). In necrosis, there is a 
release of lysosomal compartments, which triggers an 
inflammatory response, whereas in apoptosis, lysosomes 
remain intact. In terms of cell morphology, no apoptotic 
bodies are formed in necrosis and chromatin is irregular 
and unevenly distributed as clumps with no nuclear 
fragmentation and cell shrinking.  
Although these two forms of cell death are very distinct 
from each other, they do share some similarities: (a) many 
stimuli e.g. radiation, hypoxia, heat shock, viruses can 
cause both apoptosis and necrosis, (b) other external 
stimuli exist that could induce apoptosis at low doses, 
but could also trigger necrosis at high levels, (c) at a 
tissue level, in both normal and tumour tissues, a zone of 
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apoptotic cells may be surrounded by necrotic areas and 
(d) both apoptosis and necrosis can share a common 
apoptosis signalling machinery, especially caspases-8 and 
-10 that elicit apoptosis and Bcl-2 that has anti-
apoptotic activity (Hirsch et al., 1997; Leist and 
Nicotera, 1997). Another similarity (e) is the exposure of 
phosphatidylserine (PS) by both apoptotic and necrotic 
cells. However, there are differences in the oxidation 
status and physical nature of PS, as in apoptotic cells it 
occurs as patches. Indeed, it has been shown that specific 
oxidation of PS determines the recognition and engulfment 
of apoptotic cells (Jiang et al., 2004; Tyurina et al., 
2004). Moreover, a recent study by Chen et al., (2010b) 
has described that Nix/BNip3L protein that resides at the 
outer mitochondrial membrane and endoplasmic reticulum can 
induce either apoptotic or necrotic cell death via 
distinct signalling pathways, i.e. a classical Bax/Bak 
permeabilisation of outer mitochondrial membrane and 
mitochondrial-mediated apoptosis or via a cyclophilin D-
dependent opening of mitochondrial permeability transition 
pore that induces necrosis. 
Apoptotic cell recognition 
The existing mechanism that allows the recognition of 
apoptotic cells by professional phagocytes is expressed in 
the form of surface molecules on apoptotic cells, also 
known as “eat-me”  signals (Ravichandran and Lorenz, 2007) 
(Figure 2) (Table 1). These signals are evolutionarily 
conserved and arise as alterations in the surface of 
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affected cells. One of the earliest signals that enable 
the apoptotic cell recognition and phagocytosis by 
macrophages involves the externalisation of 
phosphatidylserine (PS) (Botto, 2004; Fadok et al., 1998a; 
Fadok et al., 1992; Henson, 2005). PS is usually retained 
in the inner plasma membrane, but during apoptosis it 
becomes exposed either due to the changes in cell symmetry 
or due to PS oxidation. Other phospholipids such as 
lysophosphatidylcholine (LPC) are also exposed. Moreover, 
during cell death, cellular DNA becomes exposed and 
functions as recognition signal (Palaniyar et al., 2004).  
Although the presence of a PS receptor is still debatable, 
recent studies have identified TIM-4, stabilin-2 and BAI-1 
as receptors specific for PS (Table 2) (Miyanishi et al., 
2007; Park et al., 2007; Park et al., 2008). These 
receptors are widely expressed by professional phagocytes, 
mainly macrophages and dendritic cells and mediate 
apoptotic cell engulfment via direct interactions with the 
exposed PS on the apoptotic cell surface. Special emphasis 
should also be given on the role of TIM family of genes 
that form a repertoire for the recognition of apoptotic 
cells, regulating in parallel immune responses. Its 
members TIM-1, TIM-3 and TIM-4 all display a specific 
recognition for PS, but differ in expression among cell 
types. This forms a control mechanism, which depending on 
the type of TIM molecule engaged, determines whether 
apoptotic cell recognition can result in immune activation 
or tolerance (Freeman et al., 2010). 
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Apart from all these receptors, there are also other 
molecules described to bind apoptotic cells mediating 
their clearance by phagocytes. One of the most commonly 
known is thrombospondin (Savill et al., 2002; Savill et 
al., 1990; Savill et al., 1992). Thrombospondin acts as a 
bridge molecule between apoptotic cells and CD36 and 
vitronectin receptor (αvβ3) on phagocytes. The use of 
antibodies against thrombospondin blocks apoptotic cell 
engulfment, highlighting, thereby the importance of this 
molecule in apoptotic cell recognition. Additional soluble 
proteins have been described to form molecular bridges 
between apoptotic cells and phagocytes by binding to the 
exposed PS on apoptotic cells. These include MFG-E8 (milk 
fat globule EGF-factor 8), Gas-6, protein S that is a 
homolog of Gas-6, annexin-1 and β2-glycoprotein I (β2-GPI) 
(Akakura et al., 2004; Anderson et al., 2003; Arur et al., 
2003; Balasubramanian et al., 1997; Ishimoto et al., 
2000); Hall et al., 2005; Hanayama et al., 2004; Nakano et 
al., 1997; (Borisenko et al., 2004; Greenberg et al., 
2006; Jiang et al., 2004). In addition to these molecules, 
a number of serum-derived proteins have been reported to 
bind apoptotic cells aiding their uptake by macrophages. 
These comprise serum amyloid protein (SAP), pentraxin-3 
and CRP (Gershov et al., 2000; Mold et al., 2002; Rovere 
et al., 2000).  
Apart from the exposed PS on apoptotic cell surface, other 
opsonisation molecules include lectins, such as mannan-
binding lectin (MBL) and proteins of the collectin family 
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(Kilpatrick, 2002; Lu et al., 2002; Vandivier et al., 
2002). Also, complement proteins such as C1q and C3b that 
bind to apoptotic cell surfaces allow the recognition by 
complement receptors such as CD35 (CR1), CD11b/CD18 (CR3) 
and CD11c/CD18 (CR4) on macrophages (Mevorach et al., 
1998; Nauta et al., 2002). Moreover, C1q was demonstrated 
to directly interact with PS in newly organised membrane 
patches particularly at the early stages of apoptosis 
(Paidassi et al., 2008). Also, C1q interacts via the 
CD91/calreticulin complex with calreticulin, an ER protein 
with chaperone and calcium storage activities that is 
upregulated during apoptosis (Botto et al., 1998; Henson 
and Hume, 2006).  
All these signals, also known as “eat-me signals” , are 
evolutionarily conserved and arise as alterations in the 
surface of affected cells. Other recently identified 
signals released by apoptotic cells to promote their 
clearance are the nucleotides ATP and UTP. Elliott et al. 
(2009) have demonstrated that these nucleotides are 
released by apoptotic cells and induce the directional 
migration of monocytes and macrophages. This is achieved 
via the P2Y2 receptor on the surface of monocytes and 
macrophages, as evidenced by experiments on P2Y2-deficient 
mice that have demonstrated an inefficient engulfment of 
apoptotic cells in the thymus (Elliott et al., 2009; 
Gregory, 2009). Despite the presence of these anti-
inflammatory ligand molecules, the presence of direct 
inhibitory molecules in the recognition and engulfment of 
apoptotic cells provides another clue for the regulation 
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of this anti-inflammatory mechanism. Such “don’t eat me ”  
signals involve CD31 that forms homotypic interactions to 
the CD31 on phagocytes to induce cell detachment and thus 
prevent engulfment (Brown et al., 2002). In addition, 
interactions of CD47 (integrin-associated protein) with 
signal regulatory protein (SIRP) have been previously 
shown to prevent cell uptake by phagocytes (Gardai et al., 
2005; Oldenborg et al., 2000).  
In summary, the apoptotic process is a tightly regulated 
process in order to preserve the non-inflammatory mode of 
cell clearance. For this reason, several “eat-me”  signals 
exist to stimulate monocytes or macrophages to arrive at 
the site of apoptosis and engulf apoptotic cells. Such 
signals can be in the form of soluble factors or specific 
receptors on the apoptotic cell surface. In this way, the 
physiological process of apoptosis, unlike necrosis, 
inhibits any host immune responses by creating an anti-
inflammatory environment. Failure to do so can result to 
autoimmunity and inflammatory conditions. Therefore, 
targeting factors that regulate the apoptotic process 
could be therapeutically beneficial in promoting the 
clearance of apoptotic cells in inflammatory conditions or 
in triggering an immune response when required, as for 







Recognition of “ eat-me ” signals on apoptotic cell surface 
to allow efficient phagocytosis by macrophages and other 
phagocytes. Exposed PS on apoptotic cell surface is one of 
the earliest signals that enable apoptotic cell 
recognition. Exposed PS is recognized by TIM-4, stabilin-
2, BAI-1 that are specific receptors on phagocytes. Other 
proteins that act as ligands for PS are thrombospondin, 
MFG-E8, Gas-6, annexin-1 and β2-GPI. Apart from PS, other 
phospholipids, cellular DNA and calreticulin become 
exposed and function as recognition signals, whereas other 
molecules that opsonise apoptotic cells to enable their 
recognition involve lectins, proteins of the collectin 
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Apoptosis is a major determinant in tumour growth. At its 
early stages, apoptosis limits the expansion of the tumour 
cells; however, at the later stages apoptosis rates are 
relevant to tumour growth. In reality, what determines the 
rate of tumour enlargement is the balance between 
apoptotic rate and mitosis. Apoptosis rates are elevated 
in tumour and are highly dependent on tumour type. Also, 
there is the general notion that aggressive tumours 
display a higher apoptosis rate. 
Oncogenes and apoptosis 
The link between apoptosis and tumour formation is 
genetically reflected in the involvement of tumour 
promoting and tumour suppressor genes in apoptotic 
pathways. These include p53, Rb, Ras, Raf, myc. Of 
particular emphasis is the tumour suppressor gene p53, as 
loss of p53 contributes to the pathogenesis of tumours, 
especially colon, bone, brain, liver, breast, lung and 
leukemias (el-Deiry et al., 1993; Harper et al., 1993; 
Kastan, 1997; Lane, 1992). Under normal circumstances, p53 
has a short half-life and is kept in a cell at a very low 
concentration making it undetectable in techniques such as 
immunohistochemistry. In tumours, p53 is either mutated or 
associates with other cellular or viral oncogenes making 
its detection possible by lengthening its half-life and 
consequently stimulating its accumulation in the nucleus. 
In this way, tumour-related genes that become activated 
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during tumour progression result in increased apoptosis 
rates. 
Almost every tumour type is characterised by increased Myc 
expression, except in lymphomas, where MYC gene is mutated 
at different points, especially at the T58A and P75S 
hotspot. Such mutations are interrelated to apoptosis 
levels, as cells bearing either the T58A or the P75S 
mutation display a diminished apoptosis rate due to 
reduced Bim levels that neutralise the anti-apoptotic Bcl-
2 (Evan et al., 1992; Hemann et al., 2005; Marsden and 
Strasser, 2003; Trent et al., 1996). Indeed, in lymphomas 
with Myc Box I mutations, Bim expression was absent and in 
this way, tumourigenesis is enhanced due to decreased 
apoptosis (Dang et al., 2005; Eischen et al., 1999). 
Therefore, contrary to the general notion that increased 
levels of apoptosis result to enhanced, more aggressive 
forms of tumours, it seems that in lymphomas, specific 
types of mutations in the MYC gene can result to decreased 
apoptosis and enhanced tumourigenesis. However, 
overexpression of Myc in tumours, results in increases in 
p53 and Arf levels, and hence to increased apoptosis. Myc-
induced apoptosis can also be triggered via other 
apoptosis pathways, as evidenced by redundant genetic 
experiments. Other genes activated by Myc include genes 
involved in cell cycle regulation, carbohydrate and 
nucleotide metabolism and mitochondrial biogenesis. 
Indeed, attempts towards a successful MYC-targeting 
therapy in different tumours are under way (Albihn et al., 
2010). Also, Par-4 is a protein recently characterised to 
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induce tumour cell-specific apoptosis upon binding to the 
cell surface receptor GRP78 (Shrestha-Bhattarai and 
Rangnekar, 2010). Moreover, abberations in the expression 
of Hox genes, which play a major role in apoptosis and 
development, were noted in abnormal development and 
malignancies (Shah and Sukumar, 2010). Other factors that 
contribute to the rise in tumour apoptotic index include 
the hypoxic conditions that are prevalent in the tumour, 
the loss of cell-cell contacts and matrix attachment that 
induces apoptosis and the resident immune cells that might 
become apoptotic (Bates et al., 1995; McGill et al., 1997; 
Meikrantz and Schlegel, 1995; Thomaidou et al., 1997).  
Apoptosis in tumours 
In tumours, apoptosis is a well-established and 
generalised phenomenon; however, its extent varies between 
tumour types. For example, in breast carcinomas, high-
grade tumours display more apoptosis (Lipponen et al., 
1994; Mustonen et al., 1997). This is due to withdrawal of 
hormones, such as progesterone and oestrogen, something 
that elicits apoptosis. Once these hormones are present, 
there is stimulation of the relevant receptors and an 
increase of the anti-apoptotic Bcl-2. Similarly, there is 
an increased apoptotic rate in high-grade endometrial 
adenocarcinomas (Heatley, 1995; Saegusa et al., 1996), as 
in terms of Bcl-2 expression, there is a reduction in its 
levels compared to normal epithelial cells in endometrium, 
where Bcl-2 is strongly expressed. A similar situation is 
observed in urogenital carcinomas, thyroid tumours and 
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gastric and colon carcinomas, in which apoptosis is 
tightly associated to high-grade tumours (Basolo et al., 
1997; Koshida et al., 1997; Krajewska et al., 1996; 
Staunton and Gaffney, 1995). In brain tumours, more 
apoptosis is evident in grade II gliomas than grade III 
lesions (Patsouris et al., 1996), whereas in lung 
carcinomas, small cell lung carcinomas display a higher 
apoptosis index compared to non-small cell lung carcinomas 
(NSCLCs), despite the higher expression of the anti-
apoptotic Bcl-2 (Eerola et al., 1997; Ikegaki et al., 
1994). In lymphomas, an analogous phenomenon takes place. 
High-grade malignant non-Hodgkin’s lymphomas have a higher 
apoptotic index than low-grade lymphomas and this 
correlates to Bcl-2 expression, which is increased in low-
grade lymphomas, as well as to Bax and Mcl-1 expression 
(Kiberu et al., 1996; Soini et al., 1998b).  
Finally, it should be noted that the identification of the 
molecular role of microRNAs has provided new insights on 
the pathways of apoptosis (Subramanian and Steer, 2010). 
To date, over 30 microRNAs are involved in apoptotic 
programmes, including let-7α, miR-16 and miR-21. It has 
been demonstrated that defects in the biogenesis of 
microRNAs can promote the formation of tumours, while 
tumour conditions are generally characterised by a 
downregulation of microRNAs, compared to normal situations 





This highly aggressive B-cell lymphoma was first 
identified in the middle of last century by Denis Burkitt 
in central Africa in areas endemic for falciparum malaria 
(Burkitt, 1958). It was characterised by faces that were 
grossly distorted presenting lesions in the upper and 
lower jaws as well as by enlarged abdominal masses but 
with no affected lymph nodes. In fact, Burkitt’s lymphoma 
(BL) had been the most common childhood tumour in that 
area, affecting individuals infected by the Epstein-Barr 
virus (EBV). Indeed, EBV was first identified in BL cells 
and BL remains the first identified human tumour in which 
a viral infection is involved in its pathogenesis 
(Burkitt, 1958; Burkitt, 1983). 
Following the characterisation of Burkitt’s lymphoma, 
other types of lymphomas have also been classified, 
especially undifferentiated lymphoma, Burkitt-like 
lymphoma, small non-cleaved cell lymphoma, high-grade B-
cell lymphoma etc. that display a similar pathophysiology 
(Table 3) (Blum et al., 2004; Magrath, 1990). According to 
World Health Organisation (WHO) classification, BL has 
three clinical variants: endemic, sporadic and 
immunodeficiency-associated types (Forteza-Vila and Fraga, 
2010; Kelemen et al., 2010). The endemic type of BL refers 
to affected African children (4-7 years old; male:female 
39 
 
ratio 2:1). It affects jaw and facial bones, 
gastrointestinal tract, kidneys, ovaries, breast and 
arises following EBV infection in all the affected cases. 
The sporadic type of BL has a worldwide incidence. It 
accounts for 40% of childhood lymphoma in the United 
States and Europe and 1-2% of adult lymphoma in these 
areas. It affects the abdomen and involves the kidneys, 
ovaries, breasts, terminal ileum and also displays pleural 
effusions or ascites. Lymph node involvement is most 
common in adult lymphomas. EBV infection is found in 15-
30% of cases (Klein et al., 2010). The immunodeficiency-
associated type of BL mainly affects HIV+ infected and 
immunodeficient patients as well as allograft recipients. 
In HIV+ patients, this type of BL accounts for 30-40% of 
non-Hodgkin’s lymphoma and is more commonly found in 
younger individuals with higher mean CD4 counts. The 
immunodeficiency type of BL presents the same pathogenetic 
features with the endemic type. It affects lymph nodes, 
bone marrow and abdominal sites; however HIV is not the 
cause of lymphomagenesis, but is involved in cytokine 
deregulation and reduced immune surveillance (Gaidano and 
Dalla-Favera, 1995; Knowles, 2003; Mbulaiteye et al., 
2010).  
All three forms of Burkitt’s lymphoma arise by 
translocations in the c-myc gene, as assessed by 
fluorescence in situ hybridisation (FISH) or long-segment 
polymerase reaction (Blum et al., 2004; Cairo et al., 
2003; Gaidano and Dalla-Favera, 1995; Magrath, 1990; 
Peukert et al., 1997; Wessendorf et al., 2003). In 80% of 
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BL cases, there is a translocation between c-myc gene and 
IgH gene [t(8;14)], whereas the remaining 20% arise due to 
a translocation between c-myc and the gene for κ or λ light 
chain (IgL) [t(2;8) or t(8;22), respectively). In sporadic 
and immunodeficiency-associated BL, the c-myc breakpoint 
is between exons 1 and 2, whereas in endemic BL, the c-myc 
breakpoint is 100 kb upstream of exon 1. Differences in 
the breakpoint position result in differences in the 
neoplastic transformation of B cells, as they are affected 
at different mutational stages (Wessendorf et al., 2003). 
The involvement of c-myc in lymphomagenesis is very 
important, as it consequently affects cellular functions 
such as cell cycle progression, cell adhesion, apoptosis 
and differentiation (Sanchez-Beato et al., 2003). In BL, 
the cell of origin is the germinal centre or post-germinal 
memory B cell.  
Also, mutations in p53 oncogene are implicated in the 
lymphomagenesis process, especially in the case of HIV+-
associated lymphoma. The Rb2/p130 tumour suppressor gene 
has also been implicated in BL disease pathogenesis (Cinti 
et al., 2000a; Cinti et al., 2000b). Rb2/p130 belongs to 
the retinoblastoma gene family and it is strongly 
involved, along with p107, in cell cycle regulation. In 
cases of endemic and sporadic BL, Rb2/p130 gene is mutated 
resulting in significant alterations in cell cycle 
regulation, whereas the HIV+-related BL is associated with 
Rb2/p130 overexpression. In the case of HIV infection, 
Rb2/p130, due to its ability to physically interact with 
viral oncoproteins, interacts via its pocket region with 
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the Tat protein of HIV-1 (Huang et al., 1997; Lefevre et 
al., 1999). Consequently, the B cell clones have an 
uninterrupted cell cycle and proliferation. This implies 
that Burkitt’s lymphoma subtypes arise due to different 
pathogenetic mechanisms. 
Treatment 
In recent years, efforts have been made to improve 
therapy, while reducing treatment-associated toxicity 
(Hesseling et al., 2010). Short-duration, high-intensity 
chemotherapy regimens have been developed for this 
rapidly-proliferating type of neoplasm with significantly 
high success rate and excellent survival (>90% 5 year 
survival rate in localised disease; >90% complete response 
rate in widespread disease cases) (Kasamon and Swinnen, 
2004). Usually for high-risk disease, the CODOX-M/IVAC 
regimen is followed; i.e. two cycles of CODOX-M 
(cyclophosphamide, vincristine, doxorubicin, methotrexate) 
alternating with IVAC (ifosfamide, etoposide, cytarabine 
and intrathecal therapy). For low-risk disease, three 
cycles of CODOX-M are sufficient for survival. However, 
there are treatment-associated toxicities such as 
myelosuppression, neuropathies, tumour lysis syndrome or 
even death.  
Another regimen used for BL treatment involves the use of 
rituximab, a monoclonal anti-CD20 antibody in conjuction 
with hyper-CVAD (hyperfractionated, cyclophosphamide, 
vincristine, doxorubium and dexamethasone- 89% complete 
remission rate) (Jazirehi et al., 2004; Vega et al., 
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2004). Moreover, novel therapies under development involve 
genetic ones targeted against c-myc and the use of 
inhibitors such as DNA methyltransferase inhibitors, 
cyclin-dependent kinase inhibitors, proteasome inhibitors 
etc. (Bowman et al., 1996; Magrath et al., 1996).  
Molecular Characteristics 
In terms of cell morphology, two main variants of 
Burkitt’s lymphoma have been characterised according to 
WHO: the classical form of Burkitt’s lymphoma and atypical 
Burkitt’s/Burkitt-like lymphomas (Magrath, 1990; McClure 
et al., 2005). BL classical morphology is most 
characteristic in the endemic and sporadic form of 
childhood lymphoma. BL cells are medium-sized, uniform 
cells with round nuclei and multiple small basophilic 
nucleoli. Their cytoplasm is abundant with multiple 
vacuoles due to the presence of lipids. BL cells are 
characterised by an unusually high mitotic rate. Also, the 
BL stroma has a “ starry-sky ” pattern due to the presence 
of numerous admixed tingible body macrophages, also known 
as tumour-associated macrophages (TAMs) that phagocytose 
the apoptotic cell debris (Figure 3). On the other hand, 
the atypical Burkitt’s/Burkitt-like lymphoma is prevalent 
in sporadic adult lymphomas (Cairo et al., 2003; Frost et 
al., 2004). Burkitt-like lymphoma cells show a 
plasmacytoid differentiation and have a smaller number of 
nucleoli. Despite the pathological type of BL, both types 
of BL cells express the following surface antigens CD19, 
CD20, CD22, CD79a, CD10, Bcl-6, CD43, p53 as well as the 
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monotypic surface IgM and display a high proliferative 














The BL stroma is composed of medium-sized, uniform cells 
with round nuclei and multiple small basophilic nucleoli. 
BL cells have an abundant cytoplasm and present a high 
mitotic and apoptotic rate. The BL stroma has “starry-
sky ” pattern due to the presence of numerous macrophages, 
also known as TAMs, that phagocytose the apoptotic cell 







































































The characteristic “starry-sky ” histological appearance 
of the BL stroma arises by the infiltration of monocytes 
that are later differentiated into tumour-associated 
macrophages (TAMs). Although the factors that trigger 
recruitment of TAMs in BL cells are not clearly 
identified, evidence from studies on other tumours rich in 
TAMs revealed that TAMs can infiltrate tumours in response 
to multiple chemoattractant factors such as MCP-1, MCP-2, 
MCP-3, GM-CSF and M-CSF (Bottazzi et al., 1990; Bottazzi 
et al., 1992; Dvorak et al., 1991; Fioretti et al., 1998; 
Fu et al., 1992; Graves and Jiang, 1995; Ha et al., 1999; 
Valkovic et al., 1998). In Burkitt’s lymphoma, the release 
of fractalkine by apoptotic BL cells has been found to be 
an additional chemoattractant factor that seems likely to 
stimulate monocyte migration to the tumour stroma (Truman 
et al., 2008). As with other tumours, in Burkitt’s 
lymphoma, TAMs may promote neoplastic establishment and 
progression by releasing factors such as IL-10 that have 
an immunosuppressive effect that prevent anti-tumour 
responses. Also, it has been demonstrated that macrophages 
cultured in the presence of IL-10 displayed upregulated 
capacity to recognise and engulf apoptotic tumour cells. 
This creates an anti-inflammatory environment, but also 
leads to increased levels of the B cell survival factor 
BAFF/BLyS, which in the case of a B-cell lymphoma, like 
Burkitt’s, promotes its growth (Truman et al., 2004). 
Although the synergy between TAMs and Burkitt’s lymphoma 
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is still poorly defined, it can be speculated that the 
similar mechanisms or factors that have been identified in 
other tumour types to characterise TAM activity might also 
exist in this type of lymphoma. In other words, it can be 
estimated that the mechanisms that promote tumour 
immunosurveillance are evolutionarily conserved between 
tumours and only slight differences exist between 
different tumour types.  
However, what makes Burkitt’s lymphoma a model of in situ 
apoptosis is its high apoptotic level as well as the high 
similarity between tumour microenvironment and sites where 
homeostatic apoptosis rates are high. Indeed, the tumour 
tissue retains the anti-inflammatory characteristics of 
apoptosis. These characteristics are enhanced by the 
presence of anti-inflammatory cytokines such as IL-10 that 
are released following macrophage infiltration to the site 
and engulfment of apoptotic tumour cells. It could be argued 
that no adaptive immune responses are triggered in BL 
stroma. For example, as evidenced by histological sections 
of BL, there are no neutrophils present due to a till now 
unknown mechanism; a phenomenon also evident in sites 
where homeostatic apoptosis rates are high to retain their 
anti-inflammatory characteristics (Blum et al., 2004; 
Burkitt, 1983; Frost et al., 2004). Finally, the tumour 
outcome depends on the balance between mitogenic or 
tumourigenic mechanisms and apoptosis, something that is 




All these pose Burkitt’s lymphoma as a tissue model of 
apoptosis, albeit a malignant tissue. Its molecular 
mechanisms bear strong similarities to the apoptotic 
process and the identification of the implicated factors 
would have powerful applications both in the elucidation 
of the anti-inflammatory nature of apoptosis as well as in 
the therapeutic intervention in lymphomas and types of 




Leukocytes are effector cells of the immune system with a 
pivotal role in the defense of the host organism against 
infections and foreign particles. These cells are 
distributed throughout the whole body, especially in blood 
and lymphatic system and under normal circumstances their 
number is between 4x109 and 1.1x1010 per litre of blood. 
Leukocytes are subdivided into two major types based on 
the presence of granules in their cytoplasm: 
agranulocytes, which are characterised by the absence of 
granules and mainly include lymphocytes, monocytes as well 
as macrophages, and granulocytes or polymorphonuclear 
leukocytes, which as their name suggests, possess 
cytoplasmic granules and are subdivided into neutrophils, 
eosinophils, basophils and mast cells. However, all these 
subtypes originate from a multipotent haematopoietic stem 
cell in the bone marrow (Nathan, 2006; Weiss, 1989).  
Neutrophil granulocytes represent a major class of 
granulocytes, as they comprise approximately 95% of 
circulating granulocytes as well as 70% of circulating 
leukocytes and in this way, they constitute the most 
abundant type of immune effector cell in humans. They 
belong to the family of polymorphonuclear cells (PMNs), as 
their nucleus has a multilobulated shape divided into 3-5 
lobes (Ward and Lentsch, 1999; Weiss, 1989). Under normal 
conditions, the number of circulating neutrophils is 2.5-
7.5x109 L-1; however, this number can increase up to 10-fold 
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under inflammatory or septic conditions. Neutrophils 
migrate across the endothelium hours before monocytes or 
lymphocytes and have a half-life of about 12 hours and a 
survival time into tissues of about 1-2 days following 
activation. All these characteristics of neutrophils 
suggest they are a “fighter ” cell type, as neutrophil 
activation and migration to the sites of inflammation or 
infection are linked to the release of a variety of 
cytotoxic compounds that exert an anti-microbial effect 
and kill invading pathogens.  
The Functions of Neutrophils 
The innate effector functions of neutrophils are 
represented by a multi-facet model: (a) production of 
reactive oxygen and nitrogen species (b) degranulation to 
release intracellular cytotoxic components (c) 
phagocytosis of invading organisms (d) formation of 
neutrophil extracellular traps (NETs) and finally (e) 
regulation of cytokine synthesis to control an 
inflammatory response. 
(a) Production of reactive oxygen and nitrogen species. 
Anti-microbial responses of neutrophils involve the 
generation of reactive oxygen and nitrogen species, which 
is initiated following the formation of NADPH-dependent 
oxidase complex; a process also known as oxidative burst 
(Babior, 1984). The NADPH oxidase complex (cytosolic 
p40phox, p47phox, p67phox; membrane p22phox, gp91phox) is 
phosphorylated at p47phox upon neutrophil activation and 
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associates with cytochrome b558 to become activated. In 
this way, superoxide anion (O2-) is generated, which in 
turn dismutates into H2O2, which subsequently forms 
hydroxyl radicals (OH-) (Nathan, 1987). In addition, 
myeloperoxidase (MPO), which is normally found in the 
azurophil granules of neutrophils, amplifies the toxic 
potential of H2O2 by allowing the formation of by-products 
such as hypochlorous acid (HOCl) that chlorinates many 
electron-rich substrates. Superoxide production is also 
associated with nitric oxide (NO) forming a potent toxic 
nitrogen intermediate, peroxynitrite (ONOO-) (Britigan et 
al., 1986; Hazen et al., 1998). Decomposition of 
peroxynitrite could also lead to hydroxyl radical (OH-) 
formation. Although the microbicidal role of NO is 
obscure, NO-deficient mice formed massive abscesses rich 
in enteric bacteria (Shiloh et al., 1999). 
(b) Degranulation. Upon activation, neutrophils release a 
variety of microbicidal molecules that are packed within 
neutrophils in the form of granules (Table 4) (Borregaard 
and Cowland, 1997; Elsbach, 1998; Panyutich et al., 1995; 
Spitznagel, 1990). These granules comprise the inner 
fighting machinery of the cell and are divided into the 
following categories: Azurophilic granules, also known as 
primary granules, emerge at the promyelocyte stage of 
granulocyte differentiation and contain myeloperoxidases, 
defensins, cathepsin G, elastase, proteinase 3, azurocidin 
(CAP-37) and bactericidal permeability increasing protein 
(BPI) (Egesten et al., 1994; Fouret et al., 1989). The 
contents of specific granules, also known as secondary 
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granules, include lactoferrin, cathelicidin, collagenase 
and gelatinase. These granules are formed at the 
metamyelocyte stage along with tertiary granules that 
contain gelatinase and cathepsins (Cowland et al., 1995; 
Sorensen et al., 1997). Secretory vesicles are another 
form of granule of endocytic origin that are rich in 
plasma proteins such as albumin and emerge at the mature 
stage of neutrophil development. The order of release of 
these granule types (exocytosis) is (1) secretory 
vesicles, (2) tertiary gelatinase granules, (3) specific 
granules and finally (4) azurophilic granules. The release 
of this stored material (degranulation) into the 
phagolysosome or in the extracellular space is a pivotal 
event for neutrophil functional abilities (Hoffman and 
Specks, 1998; Sengelov et al., 1993).  
(c) Phagocytosis. Neutrophil is a phagocyte. The opsonised 
particle (bacterial and viral pathogens) is engulfed by 
membrane protrusions that form a phagocytic cup; a process 
dictated by either complement receptors (CR1 and CR3) or 
Fcγ receptor aggregation, which induces the phosphorylation 
of cytoplasmic ITAM motifs and activation of Src-tyrosine 
kinases (Caron and Hall, 1998; Chuang et al., 2000; 
Greenberg et al., 1996). This in turn, triggers 
phosphoinositide 3 (PI3) and Rho protein activation. RhoA 
is responsible for F-actin recruitment and phagocytic cup 
formation, Cdc42 regulates membrane extension, while Rac-1 
and PI3 kinase are involved in membrane fusion and the 
closure of the phagocytic cup (Cox et al., 1997; Massol et 
al., 1998). As a result, the opsonised particle becomes 
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engulfed and fused with neutrophil granules to activate an 
oxidative burst reaction.  
(d) Neutrophil Extracellular Traps (NETs). One exciting 
recently described observation that enhances all the 
above-mentioned activities of neutrophils is the formation 
of neutrophil extracellular traps (NETs). These are web-
like structures of DNA that are released from activated 
neutrophils to trap and kill pathogens extracellularly 
(Brinkmann et al., 2004). NETs are rich in anti-microbial 
components and their suggested role is the creation of a 
physical barrier to prevent the spread of bacteria and 
microbes. This is particularly important in septic 
conditions, as NETs are formed within blood vessels to 
prevent exacerbation and spreading of the infection.  
(e) Regulation of cytokine synthesis by neutrophils. Apart 
from their widely known phagocytic and anti-microbial 
properties, neutrophils constitute a central cell of 
immunity, as they are able to link both innate and 
adaptive immunity. Indeed, neutrophils have the ability to 
regulate cytokine synthesis. It has been reported that 
almost all agents that are able to activate neutrophils 
can also stimulate cytokine production. Neutrophils sense 
these signals and respond via the release of a plethora of 
cytokines (Cassatella, 1995; Cassatella, 1999). For 
example, neutrophils can release proinflammatory cytokines 
such as TNF-α, IL-1α, IL-1β and IL-12 (Cassatella et al., 
1994; Cassatella et al., 1995; Dayer and Fenner, 1992; 
Lindemann et al., 1989; Marie et al., 1996). They can also 
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synthesise cytokines such as IL-1 (IL-1), macrophage-
inflammatory protein- 1α and β (MIP-1α, MIP-1β) and growth 
factors such as interferon-α (IFN-α), IFN-β, granulocyte 
colony-stimulating factor (G-CSF), Fas ligand (FasL) and 
vascular endothelial growth factor (VEGF) (McColl et al., 
1992; Tiku et al., 1986). Special emphasis should be given 
to IL-8 chemokine, as neutrophils form its primary 
cellular target, while at the same time, IL-8 is the most 
abundantly expressed chemokine by them (Baggiolini and 
Clark-Lewis, 1992; DeForge et al., 1992; Gainet et al., 
1998; Matsumoto et al., 1997; Sekido et al., 1993). 
Cytokine expression by neutrophils can also be modulated 
in both positively and negatively. More specifically, 
cytokine synthesis in neutrophils is positively enhanced 
by IFN-γ, while it is negatively regulated by IL-13 




































































Chemotaxis, first introduced by Pfeffer in 1884, is a term 
that describes the guided movement of a cell towards 
chemical gradients. It is a tightly regulated phenomenon 
necessary to attract a cell at the right time to the right 
place for a specific purpose (Adler and Tso, 1974; 
Sanchez-Madrid and del Pozo, 1999). Chemotaxis is highly 
evolutionarily conserved between organisms. Specifically, 
the slime mold Dictyostelium discoideum and neutrophils 
constitute the central cells in the study of chemotaxis as 
they both move very fast (10-40 μm per minute) and display 
striking similarities in the molecular mechanisms that 
regulate chemotactic movements (Parent and Devreotes, 
1999; Servant et al., 2000; Stephens et al., 2008). 
Indeed, genetic studies on Dictyostelium have revealed the 
presence of homologous regulatory proteins in neutrophils 
with a role in neutrophil chemotaxis (Parent, 2004).  
Steps of chemotaxis 
Neutrophils are normally found in the bloodstream. In 
order to reach the site of inflammation or infection, a 
series of events comprising the leukocyte adhesion cascade 
is followed. Although this cascade was originally 
described almost 200 years ago, recent evidence suggests 
that it is comprised of leukocyte rolling, strengthening 
of leukocyte adhesion to the endothelial wall, 
intravascular crawling, paracellular and transcellular 
migration and finally migration through the basement 
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membrane to reach the inflamed site (Figure 4) (Ley et 
al., 2007).  
All these processes initiate in response to the 
recognition of chemoattractant molecules, such as 
formylated peptides and lipopolysaccharides (LPS) present 
in bacteria, chemokines, mainly interleukin-8 that 
specifically attracts neutrophils, as well as leukotriene 
B4, complement factor 5a, platelet-activating factor (PAF) 
produced by epithelial or dying cells (Premack and Schall, 
1996; Rollins, 1997). It should be noted that there is a 
hierarcy in the way that neutrophils respond to these 
chemoattraction signals, as those expressed by the 
pathogens or by the mitochondria of dying cells receive a 
‘sensing’ priority, compared to those expressed as 
epithelial-cell attractants (Foxman et al., 1999; Kitayama 
et al., 1997). 
There are distinct regulatory processes that control each 
phase of the leukocyte adhesion cascade. At a first stage, 
leukocyte rolling is mediated by interactions between L-
selectin expressed by neutrophils and E-selectin and P-
selectin expressed by the endothelial cells (Muller, 
2003). PSGL-1 acts as a ligand for all these three types 
of selectins and is expressed by both neutrophils (in 
glycosylated form) and endothelial cells (da Costa Martins 
et al., 2007; Sperandio et al., 2003). These selectins 
stably bind only in the presence of shear stress created 
by the bloodstream, as the rolling cells were observed to 
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detach when flow is stopped (Alon et al., 1995; Finger et 
al., 1996).  
During rolling, neutrophil arrest is triggered by the 
recognition of chemoattractants and involves the binding 
of integrins on neutrophils to the immunoglobulin 
superfamily members, ICAM-1 and VCAM-1 on endothelial 
cells (Simon et al., 2000). The most studied integrins 
involved in neutrophil arrest are those of the β1-integrin 
family, especially β1-integrin VLA-4 (CD49d/CD29) and of 
the β2-integrin family, especially the β2-integrin LFA-1 
(CD11a/CD18; αLβ2-integrin). In order to mediate firm 
rolling and neutrophil adhesion, the engagement of P-
selectin or E-selectin induces a subsequent conformation 
of LFA-1 on neutrophils to acquire intermediate affinity, 
which allows it to become bound to its ligand ICAM-1 on 
the endothelium (Chesnutt et al., 2006; Salas et al., 
2004). Again, as in the case of selectins, the acquisition 
of the intermediate affinity conformation of LFA-1 under 
shear stress is necessary to increase its ligand-binding 
affinity (Astrof et al., 2006).  Apart from LFA-1, binding 
of MAC-1 (CD11b/CD18) to E-selectin is necessary to 
mediate firm adhesion (Dunne et al., 2002).  
The avidity of integrin-mediated interaction is controlled 
by the degree of integrin affinity, i.e. the 
conformational changes of integrin heterodimers and the 
valency of ligand binding, which corresponds to the 
density of integrin heterodimers (Bazzoni and Hemler, 
1998; Carman and Springer, 2003). Accordingly, 
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fluctuations between low affinity and high affinity states 
determine the formation and the dissociation of molecular 
bonds. Other factors that determine the degree of integrin 
activation also involve quantitative variations in the 
expression levels of chemokine receptors and variations in 
the affinities for chemokines (Constantin et al., 2000; 
Ley et al., 2007). In all cases, firm neutrophil adhesion 
is mediated by high affinity forms of integrins. Special 
emphasis should be given on the role of talin-1, which is 
an actin-binding protein that regulates the level of 
integrin affinities, as it wedges between the α- and β-
cytoplasmic tails of integrins (Tadokoro et al., 2003; 
Wegener et al., 2007). Apart from talin-1, at present, 
more than 47 proteins are involved in the regulation of 
integrin-mediated adhesion (Kinashi, 2005; Ley et al., 
2007).  Members of the kindlin protein family were also 
demonstrated to bind to β-integrin cytoplasmic tails, 
activating in this way, integrins. Especially, the FERM 
domain of kindlin-1 displays great similarity to that in 
talin-1. Mutations in the kindlin genes are linked to 
inherited and acquired human diseases such as the Kindler 
syndrome, leukocyte adhesion deficiency and malignancies 
(Meves et al., 2009). 
The final steps in neutrophil migration to reach an 
inflamed site involve its intravascular crawling and its 
paracellular and transcellular migration through the 
endothelial basement membrane. During intravascular 
crawling, different levels of shear stress exist depending 
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on the cell type. Again, there are interactions between 
integrins on neutrophils and endothelial ligands, such as 
ICAM-1 and VCAM-1, which form transmigratory cups along 
with the cytoplasmic molecules ezrin, radixin and moesin 
and the cytoskeletal proteins vinculin and α-actinin 
(Barreiro et al., 2002; Carman and Springer, 2004; 
Phillipson et al., 2006). In order to further actively 
mediate transendothelial migration of neutrophils, there 
is an expression of endothelial junctional molecules such 
as PECAM-1, JAM-A, JAM-B, JAM-C, ICAM-2, CD99 and ESAM, 
which become bound to PECAM-1, JAM-1, MAC-1 and LFA-1 
expressed on neutrophils (Vestweber, 2002). The existence 
of vesiculo-vacuolar organelles (VVOs) on endothelial 
membrane acts as a gateway for neutrophil transmigration 
(Dvorak and Feng, 2001).  
As a final step, neutrophil transmigration through 
endothelial basement membrane is facilitated by the 
presence of regions within the membrane, which display 
lower than average expression of matrix proteins, such as 
laminin-10 and collagen IV (Wang et al., 2006). In this 
way, neutrophil migration takes place through these 
regions of least resistance. Also, in parallel, such 
regions are more permissive to chemoattractant molecules.  
Finally, once the extravasation process is complete, 
neutrophils migrate along a concentration gradient of 
chemokines and other chemoattractants secreted by cells at 
the site of inflammation or infection. In general, this 
interplay of regulatory molecules controls the migration 
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of neutrophils into tissues. The importance of this 
tightly regulated mechanism is significant, as the 
inappropriate or uncontrolled migration of such effector 
cells with their histotoxic properties may result in an 
unfavourable outcome such as host tissue damage. 
In summary, the achievement of successful neutrophil 
adhesion and transmigration is a tightly-regulated multi-
step process that involves an interplay of integrins based 
on alterations in their affinity state. Targeting 
integrins is an area of intensive research for the therapy 
of inflammatory conditions, characterised by aberrant 
neutrophil infiltration. For example, the use of the 
monoclonal antibody, natalizumab in multiple sclerosis 
patients targets VLA-4, while efalizumab, is a monoclonal 
antibody specific for LFA-1 used in individuals with 
psoriasis (Ley et al., 2007). A very recent study by 
(Deban et al., 2010) identified pentraxin PTX3 as a 
protein that dampens neutrophil recruitment by inhibiting 
their rolling on P-selectin, providing in this way further 
evidence that identification of regulatory molecules 








The steps followed so as a neutrophil to leave the 
bloodstream and reach the inflamed site involve: 
neutrophil capture, slow rolling, strengthening of 
adhesion to the endothelial surface, intravascular 
crawling and paracellular and transcellular migration. The 
whole process is orchestrated by the interaction between 
adhesion molecules expressed on the endothelial cell wall, 





Almost all the chemoattractant molecules are recognised by 
specific seven-transmembrane receptors on neutrophil 
surfaces that are associated with intracellular GTP-
binding heteroproteins (De Nardin et al., 1991; Thomas et 
al., 1990). Indeed, the activity of these specific 
receptors is modulated by their interaction with G 
proteins, which in the inactive state, their three 
subunits (α, β, γ) form heterodimers. Upon activation, a 
conformational change of the receptor induces the GDP 
(inactive) to GTP (active) exchange in the α subunit and 
thus the dissociation of the heterodimeric complex and the 
subsequent release of the α subunit from the βγ subunit 
complex (Jin et al., 2000; Malech et al., 1985; Wieland 
and Chen, 1999).  
Based on comparative studies on Dictyostelium, neutrophil 
activation, prior to movement, is accompanied by the 
acquisition of a polarised morphology characterised by a 
leading actin-rich lamellipodium and a tail-like uropod at 
the distal end (Benard et al., 1999; Lauffenburger and 
Horwitz, 1996; Mitchison and Cramer, 1996) (Figure 5A). In 
this way, the leading machinery that promotes cell 
movement involves cytoskeletal modifications mainly in the 
actin cytoskeleton (Figure 5B). Modifications in the 
organisation or de-organisation of actin are necessary for 
directional neutrophil crawling along surfaces, as 
neutrophils need to extend their cell membrane, adhere to 
the surface and finally contract their body in order to 
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move (Parent and Devreotes, 1999). As a requisite to 
extend or protrude, actin assembly creates small trigger-
like projections, known as lamellae (also called filopodia 
in Dictyostelium), from the leading edge of the 
neutrophils. Lamellae are sheet-like structures rich in 
actin filaments that provide a base so that the neutrophil 
pushes its membrane forward and in this way, moves (Jones 
and Sharief, 2005). The tight and well-organised 
regulation of this migratory mechanism creates a 
continuous neutrophil movement (Glogauer et al., 2000). 
This is also enriched by the identification of actin 
regulating proteins, such as actin-filament capping 
proteins e.g. capping protein-beta 2, gelsolin and villin 
that regulate monomer addition in the filament end and the 
actin-nucleation factors e.g. JMY, mDia1 that bind to 
actin monomers under unfavourable conditions and promote 
their binding to generate new actin filaments (Pollard et 
al., 2000; Puius et al., 1998). The importance of this 
process is reflected by the use of the reagent 
cytochalasin, which binds to the growing plus ends of 
microfilaments and inhibits the assembly of actin 
filaments and the disassembly of individual monomers from 
the bound end; completely blocking in this way neutrophil 
motility (Cooper, 1987).  
The whole process of actin assembly is regulated by 
multiple pathways. For example, the formation of a complex 
of actin-related proteins 2 and 3 (Arp2/3 complex) 
nucleates actin polymerisation by binding to profilin and 
to a complex of Cdc42, N-WASP (Wiskott Aldrich Syndrom 
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Protein family) and PI(4,5)P2 (Higgs and Pollard, 2000; 
Machesky et al., 1997; Zigmond et al., 1998). The 
formation of this complex was demonstrated to be 
necessary, as by blocking one of these factors, half of 
the total actin assembly is also blocked. Finally, other 
cytoskeletal proteins that are critical for the normal 
migration of the neutrophils include gelsolin and 
lymphocyte-specific protein-1 (LSP-1) (Howard et al., 
1998; Janmey et al., 1985; Zhang et al., 2000). Gelsolin 
is an effector protein of Rac that binds tightly to the 
high-affinity end of the actin filament following its 
activation by calcium ions and is removed from the actin 
filament end when Rac is in the active GTP-bound form. 
LSP-1 on the other hand, is a calcium-binding protein that 
is associated with the cytoplasmic side of the plasma 
membrane and promotes the bundling of actin filaments. In 
fact, studies on LSP-1 deficient mice presented an 
enhanced migration of neutrophils and macrophages to the 
peritoneum (Liu et al., 2005a).  
Following the engagement of the chemoattractant receptor, 
there are subsequent downstream signalling cascades 
(Bokoch, 1995; Ono et al., 2003; Selvatici et al., 2006). 
Indeed, once the G-protein-αβγ complex becomes activated 
and therefore dissociated, the α subunit interacts mainly 
with phospholipase C (PLC) and this leads to the 
hydrolysis of phosphatidylinositol-4,5-bisphosphate 
[PI(4,5)P2] to generate IP3 (inositol-1,4,5-triphosphate) 
that induces [Ca2+]i mobilisation and DAG (diacylglycerol) 
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that activates protein kinase C (PKC) (Park et al., 1993). 
The activation of PLC is not associated with neutrophil 
chemotaxis per se, but mainly with the production of 
reactive oxygen intermediates. On the other hand, the 
association of βγ subunits with PI3 kinases plays a key 
role in the promotion of chemotactic movement (Clapham and 
Neer, 1993). In detail, PI3 kinases phosphorylate inositol 
phospholipids such as phosphatidylinositol-3-phosphate 
[PI(3)P], phosphatidylinositol-3,4-bisphosphate [PI(3,4)P2] 
and phosphatidylinositol-3,4,5-trisphosphate [PI(3,4,5)P3]. 
Especially the last two are strongly implicated in re-
arrangements of the actin cytoskeleton and cell 
polarisation (Gillooly et al., 2000; Li et al., 2000; 
Rhee, 2001; Wu et al., 2000). The activity of PI3 kinase 
signalling in chemotactic movement is also implied from 
the use of the PI3 kinase inhibitors, wortmannin and 
LY294002, which completely block (a) respiratory burst, 
(b) activation of phospholipase D, (c) phosphorylation of 
MAP/ERK2 (Extracellular-signal-regulated kinase 2) as well 
as (d) cell polarisation and chemotaxis (Baggiolini et 
al., 1987; Downey et al., 1996; Niggli and Keller, 1997; 
Reinhold et al., 1990; Thelen et al., 1995; Thelen et al., 
1994; Wu et al., 2000; Wymann et al., 2000). Indeed, the 
activity of PI3-kinase is essential for the establishment 
of cell polarity, as evidenced by the high concentration 
of PI(3,4,5)P3 in the leading edge of an activated 
neutrophil (Gillooly et al., 2000; Rameh and Cantley, 
1999; Servant et al., 2000; Toker and Cantley, 1997). 
However, studies on PI3 kinase γ-/- mice have failed to 
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block actin polymerisation completely, suggesting in this 
way the existence of a PI3 kinase-independent pathway 
(Hirsch et al., 2000; Sasaki et al., 2000).  
The activity of PI3 kinases has also been linked to the 
activity of Ras GTPases that are small GTP-binding 
proteins that include Rho, Rac and Cdc42; all of which 
being important regulators of cell motility (Servant et 
al., 2000). These proteins interchange between a GTP-bound 
active state and a GDP-bound inactive state. Their 
activity is also controlled by accessory proteins such as 
guanosine dissociation inhibitors (GDIs), GTPase 
activating proteins (GAPs) and guanosine exchange factors 
(GEFs). Vav isoforms (Vav1, Vav2 and Vav3) can also 
promote PI3 kinase signalling with small GTPase proteins; 
however, little is yet known about the exact activity of 
these proteins (Cherfils and Chardin, 1999; Gakidis et 
al., 2004; Han et al., 1998; Quilliam et al., 1995; 
Servant et al., 2000). Although the exact role of Rho 
still remains unclear, it has been proposed to interact 
with myosin II to induce stress fibres and cell 
contraction and thus forming bipolar filaments. Indeed, 
the activity of myosin II, as also supported by studies in 
Dictyostelium, is critical for cell contraction and 
release at its rear as the cell moves forward. The 
activity of other GTPases, such as Cdc42 and Rac, is also 
necessary for the stimulation of actin filament assembly, 
as mutations in the RAC2 gene have resulted in ineffective 
bactericidal and motile function of neutrophils (Glogauer 
et al., 2000; Zigmond et al., 1998). 
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In summary, PI3 kinases and their effector activities are 
necessary to promote actin reorganisation and therefore a 
change in neutrophil morphology that would trigger 
directional migration. Genetic studies on Dictyostelium 
confirmed the regulatory role of these proteins. However, 
as evidenced by the genetic studies or by the use of 
inhibitors, the precise signalling pathway that follows 
chemoattractant signalling has not been fully 
characterised, as blocking the activity of one or more of 
these effector proteins fails to completely block 






(A) Characteristic images of an activated neutrophil. 
Prior to movement, neutrophils become activated and 
acquire a polarised morphology. Neutrophil polarisation is 
characterised by a leading actin-rich lamellipodium and a 
tail-like uropod at the distal end. Microscopy image was 
kindly provided by S. Bournazos. (B) Actin organization 
for directional neutrophil movement. Modifications in the 
organisation or de-organisation of actin in the 
lamellipodium are necessary for directional neutrophil 
crawling along endothelial surfaces. Actin assembly leads 
to the creation of lamellae, which are sheet-like 
structures rich in actin filaments. The process is 
controlled by actin-capping proteins that regulate monomer 
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addition in the filament end and actin-nucleation factors 
that promote the binding of actin monomers to generate new 




The fundamentally important contribution of granular 
proteins to the anti-microbial environment is reflected by 
the pathophysiology of many inherited defects: Chronic 
granulomatous disease (CGD) is a genetic disorder in which 
affected individuals display defects in any of the four 
subunit genes of the NADPH oxidase (Sanmun et al., 2009). 
Phagocytes of CGD patients fail to trigger a respiratory 
burst, are incapable of producing reactive oxygen species 
(ROS) and therefore present impaired killing of ingested 
pathogens (Gallin et al., 1992; Segal and Abo, 1993). In 
in vivo CGD mouse models, neutrophils lack NADPH activity 
and mice die prematurely due to recurrent bacterial and 
fungal infections (Dinauer et al., 1999; Mardiney et al., 
1997). Specific granule deficiency is another genetic 
disorder that is marked by severe recurrent bacterial 
infection due to the absence of specific granules and due 
to abnormalities in neutrophil locomotion (Lekstrom-Himes 
et al., 1999). Chediak-Higashi hereditary syndrome is 
marked by a defect in the formation of neutrophil 
granules, a lack of NK cell function and is manifested 
clinically with neutropenia and a lymphoma-like 
symptomatology, which can be life-threatening (Nagle et 
al., 1996). Likewise, inherited MPO deficiencies are 
linked to severe infections with Candida as evidenced by 
MPO-knockout mouse models (Aratani et al., 1999; Reynolds 
et al., 1997; Reynolds et al., 1999), whereas in α-1-
antitrypsin deficiency, there is no inhibition of 
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neutrophil elastase, leading to tissue damage in the form 
of pulmonary emphysema. 
Moreover, failure to control the migratory program of 
neutrophils gives rise to chronic pathological conditions. 
Such conditions range from vasculitis and ischaemia 
reperfusion injury to glomerulonephritis, rheumatoid 
arthritis and acute graft rejection (Weiss, 1989). 
Clinical manifestations of inappropriate neutrophil 
infiltration are more eminent in hereditary syndromes, 
such as familial Mediterranean fever (FMF) or familial 
Hibernian fever (FHF); both autosomal recessive diseases 
that affect serosal or synovial membranes due to the 
massive influx of neutrophils (Livneh and Langevitz, 2000; 
Williamson et al., 1982). On the other hand, neutropenia 
is a disorder characterised by abnormally low neutrophil 
counts (Hsieh et al., 2007). Affected individuals are 
highly susceptible to infections and might later develop 
aplastic anaemia and leukemia. 
In general terms, the clinical symptoms manifested by all 
these disorders highlight the functional importance of 
neutrophils in a living organism. Moreover, they reveal 
the continuous presence of regulatory feedback mechanisms 






The last step of an inflammatory response involves the 
resolution of the infection by eliminating the invading 
pathogen via phagocytosis and by spontaneously decreasing 
neutrophil infiltration (Dibbert et al., 1999; Savill, 
1997). The latter event is associated with the apoptosis 
and clearance of the leukocytes present at the 
inflammatory mileu. Indeed, it has been demonstrated that 
at inflammatory sites, negative signals exist that prevent 
neutrophil recruitment, dampen neutrophil responsiveness, 
and counterbalance or terminate the inflammatory response 
(Liles and Klebanoff, 1995; Serhan and Savill, 2005).  
This anti-inflammatory program is characterised by 
cessation of neutrophil infiltration, as arachidonic acid–
derived prostaglandins and leukotrienes are switched to 
lipoxins, resolvins, and protectins. In fact, the initial 
phase of the resolution of an inflammatory response is 
ultimately achieved through neutrophil apoptosis. The 
proinflammatory cytokines, such as MIP-2α/β that are 
released by neutrophils trigger the migration of 
professional phagocytes, such as macrophages, to enable 
phagocytosis, a process that leads to the release not only 
of anti-inflammatory cytokines but also of anti-
inflammatory lipid mediators as lipoxin A4, resolvin E1, 
and protectin D1 (Brown and Savill, 1999; Dibbert et al., 
1999; Schwab et al., 2007; Serhan and Savill, 2005; 
Soehnlein and Lindbom, 2010). In parallel, termination of 
neutrophil recruitment occurs as a result of (i) 
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alterations in the balance of pro-and anti-inflammatory 
cytokines (TNF-α, IL-10, IL-4, IL-13) (Cassatella, 1999; 
Cox, 1996; Fadok et al., 1998b; Kuhn et al., 1993; Lentsch 
et al., 1999; Wang et al., 1994), (ii) the inactivation of 
chemoattractants, (iii) the elimination of adhesion 
molecules in endothelial cells (Sironi et al., 1993; Vora 
et al., 1996) and (iv) the release of molecules that 
actively inhibit neutrophil recruitment (Diamond et al., 
1999; O'Meara and Brady, 1997; Schwab et al., 2007).  
Negative regulators of neutrophil recruitment 
Although the molecules that positively regulate neutrophil 
infiltration (chemoattractants) during an inflammatory 
process are well characterised and their mechanism of 
activity has been unravelled, little is known about the 
molecules that are synthesised within the host organism to 
either prevent or stop neutrophil recruitment. Two of the 
most well-known are: lipoxins and annexin-1. Lipoxins 
(lipoxin A4 [LXA4] and lipoxin B4 [LXB4]) (Fierro et al., 
2003) are endogenously produced eicosanoids that are 
enzymatically derived from arachidonic acid (ω-6 fatty 
acid). Lipoxins have been demonstrated to slow neutrophil 
infiltration to inflammatory sites, promote monocyte 
infiltration, enhance engulfment and phagocytosis of 
apoptotic neutrophils as well as reduce vascular 
permeability. Also lipoxins have been reported to inhibit 
superoxide generation and NF-κB activation. An analogous 
class of lipid-mediators, the resolvins, which include 
resolvin E1 (RvE1) and protectin D1 (PD1) (Schwab et al., 
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2007; Serhan and Savill, 2005), are another type of lipid 
mediators that are derived from EPA and DHA ω-3 fatty 
acids. RvE1 and PD1 inhibit leukocyte infiltration both in 
vivo and in vitro and promote phagocytic removal by 
increasing macrophage recognition and engulfment of 
apoptotic neutrophils, as evidenced by the presence of 
zymosan-engulfing phagocytes in lymph nodes and spleen. 
Moreover, aspirin-triggered 15-epi-LX45 lipoxins (ATLs) 
and stable analogues of lipoxins possess similar anti-
inflammatory activities in terms of neutrophil recruitment 
(Serhan et al., 2008).  
Apart from lipoxins, annexin-1 (ANXA1) is a 37-kDa 
glucocorticoid mediator protein that also inhibits 
neutrophil extravasation both in vitro and in vivo as 
evidenced in models of acute and chronic inflammation 
(Hayhoe et al., 2006). The use of ANXA1-null mice and of 
the ANXA1 N-terminal bioactive peptide Ac2-26 revealed 
that ANXA1 binds to formyl-peptide receptors on neutrophil 
surface (FPR) or FPRs activated by lipoxin A4 (FPRL-1/ALX), 
demonstrating in this way a similarity in the mode of 
activity of the two molecules: annexin-1 and lipoxins. 
Other molecular factors that also inhibit neutrophil 
extravasation (Tables 5-8) include antiflammins 
(inhibitors of PAF synthesis) (Camussi et al., 1990), 
calpain (Katsube et al., 2008; Noma et al., 2009), 
cathepsin G (Tralau et al., 2004), the 
metalloendopeptidase CD10 (Shipp et al., 1991), CD47 (Chin 
et al., 2009; Cooper et al., 1995; Parkos et al., 1996), 
C-reactive protein (Heuertz et al., 1996; Mortensen and 
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Zhong, 2000), galectin-1 (La et al., 2003), resistin 
(Cohen et al., 2008), prostaglandin E1 and E2 (Burelout et 
al., 2004; Mikawa et al., 1994b), TGF-β1 (Shen et al., 
2007) as well as nitric oxide and reactive oxygen and 
nitrogen species (Dal Secco et al., 2006; Sato et al., 
2000a; Sato et al., 2000b). Moreover, in neural systems, 
leukocyte migration is inhibited by the release of 
molecules such as netrin-1 (Kaplan et al., 2005), slit (Wu 
et al., 2001) and sphingosine-1-phosphate (Kawa et al., 
1997).  
Neutrophil recruitment is also affected by varying 
concentrations of certain cytokines. For example, high 
concentrations of IL-8 exert a chemorepulsive effect on 
neutrophils (Tharp et al., 2006), while low doses of 
chymotrypsin exert an analogous effect (Jutila et al., 
1991). Semaphorins have also been characterised to exert a 
chemorepulsive effect (Goshima et al., 2002; Klostermann 
et al., 1998; Vianello et al., 2005) 
There are also other molecules reported to negatively 
regulate neutrophil migration. More specifically, many 
pharmacological agents inhibit leukocyte migration. These 
include non-steroidal anti-inflammatory compounds (e.g. 
ketoprofen, piroxicam, nimesulide; (Bizzarri et al., 2001; 
Dapino et al., 1994; Sordelli et al., 1993; Tool et al., 
1996), corticosteroid drugs (fluticasone propionate, 
dexamethasone; (Hofbauer et al., 1999b; Llewellyn-Jones et 
al., 1994), antibiotics (azythromycin; (Tsai et al., 2004) 
as well as drugs used for diabetes (gliclazide;  (Okouchi 
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et al., 2004), rheumatoid arthritis (leflunomide; (Kraan 
et al., 2000), inflammatory bowel disease (cyclosporine A; 
(Dalmarco et al., 2008; Yan et al., 2006), respiratory 
disorders (fenspiride; (Cunha et al., 1993), barbiturates 
(thiopental, thiopentone, midazolarim;  (Heine et al., 
1997; Nishina et al., 1998), cannabinoids (McHugh et al., 
2008), class III antiarrhythmic methanesulfonamides (Brown 
et al., 2007). 
Furthermore, based on the knowledge of the signalling 
pathways that control cell migration, a number of 
molecules that are specifically developed to inhibit these 
pathways have been identified as key neutrophil inhibitory 
molecules. Such molecules include chemokine receptor 
antagonists, such as CXC chemotaxis receptor antagonist 
(McColl and Clark-Lewis, 1999), CXCR2 antagonist (Matzer 
et al., 2004), SC-51146 (LTB4 receptor antagonist) (Tsai et 
al., 1994) and Sch527123 (CXCR1/2 R antagonist) (Chapman 
et al., 2007). Other inhibitors used to cease neutrophil 
recruitment involve the carbohydrate selectin inhibitor 
CY-1503 (Schmid et al., 1997), CI-949 allergic inhibitor 
(Wright et al., 1991), PI3-kinase inhibitors (RO31-
8220/CGP 41.251, wortmannin) (Ferrandi et al., 2007; 
Niggli and Keller, 1997), repertaxin (IL-8 inhibitor) 
(Cavalieri et al., 2005) (Souza et al., 2004), sivelestat 
(neutrophil elastase inhibitor) (Hagio et al., 2005) and 
Rho kinase inhibitors (Meyer-Schwesinger et al., 2009).  
All these pharmaceutical compounds and antagonists do not 
occur naturally, and therefore, cannot be synthesised in a 
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host organism. For this reason, the number of factors or 
molecules that are synthesised by a host organism to 
negatively regulate and interact with neutrophil 
locomotion is limited. In all cases, the existence of 
these negative factors accounts for the cessation of an 
inflammatory response and has significant therapeutic 









































































































































































































Eosinophils, though they constitute only about 1-6% of 
leukocytes, are important in defense against invading 
parasites and play prominent effector roles in several 
inflammatory disorders (Rothenberg, 1998). Normally, 
eosinophils are essentially limited to the digestive tract 
and are absent from other tissues (Kato et al., 2001). 
However, the inflammatory responses observed in bronchial 
asthma, allergic rhinitis, dermatitis or in allergic 
gastrointestinal diseases are characterised by the local 
accumulation of eosinophils within the affected tissues 
(Wardlaw et al., 1995). The presence of eosinophils is 
associated with the release of eosinophil-derived toxic 
inflammatory mediators, such as major basic protein, 
eosinophil cationic protein, eosinophil-derived neurotoxin 
and eosinophil peroxidase, all of which are stored in 
intracellular granules within eosinophils (Gleich et al., 
1986; Rothenberg and Hogan, 2006). The release of these 
products, evolved to deal efficiently with invading 
parasites, is also believed to contribute to the 
pathophysiology of the underlying inflammatory disorders 
(Simon et al., 2004). 
As in the case of neutrophils, recruitment of eosinophils 
to inflammatory sites is tightly regulated and occurs in 
response to chemokines, especially eotaxin, and cytokines 
expressed at sites of allergic inflammation, such as IL-1 
and TNF-, along with the Th2 cytokines, IL-5, IL-4, IL-13 
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and IL-9 that promote eosinophil recruitment and 
activation either directly or by regulating local IL-5 and 
eotaxin synthesis and by suppressing IFN- production. 
Leukotrienes and prostaglandins, mainly LTB4 and PGD2 
respectively, along with PAF, are also implicated in 
promoting eosinophil chemotaxis (Pinho et al., 2005; 
Rothenberg and Hogan, 2006; Rothenberg et al., 1995; Simon 
et al., 2004). 
Although such positive chemoattractant signals have been 
well characterised (Lukacs et al., 1996; Numao and 
Agrawal, 1992; Roviezzo et al., 2004), little is known 
about the mechanisms or the presence of regulatory 
molecules that negatively influence eosinophil migration 
and thus, may contribute to the paucity of eosinophils in 
normal tissues. Indeed, agents that can influence 
eosinophil infiltration and activation have been applied 
in the treatment of allergic disorders and for this reason 
several therapeutic agents that target multiple mechanisms 
underlying eosinophilia are being investigated. For 
example, glucocorticoids limit eosinophil cytokine 
production and promote eosinophil apoptosis (McColl et 
al., 2007), leukotriene antagonists and inhibitors 
interfere with eosinophil recruitment, while therapeutic 
antibodies against IL-5 and eotaxin-1 are under 
development to treat allergic conditions (Rothenberg and 
Hogan, 2006). Recently, it has also been found that 
lipoxin A4 blocks eosinophil trafficking (Bandeira-Melo et 
al., 2000), while IL-6, IL-11 and IL-12 cytokines inhibit 
Th2 cytokine expression, VCAM-1 expression and 
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eosinophilia (Wang et al., 2000a; Zhao et al., 2000) 







Although many leukocyte types have been characterised to 
be present in the tumour stroma and promote the neoplastic 
process, the role of neutrophils in tumour progression has 
been characterised as controversial. There has been an 
ever increasing number of studies over the last decade 
that support the anti-tumour effect of neutrophils over 
other inflammatory cells due to their cytostatic effects 
(Dallegri and Ottonello, 1992). However, there are also 
tumours such as gliomas, gastric carcinomas and melanomas 
that have been reported to display a strong correlation 
between tumour grade and the extent of neutrophil 
infiltrate, proposing in this way a tumour enhancing role 
of neutrophils (Fossati et al., 1999; Schaider et al., 
2003; Takematsu et al., 1994).  
In a very recent study by Fridlender et al. (2009) it was 
shown that TGF-β within the tumour microenvironment allows 
the generation of a population of specialised CD11b+/Ly6G+ 
TANs (tumour-associated neutrophils) that exhibit a pro-
tumour phenotype. However, once TGF-β becomes blocked as a 
means of tumour therapy to slow tumour growth and increase 
neutrophil-attracting chemokines, an influx of TANs was 
induced, which were hypersegmented, more cytotoxic to 
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tumour cells and generally, expressed an anti-tumour 
phenotype. These findings compare TANs with TAMs and 
support two populations of TANs: N1 polarised neutrophils 
that in the absence of TGF-β induced increased neutrophil 
recruitment and anti-tumour effects and a second 
population that has a N2 polarisation phenotype, which in 
the presence of neutrophils promote tumour progression. 
These two populations reveal for another time the 
controversial role of neutrophils in tumours and how they 
can exert tumour regression (Hicks et al., 2006; Nozawa et 
al., 2006). Moreover, preliminary studies from our group 
have shown that co-culture of neutrophils with BL cells 
had cytostatic effects on BL cell growth by decreasing 
both viable and apoptotic cell populations (I. Bournazou, 
unpublished data).  
In this way, a new model of cancer immunotherapy could be 
proposed that is based on the cytostatic effects of 
neutrophils as a new approach (Allendorf et al., 2005). 
For example, picibanil, an extract from Streptococci, has 
been widely utilised to treat malignant ascites and its 
anti-tumour mechanism involves complement-mediated 
neutrophil activation (Yang et al., 1992). Also, murine 
granulocyte infiltration to SCID mice was demonstrated to 
delimit the human tumour mass and treatment of such mice 
with anti-murine granulocyte antibody markedly improved 
the growth of human tumour cell lines of different origin 
by suppressing the host granulocyte reaction (Lozupone et 
al., 2000). Moreover, the use of replicating viruses for 
cancer therapy (virotherapy) was predominantly 
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characterised by an influx of neutrophils that in turn, 
slowed tumour progression considerably. For example, 
measles virus was found to be oncolytic for lymphomas in 
vivo (Grote et al., 2003; Grote et al., 2001; Peng et al., 
2001; Peng et al., 2002). 
Based on the anti-tumour effect of neutrophils combined 
with substantial histological evidence that reports the 
absence of neutrophils from the stroma of several tumour 
types, it could therefore be proposed that negative 
signals are likely to exist to prevent their infiltration 
to the tumour site. These outcomes might also probably 
arise by the distortion of the balance of the type and of 
the amount of cytokines, e.g. IL-1, IL-2, IL-10, IL-12, 
TNF-α, TNF-β, TNF-γ, G-CSF released by tumour cells to 
suppress the massive local inflammatory response triggered 
by the degree of recruited neutrophils as well as by 
neutrophil cytostatic effects (Musiani et al., 1996; 
Musiani et al., 1997). This overall phenomenon seems 
highly dependent on the heterogeneity of the tumour, as in 
most cases neutrophils do not constitute a component of 
the inflammatory milleu of the tumour stroma. In this way, 
tumour itself seems to actively suppress neutrophil 
effector activity and render them hypofunctional, as in 
the case of other inflammatory cells resident in the 
tumour as part of its cancer immunoediting process (Dunn 
et al., 2002; Dunn et al., 2004; Lollini and Forni, 2003).  
Despite the difficulties to identify the exact mechanisms 
or the factors involved in the prevention of neutrophil 
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migration to the tumour site, it could be proposed that 
this process is orchestrated by the dynamic tumour 
microenvironment itself. There are many possibilities that 
for instance, (i) tumour cells actively inhibit neutrophil 
migration via the release of several factors; (ii) the 
tumour microenvironment stimulates or abrogates neutrophil 
migration via a regulation of adhesion molecules on tumour 
or pericapillary endothelial cells and finally, (iii) the 
whole process is orchestrated by the intratumoural 
cytokine network. Indeed, upregulation of the expression 
of endothelial adhesion molecules in tumours was shown to 
trigger the recruitment of neutrophils intratumourally and 
thus, elicit an anti-neoplastic response (Colombo et al., 
1996; Kushner and Cheung, 1992). For example, tumour cells 
transfected to release G-CSF, IL-2, IL-4, IL-12 and TNF-α 
also displayed an upregulation of ICAM-1 in blood vessels 
as well as elevated production of chemokines such as 
GRO/KC (growth-related oncogene/cytokine-induced 
neutrophil chemoattractant; a murine functional homologue 
of IL-8) (Cavallo et al., 1999; Di Carlo et al., 2000; 
Hirose et al., 1995; Musiani et al., 1996). As a result, 
integrin-mediated adhesion and extravasation of 
neutrophils to the tumour site was elevated with oncolytic 
effects. On another study of transfected TSA-LEC (liver 
expressed chemokine), LEC expression is chemotactic for 
dendritic cells, monocytes, but not neutrophils; however, 
when triggered by IL-10, LEC became upregulated and had 
oncolytic effects for the transfected tumours accompanied 
by the recruitment of neutrophils, CD8+ lymphocytes and 
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natural killer cells (Giovarelli et al., 2000; Hedrick et 
al., 1998). Moreover, as evidenced by several studies 
using cytokine-engineered tumour cells, some types of 
cytokines found in the tumour microenvironment, such as 
IL-2, IL-3, IL-4, IL-7, IL-10, IFN-α, IFN-β, IFN-γ and 
TNFα, when sustainedly released by engineered tumour 
cells, resulted in the rejection of tumour cells and the 
establishment of a massive anti-tumour immune reaction 
(tumour immunoprevention) (Hirose et al., 1995). In most 
cases, this was accompanied by a decreased intratumoural 
microvessel density, increased infiltration of 
neutrophils, augmented CD4+ and CD8+ T cell proliferation 
and survival and finally induction of cell death in the 
tumour microenvironment. For example, in recombinant IL-2 
infusional therapy of cancer patients, there was a marked 
activation of neutrophils and a subsequent interaction 
with tumour and endothelial cells that results to tumour 
cell lysis (Blay et al., 1990; Gemlo et al., 1988). 
Another case is that of a 56-year-old patient with 
advanced hepatocarcinoma that was cured after treatment 
with granulocyte colony-stimulating factor (G-CSF), a key 
regulator of neutrophil production, providing in this way 
merit for the use of G-CSF in anti-cancer therapies 
(Lopez-Lazaro, 2006). In mice, tumour cells engineered to 
release G-CSF were directly killed by neutrophils, which 
were observed histologically forming prominent cytoplasmic 
projections in close contact with dead tumour cells well 




Eosinophils also possess an anti-tumour efficacy (Kataoka 
et al., 2004). In particular, IL-4 transfection in tumour 
cell lines of various histologic types appeared to prevent 
tumour formation via the infiltration of eosinophils and 
macrophages to the tumour site, while tumour formation 
reoccurred despite the presence of macrophages in 
eosinophil-depleted animals that received the IL-4 
transfected cancer cell lines (Rothenberg et al., 1995; 
Tepper et al., 1992; Tepper et al., 1989). This phenomenon 
was attributed to the cytotoxic activity of eosinophils 
and is further supported by the localised expression of 
eotaxin, an eosinophil-specific chemoattractant. Analogous 
results were observed in models of hepatocellular 
carcinoma, in which the co-operative expression of IL-5 
and eotaxin induced the antitumour activity of 
eosinophils. Because of the scarcity of these cell types 
in circulation, the exact tumour-killing mechanisms remain 
largely unknown.  
To sum up, it is evident that tumour establishment and 
progression, as it is until now evidenced by studies 
investigating the anti-neoplastic potential of 
neutrophils, is orchestrated by the intratumoural cytokine 
network (Coussens and Werb, 2002; Frederick and Clayman, 
2001). Moreover, the identification of the adhesion 
molecules participating in the tumour-PMN interaction will 
be very important for the exploitation of neutrophil 
effector systems as a form of immunotherapy (Allendorf et 
al., 2005). Indeed, it has been recently identified that 
PMNs increase the adhesion of circulating tumour cells to 
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microvascular endothelium via ROS production and in this 
way, set a first step to prevent metastasis by preventing 
tumour recurrence at distant sites (Ten Kate et al., 
2007). In addition, emphasis should be given on the fact 
that tumour progresses using a low immunogenicity dynamic 
equilibrium as a basis. Any distortion in the level of 
local inflammation from moderate to acute by disturbing 
the intratumoural cytokine availability seems to have 
detrimental effects at a first stage on endothelial 





Uncontrolled neutrophil influx is a characteristic of 
chronic inflammatory diseases that range from vasculitis 
and ischaemia reperfusion injury to glomerulonephritis, 
rheumatoid arthritis and acute graft rejection. In tumours 
though, uncontrolled neutrophil influx switches the 
balance from tumour progression to tumour rejection via 
the release of proteases, reactive oxygen species, 
membrane-permeabilisation agents and soluble mediators of 
cell lysis such as IFN-γ and TNF-α. Tumour cell lysis is 
also mediated by the release of hypochlorous acid (HOCl) 
from activated neutrophils that in turn reacts with 
primary amines to form chloramines with immunostimulatory 
properties (She et al., 1993) (Table 9).  
Accumulation of proteases and antimicrobial peptides has 
also been presented to lead to endothelial damage and 
matrix degradation. For instance, defensins, a family of 
antimicrobial peptides, are highly toxic against several 
tumours, whereas elastase and cathepsin G cause severe 
injury to endothelial cells (Ganz et al., 1985; Okrent et 
al., 1990; Westlin and Gimbrone, 1993). Another mechanism 
that accounts for neutrophil-mediated tumour lysis is 
antibody-dependent cell-mediated cytotoxicity (ADCC) that 
is augmented by GM-CSF administration in cases of melanoma 
and colorectal cancer (Kindzelskii and Petty, 1999). 
Moreover, as evidenced by histological analyses, 
neutrophil-mediated tumour cell killing is also associated 
to a local ischemic and/or haemorrhagic necrosis 
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(Hainsworth, 2000). Thus, unlike other inflammatory cells, 
neutrophil effector activities are not affected by the 
tumour immunoediting process and remain competent to exert 
their cytostatic effects once recruited to the tumour 
stroma.  
Based on these observations, recent anti-neoplastic 
studies have been directed to the identification of 
molecules or strategies that would stimulate neutrophil 
migration to the tumour stroma so as to increase local 
inflammation and consequently elicit an innate anti-tumour 
response (Di Carlo et al., 2001; Giovarelli et al., 2000; 
































In general, over the last decade, there has been an 
emerging effort to identify new anti-neoplastic approaches 
or increase the potency of the existing ones. Especially, 
new directions have focused on the use of agonists or 
blockers of TNF-α (Jackson, 2007), cyclooxygenase-2 (COX-
2) (Ragel et al., 2007), transcription factor activator 
protein 1 (AP-1) (Matthews et al., 2007), naturally-
occuring cytokines (van de Vosse and van Agtmael, 2007), 
tissue factor (TF) (Lwaleed et al., 2007), cJun-N-terminal 
kinases (Salh, 2007) as well as DNA vaccines in order to 
stimulate cytotoxic T lymphocyte activity (Lollini and 
Forni, 2002; Lollini and Forni, 2003; Stevenson et al., 
2002). However, neutrophils seem to represent the most 
promising and successful type of tumour therapy, as 
evidenced by an ever-increasing number of studies based on 
the anti-tumour effector activities of neutrophils. In 
most, if not all of these studies, there has been a 
complete eradication of the tumour (Dranoff et al., 1993; 
Suttmann et al., 2006). Notably, the exploitation of 
neutrophils as anti-neoplastic immune cells in these 
studies has a potent advantage over other inflammatory 
cells, as according to Carl Nathan (2006), “neutrophils 
might be especially valuable as anti-tumour effector cells 
when one considers their enormous numerical preponderance 
over tumour-specific cytoxic T cells ”. 
Some of the most recent strategies directed to trigger 
neutrophil recruitment to the tumour site are presented 
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below. Apart from the studies using cytokine engineered 
tumour cells as described before that aim at the 
distortion of intratumoural cytokine balance to elicit an 
inflammatory response, other relevant attempts have been 
made to create human tumour cells engineered to release 
neutrophil chemoattractant molecules such as IL-8, human 
MIP-1α and GROα (Hirose et al., 1995). For example, protein 
intratumoural transfer of neutrophil chemotactic molecules 
and other molecules such as FasL, 4-IBBL and TNF-α in the 
L5178Y lymphoma model resulted in a strong anti-tumour 
response and the acquisition of a long-term systemic anti-
tumour immunity (Liu et al., 2007). This was accompanied 
by an increase of tumour-infiltrating neutrophils, IL-12-
producing DCs, IFN-γ- producing CD4+ and CD8+ T cells and a 
decrease of intratumoural IL-10 producing Treg cells. 
Furthermore, knockout of IL-8 using RNA interference also 
was found to exert potent effects on tumour establishment 
and growth in oestrogen receptor (ER) positive and ER 
negative breast cancer models correlating to neutrophil 
influx (Yao et al., 2007).  
A dramatic transcriptional activation of neutrophil 
chemoattractant genes CXCL1 and CXCL5 was also found 
following the in vivo tumour killing activity of two 
oncolytic viruses: vesicular stomatitis virus (VSV) 
(Breitbach et al., 2007) and vaccinia virus. This effect 
was accompanied by an infiltration of neutrophils after 
chemokine induction, according to histological evidence 
from infected tumours. Based on this example, special 
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emphasis should be given on the use of bacterial and viral 
agents. Their use in anti-neoplastic therapy has been 
widely accepted as a mean to trigger neutrophil 
infiltration to the tumour site. For instance, 
systemically administered Salmonella choleraesuis in the 
ML-1 orthotopic tumour model was associated to increased 
infiltration of neutrophils and was marked by significant 
prolongation of animal survival, reduction of tumour size 
and upregulation of IFN-γ and IL-10 production (Lee et al., 
2008). Bordetella pertussis was also used recently as a 
vaccine vector in a tritherapy model and led to potent 
therapeutic immune responses against TC1 tumours in a 
murine model of cervical carcinoma. Again, tumour 
regression was marked by a large expansion of splenic 
neutrophils (Berraondo et al., 2007). In addition, the 
immunotherapeutic potential of tumour-specific phages to 
treat established solid tumours in a mouse model of 
melanoma (B16-F10, B16/ATK) resulted in a massive 
infiltration of neutrophils and a complete tumour 
regression and long-term survival in 50% of the mice 
(Eriksson et al., 2007).  
Recently, several molecular-based gene therapy approaches 
have also been developed. A characteristic example 
includes the overexpression of the C-terminal fragment of 
the human telomerase reverse transcriptase (hTERC27) via 
intratumoural injection of an adenoassociated virus that 
inhibited the growth and tumourogenicity of human cervical 
cancer HeLa cells as well as the growth of established 
human glioblastoma xenografts in nude mice (Ng et al., 
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2007). In both cases, this type of treatment was marked by 
profound necrosis, elevated infiltration of neutrophils 
and reduced microvessel density. Other examples involve 
the regulation of the levels of the apoptosis-inducing Fas 
ligand (FasL) in a variety of human cancers. Ectopic 
expression of FasL in experimental tumours triggered a 
neutrophil-mediated inflammatory response and tumour 
rejection, while FasL (low) tumours were found to grow 
faster in parental cells in mice that had acquired tumour-
specific immunity (Wada et al., 2007).  
Accordingly, in support of these studies, ongoing research 
using various chemotherapeutic agents highlighted the 
requirement of neutrophils to elicit an anti-tumour 
response. For example, topical treatment with the new 
anti-cancer agent ingenol-3-angelate (PEP005) induced the 
presence of neutrophils that were in turn required to 
prevent relapse of skin tumours (Challacombe et al., 
2006). In detail, PEP005 activated human endothelial cells 
in order to enable neutrophil adhesion and the release of 
tumouricidal reactive oxygen intermediates. Similarly, the 
use of anti-angiogenic molecules in the eradication of 
tumours has also been extensively studied. Plasminogen 
kringle 5 (K5) suppressed cancer growth in tumour 
xenograft models and on an immune competent model of 
breast cancer (Perri et al., 2007). Its activity involved 
the anti-tumour role of T lymphoid cells, accompanied by a 
significant decrease in tumour-associated microvessel 
length and density as well as a robust neutrophil 
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infiltration due to the neutrophil chemotactic activity of 
K5. 
All these studies indicate that further research is 
required to unravel the exact molecular mechanisms that 
enable neutrophil anti-tumoural activity and identify the 
molecules that tumour cells employ in order to prevent 
neutrophil recruitment. It is evident that the 
manipulation of the underlying mechanisms that induce 
neutrophil migration and their cytostatic responses can be 
very successful in order to decrease the rate of tumour 
proliferation and finally succeed in the total eradication 




The concept that inflammation promotes oncogenesis has 
long been established (Balkwill and Mantovani, 2001; 
Coussens and Werb, 2002; Frederick and Clayman, 2001; 
Monks et al., 2002; Talmadge et al., 2007; Wouters, 2005). 
Virchow, back in 1863, first hypothesised that the 
infiltration of leukocytes to tumours is a pivotal step 
for the origin of tumourigenesis and its link to 
inflammation. However in the last decade, novel approaches 
in tumour immunotherapy have revealed that inflammation 
can exert anti-tumour effects (Allendorf et al., 2005; 
Giovarelli et al., 2000; Lollini and Forni, 2002). Indeed, 
there is an ever-increasing number of studies that 
demonstrate that the presence of leukocytes within tumour 
tissues could elicit both pro- and anti-tumour mechanisms 
(Lehrnbecher et al., 2008; Lin and Pollard, 2004; Yu and 
Rak, 2003). In fact, the type and number of the immune 
cells infiltrating to the tumour stroma have mild anti-
inflammatory potential and indeed, they establish a 
symbiotic relationship to the tumour-contrary to 
inflammatory lesions- via the release of a plethora of 
proinflammatory cytokines as well as vascular epithelial 
growth factors.  
Therefore, contrary to inflammatory lesions, tumours do 
not display self-limiting processes for the clearance of 
the infiltrating immune cells and are thus fairly 
characterised as wounds that never heal, as they 
selectively direct the immune system in favour of their 
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development (cancer immunoediting) (Dunn et al., 2002; 
Lollini and Forni, 2003). This tight association of 
inflammation and tumourigenesis placed the presence of an 
immune response as a prerequisite for tumour 
establishment, as virtued by histological evidence on a 
wide range of solid tumour types, in which a high density 
of leukocytic infiltration is linked to increased 
prognosis (Dinarello, 2006; Graves et al., 1989; 
Lehrnbecher et al., 2008; Lin and Pollard, 2004; Yu and 
Rak, 2003). This is further strengthened by the fact that 
chronic inflammatory conditions or infections account for 
many malignancies e.g. colon carcinogenesis and 
inflammatory bowel disease (Crohn’s disease), thyroiditis 
and papillary thyroid carcinoma, H.pylori and stomach 
cancer, hepatitis C and liver cancer (Blaser et al., 1995; 
Crowe, 2005; Penn, 1999). Also, cells with DNA alterations 
due to chemical carcinogens do not allow tumour formation 
until exposed to a secondary stimulus such as chronic 
irritants or inflammatory agents. Perhaps the best 
evidence for the coupling of the chronic inflammatory 
condition with tumourigenesis is the reduced risk of 
colon, lung, oesophagus and stomach cancers in long-term 
users of aspirin and non-steroidal anti-inflammatory drugs 
(NSAIDs) (Baron and Sandler, 2000; Garcia-Rodriguez and 
Huerta-Alvarez, 2001). 
All these examples strengthen the assumption that 
immunocompromised individuals are protected from cancer. 
However, both animal and human studies have abolished this 
hypothesis, as immunity is necessary to combat a tumour at 
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its earlier stages, especially if this tumour arises as a 
result of a viral infection e.g. increased incidence of 
lymphoma in AIDS patients (Boshoff and Weiss, 2002; Gatti 
and Good, 1971). This forms the cornerstone of the 
“ cancer immunosurveillance ” theory and constitutes a 
protective response of a host organism towards malignant 
mutations. However, immunity turns out to be Damocles’ 
sword in favour of tumour establishment. This is supported 
by the principle of cancer immunoediting, as tumour cells 
are initially eliminated at the immunosurveillance stage 
and undergo selective pressure to establish tumour 
variants with low immunogenicity (Dunn et al., 2004). This 
process sculpts the immunogenic phenotypes of tumours and 
allows low immunogenicity tumours to establish and finally 
direct the immune cells towards malignant favour. In this 
way, the tumour enters a dynamic equilibrium, in which it 
not only avoids anti-inflammatory cytotoxic effects, but 
also manipulates immune cells via the secretion of 
chemokines, cytokines and growth factors (such as IL-10, 
VEGF) that promote vascularisation and tissue remodelling, 
reduced expression of MHC, NK and NKT cell recognition, 
rendering T cell anergy (Condeelis et al., 2005; Dunn et 
al., 2002; Smyth et al., 2001; Subramanian et al., 2007). 
Therefore, recent immunotherapies are orientated towards 
the distortion of this equilibrium and the switch of the 
nature of the immune system from tumour promoting to 
tumour regressing (Colombo and Mantovani, 2005; Lokich, 




In a developing neoplasm, the inflammatory component 
comprises a diverse immune cell population, e.g. 
macrophages, mast cells, dendritic cells and lymphocytes, 
all of which provide a diverse set of cytokines, 
metalloproteinases and growth factors that promote 
cellular proliferation, tissue remodelling, angiogenesis 
and influence DNA stability. Especially macrophages 
derived from circulating monocytes represent a major 
component of the infiltrated leukocyte population 
(Condeelis and Pollard, 2006; Murdoch et al., 2008).  
Tumour-associated macrophages (TAMs) are derived from 
circulating monocytes and constitute a key component of 
the infiltrating leukocytes in the neoplastic tissues 
(Table 10). Although their content in tumours varies 
between tumour types, the mechanisms that trigger monocyte 
recruitment to the tumour stroma remain common and 
sometimes involve even danger signals from apoptotic 
tumour cells. One well-characterised monocyte chemotactic 
factor is monocyte chemotactic protein-1 (MCP-1), a 12-kDa 
protein that is released by tumour cells and induces the 
synthesis of gelatinase, urokinase type plasminogen-
activator (uPA) that binds to the uPA receptor in 
monocytes, as well as of IL-1 and IL-6 by monocytes. 
Indeed, in human ovarian carcinomas there is a significant 
correlation between TAMs and MCP-1 expression (Bottazzi et 
al., 1992; Hildenbrand et al., 1999; Opdenakker and Van 
Damme, 1992; Valkovic et al., 1998; Zachariae et al., 
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1990). Other mediators that chemoattract monocytes to the 
tumour stroma involve MCP-2 (Graves and Jiang, 1995), MCP-
3 (Fioretti et al., 1998), GM-CSF (Fu et al., 1992), M-CSF 
(Bottazzi et al., 1990), vascular permeability factor 
(VPF) (Dvorak et al., 1991) and IL-12p40 (Ha et al., 
1999). CSF-1 (colony stimulating factor-1) is also 
implicated in macrophage recruitment to tumours, as in 
CSF-1 null mice, a failure to recruit macrophages to the 
tumour stroma has been noted. Restoration of CSF-1 
expression in CSF-1 null/PyM2 mice was linked to 
restoration of macrophage recruitment and tumour 
development and metastasis (Lin et al., 2002). CCL5/RANTES 
is another chemokine involved in TAMs infiltration, as the 
use of the Met-RANTES antagonist resulted in reduced 
macrophage infiltration and decreased tumour growth in a 
model of 410.4 mammary carcinoma (Robinson et al., 2003).  
Though the exact mechanism of action is still under 
investigation, the regulation of the activation phenotype 
of resident intratumoural macrophages is a characteristic 
example of the immunoediting process occurring upon tumour 
establishment. In the tumour microenvironment, infiltrated 
macrophages display an M2 phenotype (Biswas et al., 2006; 
Gordon, 2003; Karin and Greten, 2005; Mantovani et al., 
2004; Wyckoff et al., 2004). This type of phenotype, also 
known as alternatively activated macrophages, presents low 
IL-12, low IL-23 and high IL-10 levels and arises upon 
stimulation with IL-23, IL-4 and glucocorticoids. M2 
macrophages are tumour-friendly and accumulate mainly in 
the hypoxic areas of the tumour mainly in response to an 
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upregulation of hypoxia-dependent chemokine receptor 4 
(CXCR4) (De Palma et al., 2005; Mantovani et al., 2002; 
Murdoch et al., 2004). Classically activated macrophages 
(M1 phenotype) that mediate resistance against tumours are 
efficient producers of ROS and nitrogen intermediates, IL-
1 and IL-6, but have not been reported in the tumour 
environment (Verreck et al., 2004). This is further 
supported by a study using mice deficient in Src homology-
2-containing inositol 5-phosphate (SHIP) that displayed 
increased proliferation of transplanted tumours in 
association to spontaneous establishment of the M2 
polarisation phenotype (Rauh et al., 2005). TAMs produce 
pro-angiogenic growth factors, cytokines and proteases 
that have a positive effect on neoplastic progression, 
whereas when they are activated by IL-21 and IFN-γ, they 
promote immune responses that lead to neoplastic cell 
destruction (Reddy et al., 2003). In general, the presence 
of TAMs in tumours, such as breast and lung cancer, has 
been linked to increased angiogenesis, increased tumour 
growth and poor prognosis. In other words, there is a 
correlation between TAMs’ infiltration and malignant 
outcome, posing in this way the involved cytokines or 
chemokines as potential target in tumour therapeutics (Ali 
and Lazennec, 2007; Frederick and Clayman, 2001; Singh et 
al., 2007).  
Although no direct association between tumour apoptosis 
rate and the level of macrophage infiltration has been 
established, the role of apoptosis should not be 
undervalued as tumour cells have been shown to release 
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factors upon apoptosis induction that act as 
chemoattractants for monocytes. One of such factors is 
fractalkine, a glycoprotein that was recently identified 
to be released by apoptotic lymphoma cells and stimulate 
monocyte recruitment to the tumour stroma in vitro (Truman 
et al., 2004). Therefore, it seems that the regulation of 
the released cytokines could be a major determinant in the 
final outcome that promotes tumour growth or tumour 
regression. TAMs are pivotal players in both of these 
processes. They enhance tumour growth via the release of 
growth factors, such as EGF, PDGF and TGF-β, promote 
tumour invasion and dissemination, and enhance 
angiogenesis through the production of various cytokines 
(GM-CSF, TGF-α, TGF-β, IL-1, IL-6, IL-8) and the release of 
prostanoids (Leek et al., 1996; Salvesen and Akslen, 1999; 
Takanami et al., 1999). Prostanoids, such as 
prostaglandins E2 (PGE2) have also been demonstrated to 
pose an immunosuppressive effect to evade anti-tumour 
responses via cell-mediated immune mechanisms. Also, the 
fact that PGE2 was found to inhibit neutrophil 
recruitment, augments the role of this prostanoid in 
tumour immunosurveillance. In addition, TGF-β acts by 
inhibiting Th1 activity and thus cytotoxic T cell 
responses as well as NK cell and LAK (lymphokine-
associated killer) cell cytotoxicity (Akdis and Blaser, 
1999; Metzger et al., 1980; Young et al., 1992).  
By contrast, when infiltrated or resident macrophages 
become classically activated, they can be cytostatic or 
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cytotoxic for tumour growth. For example, phorbol 
myristate acetate (PMA) when used in combination with the 
calcium ionophore A23/8771 has been found to prime 
peritoneal macrophages and elicit an anti-tumour response 
(van Hilten et al., 1990). In general, the mechanism that 
classically-activated macrophages might promote tumour 
regression is via antibody-dependent cellular cytotoxicity 
(Fc receptor CD16) (Bonta and Ben-Efraim, 1993; De Young 
and Gill, 1984; Mantovani, 1994). They can also act 
synergistically with secretory products with cytostatic 
activity such as the eicosanoids PG, LTs, IL-1 and TNF-α 
cytokines to kill a range of tumour cells. Moreover, the 
release of free radicals (ROI, NO) can exert analogous 
tumour-regressive effects. It should be noted that in the 
case that macrophages impose such an inhibitory effect on 
tumour growth, the tumour itself activates a rescue 
homeostatic mechanism. Such mechanism involves the release 
of a plethora of tumour-derived molecules, such as TGF-β, 
macrophage-deactivating factor, PGE2, M-CSF, p15E, IL-4, 
IL-6 and IL-10; all of which suppress the cytotoxic 
effects of macrophages. Indeed, the activity of IL-18 and 
IL-12, which are macrophage-derived anti-tumour cytokines 
is modulated and compromised (Brunda, 1994; Micallef et 
al., 1996; Romagnani, 1992). A similar effect is observed 
with GM-CSF that might act as macrophage activator and 
proliferation molecule, as tumour macrophages become 
hyporesponsive to GM-CSF and stimulated to release IL-10 
that in turn, inhibits GM-CSF synthesis (Kato et al., 
1990; Sunderkotter et al., 1994; Walker et al., 1994). In 
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general terms, within a tumour site complementary 
mechanisms exist that subvert the host immune responses to 























In essence, the tumour itself orchestrates the 
inflammatory response and the nature of the infiltrating 
immune cells reaching its stroma. Apart from the direction 
of the immunogenicity of resident macrophages, tumours 
also have a direct effect on other cell types such as B, T 
lymphocytes, NK, NKT and dendritic cells. In the case of B 
cells, it has been shown that these cells contribute to 
oncogenesis in many animal models as well as in human 
studies in which tumour-specific antibodies were 
identified in cancer patients (Ammirante et al., 2010; de 
Visser et al., 2005; DeNardo et al., 2009; Gallimore and 
Simon, 2008; Karin, 2006; Mosser, 2003). Based on these 
studies, it was shown that B cells do not infiltrate the 
tumour lesion but are remote regulators of the 
intratumoural infiltration of other immune cell types via 
the deposition of immune complexes in the extracellular 
matrix of the tumour.  
Concerning other lymphocytes, there is a positive 
correlation between T lymphocytes in tumour stroma, 
especially CD8+ T lymphocytes and increased patient 
survival (Clark et al., 1989; Clemente et al., 1996; 
Kolbeck et al., 1992; Matsui et al., 1999; Naito et al., 
1998; Ohtani, 2007; Shimizu et al., 1999). Although this 
observation depends on tumour heterogeneity and varies 
among tumour types, a characteristic example is that of a 
model of skin tumourigenesis induced by 7, 12-
dimethylbenzantracene (DMBA) and 12-O-
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tetradecanoylphorbol-13-acetate (TPA) (Girardi et al., 
2001). In this model, γ/δ T-/- cell mice were more 
susceptible to tumour formation and papilloma-to-carcinoma 
progression than wildtype mice, while α/β T-/- cell did not 
present such an effect. A similar discrepancy also occurs 
in different types of NKT cells, as type I NKT cells 
enhance anti-tumour responses and type II NKT cells 
suppress these responses (Ambrosino et al., 2007; 
Kronenberg, 2005; Park et al., 2005; Smyth et al., 2000; 
Subleski et al., 2006). 
This paradoxical role of NKT cells is evident in a study 
using CD1d-/- mice (deficient in both type I and type II NKT 
cells) and Ja18-/- mice (deficient in type I NKT cells only) 
(Terabe et al., 2005). CD1d-/- mice were resistant to tumour 
growth, while Ja18-/- mice behaved similar to wild-type 
mice; an effect abrogated upon anti-CD4 treatment. These 
results indicated that the promotion of oncogenesis is 
established specifically by CD4+ type II NKT cells contrary 
to type I NKT cells. 
The ability of tumours to direct the local immune response 
away from an anti-tumour response is further validated by 
the systemic effect of the tumours on dendritic cells 
(DCs). Although DCs normally bridge innate with adaptive 
immunity, DCs in cancer patients display impaired function 
(Bell et al., 1999; Gabrilovich, 2004). Immature DCs are 
found in more than 90% of breast cancers, whereas in 60% 
of them, mature DCs are confined to the peritumoural areas 
surrounded by T cell clusters. Again, tumours interfere 
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with DC immunogenicity by means of the expression of 
tumour glycoproteins, e.g. mucin-1, carcinoembryonic 
antigen, arachidonic acid metabolites by viable and 
apoptotic tumour cells as well as by elevated VEGF and IL-
10 production that interferes with DC maturation rendering 
them tolerogenic and inducing tumour-specific anergy 
(Aarnoudse et al., 2006; Cambi and Figdor, 2005; Vlad et 
al., 2004). 
Moreover, apart from all the above-mentioned cell types, 
the role of mast cells and eosinophils in tumourigenesis 
has also been elucidated in recent years. Many types of 
cancer, such as non-small-cell lung cancer, colorectal 
cancer, breast cancer, pulmonary adenocarcinoma, basal 
cell carcinoma and colonic epithelial tumours are 
characterised by a vast infiltration of mast cells that 
become activated via CD30L and stimulated to migrate to 
the tumour site by the production of stem cell factor from 
tumour cells (Coussens et al., 1999; Diaconu et al., 
2007). Surprisingly, unlike the other types of immune 
cells, the presence of eosinophils in the tumour stoma is 
very scarce. Indeed, eosinophils have been reported to be 
present in some types of tumours such as Hodgkin’s 
lymphoma and colonic carcinoma however, there has been 
evidence supporting their anti-tumour role, as IL-4 
transfection in tumour cell lines of various histologic 
types prevented tumour formation via the infiltration of 






First discovered in milk almost 70 years ago, lactoferrin 
is an 80-kDa glycoprotein with non-haem iron-binding 
properties and is part of the transferrin family of 
proteins (Ward et al., 2005). It is mainly expressed in 
the secondary granules of neutrophils as well as in 
epithelial cells of the digestive and respiratory tracts 
and is found in exocrine fluids such as colostrum, bile, 
saline, tears, gastrointestinal fluids, vaginal fluid, 
semen, nasal secretions and urine (Figure 6A). In fact, it 
is the second most abundant protein in milk after caseins. 
It is secreted in the apo (non-iron saturated) form and 
its concentration varies from 1 g L-1 (mature milk) to 7 g 
L-1 (colostrum). In plasma, its concentration under normal 
conditions is as low as 0.4 – 2 ng L-1, whereas in septic 
conditions it can increase up to 0.2 g L-1 (Bennett and 
Kokocinski, 1978; Houghton et al., 1985; Masson et al., 
1969).  
The lactoferrin gene is highly evolutionarily conserved in 
mammals and displays extensive homology. At the 
chromosomal level, it is located at chromosome 3 in 
humans, while in mouse at chromosome 9. It is organised in 
17 exons, 15 of which are identical among species (Teng et 
al., 1987). The length of the gene varies widely, but it 
ranges from 23 kb to 35 kb, mainly due to deletions and 
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other mutations in the stop codon. Additionally, there are 
many regulatory molecules that control the expression of 
the lactoferrin gene, especially the ERE (estrogen 
response element) region located in the 5’ flanking region 
of the gene (Liu and Teng, 1992). The location and 
expression of ERE overlaps the binding site of the COUP 
transcription factor that acts as a negative regulator of 
oestrogen. Within a species’ mammary gland, lactoferrin 
gene activity is dependent on prolactin expression (Green 
and Pastewka, 1978), whereas the uterine lactoferrin gene 
expression is highly dependent on 17β-oestradiol treatment 
(Pentecost and Teng, 1987; Teng et al., 1989). The cDNA 
sequence for neutrophil human lactoferrin displays a 99.7% 
agreement to that of human mammary gland (Powell and 
Ogden, 1990; Rado et al., 1987).  
As a protein, lactoferrin encodes a mature protein of 692 
amino acid residues with a 19-amino acid signal peptide 
(Rejman et al., 1989; Rey et al., 1990). Among species, 
bovine lactoferrin is highly homologous to human 
lactoferrin (77%), mouse lactoferrin (72%), human 
transferrin (68%) and porcine transferrin (67%). In 
general, lactoferrin displays a very high homology (over 
85%) to other mammals, moderate homology to other 
vertebrates (e.g. 55% homology to zebrafish and 68% to 
chicken) and low or non-homology to nematodes and insects. 
However, the iron-binding domain of lactoferrin is 
evolutionarily conserved to invertebrates. Despite its 
high homology, its concentration among mammalian species 
varies (Masson and Heremans, 1971). For example, human, 
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pigs and mice milk are high in lactoferrin, while cow and 
other ruminant’s milk is low in lactoferrin content. Rat 
milk on the other hand has no lactoferrin at all. 
Lactoferrin is also even produced by fish, as evidenced by 
analysis of rainbow trout eggs.  
As defined by X-ray crystallographic analysis, lactoferrin 
consists of two highly homologous symmetrical globular 
lobes (N-lobe and C-lobe) that are linked by a protease-
sensitive α-helix at amino acids 333 and 343, which 
provides flexibility to the molecule (Figure 6B). In the 
polypeptide chain, amino acids 1-332 correspond to the N 
lobe, whereas amino acids 344-703 correspond to the C lobe 
(Anderson et al., 1987; Anderson et al., 1989). Each lobe 
structurally consists of an α-helix and β-pleated sheet 
structure with two domains (I and II). The binding region 
of each lobe incorporates iron in its ferric (Fe3+) form 
and one atom of bicarbonate (CO3
2-), an anion that is 
important for metal binding as its incorporation 
facilitates iron saturation. The metals that bind include 
iron (Fe2+ or Fe3-4+ ions), Cu2+, Zn2+ and Mn2+ ions; however, 
the binding of lactoferrin to iron is 2000-times more 
stable and stronger than to any other metal (Lonnerdal et 
al., 1985). The conformation of each lobe is different and 
the iron-affinity slightly varies. Lactoferrin can exist 
in its iron-free form (apo-LTF) or associated with Fe3+ 
(holo-LTF). Apo-LTF presents an open conformation, while 
holo-LTF is a closed molecule. In its apo-form (iron-free) 
the change in the conformation of the lobes has 
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consequences to the sensitivity of the molecule to 
proteases. The amino acids found in each lobe that are 
directly involved in the binding of iron include Asp, Tyr 
and His, while Arg is responsible for the interaction with 
the carbonate ion (CO3
2-) (Anderson et al., 1989).  
Also, what is characteristic of lactoferrin as a protein 
is its proteolytic resistance, as it can survive digestion 
by pepsin and pancreatic enzymes in the gastrointestinal 
tract and is excreted in the intact form (Brines and 
Brock, 1983; Brock et al., 1976; Goldblum et al., 1989; 
Hutchens et al., 1991). It is glycosylated at two sites, 
possesses intramolecular disulfide bonds and no free 
sulfhydryl groups. Distinct poly-N-acetyllactosaminic 
glycans are contained in both human milk-derived and 
neutrophil-derived lactoferrin.  
In comparison to human transferrin, human lactoferrin has 
a 60% identity as a protein with major differences in the 
surface-exposed sequences (Harrington, 1992; Metz-Boutigue 
et al., 1984; Park et al., 1985). Transferrin is an acidic 
molecule with a pI of 6.5, whereas lactoferrin has a pI of 
8.5-9 and is thus a basic protein. There are also 
differences in terms of iron stability of these two 
proteins as lactoferrin has a higher affinity and 
stability by retaining iron to pH values as low as 3, 
while transferrin releases iron at a pH of 5. The pepsin 
digestion of human lactoferrin between residues 1-19 and 
20-37 results in the generation of lactoferricin (LFcin), 
a peptide arising from domain N1 (Wakabayashi et al., 
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2003). LFcin has a β-sheet-α-helical structure of basic 
amino acid residue repeats, has a highly cationic nature 
and accounts for most of the bactericidal, anti-microbial 
and anti-inflammatory properties of the protein (Gifford 
et al., 2005; Valenti and Antonini, 2005). Lactoferrampin 
is another peptide close to LFcin that also possesses 
bactericidal activity (van der Kraan et al., 2004).  
Apart from its bacteriostatic properties that are 
attributed to its iron-binding activities, lactoferrin is 
a pleiotropic molecule with a wide spectrum of functions 
in a living organism (Ward et al., 2005). Its 
physiological roles range from regulation of iron 
homeostasis and host defense against microbial 
microorganisms to a plethora of anti-inflammatory 
functions, activity as a growth factor and against tumour 
development and metastasis (Baker and Baker, 2005; Ward 

















(A) Concentrations of lactoferrin under physiological and 
septic conditions.        (B) Crystal structure of 
lactoferrin. Lactoferrin consists of two highly-homologous 
symmetrical globular lobes [N-lobe (aa 1-332) and C-lobe 
(aa 344-703)] that are linked by a protease-sensitive α 
helix (aa 333-343). Each lobe consists of an α-helix and β-
pleated sheet structure with two domains (I and II). The 
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binding region of each lobe incorporates iron in its 
ferric (Fe3+) form and one atom of bicarbonate (CO3
2-).   
Functional Characteristics 
The most well-known activity of lactoferrin is the 
regulation of iron homeostasis (Ward et al., 2005). 
Indeed, excessive free iron in tissues turns out to be 
harmful, as it promotes microbial growth and cellular 
damage caused by free radicals. Lactoferrin is an iron-
binding molecule and thus, iron saturation restricts 
microbial multiplication. One of its roles is also the 
regulation of iron absorption, as evidenced by the high 
concentration of lactoferrin in breast milk, the 
absorption of iron in the neonatal intestine as well as 
the fact that lactoferrin survives the proteolytic 
mechanisms in the digestive tract and is excreted intact. 
Indeed, infants fed on lactoferrin-rich breast milk 
displayed a lower rate of iron absorption compared to 
those fed lactoferrin-free breast milk (Davidson and 
Lonnerdal, 1988). This observation supports the notion 
that lactoferrin transferred to the neonate via lactation 
acts primarily by controlling free iron in the gut and in 
this way limiting microbial pathogenesis and cellular 
oxidative damage. Lactoferrin is released from the 
circulation in its apo-form and this regulation of iron 
overload should be evaluated in neurodegenerative diseases 
that are characterised by increased deposits due to 
oxidative stress (Bullen, 1972; Fillebeen et al., 2001; 
Sanchez et al., 1992).  
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The bacteriostatic ability of lactoferrin is attributable 
not only to its iron-binding ability, but also to its 
ability to bind directly to the outer surface of the Gram 
negative bacteria; this induces the rapid release of LPS 
and increases membrane permeability and damage (Ellison et 
al., 1988). The similar and more potent effect is more 
evident by the peptide lactoferricin (Lfcin) that exerts 
negative effects on Gram negative, Gram positive bacteria, 
yeast, fungi, viruses etc. (Bellamy et al., 1992). 
Characteristically, lactoferrin prevents the biofilm 
formation of Pseudomonas aeruginosa by inhibiting 
bacterial twitching and attachment to epithelial cell 
surface (Singh et al., 2002). Moreover, oral 
administration of lactoferrin has been demonstrated to 
present host protective effects during septic shock, 
lethal bacteraemia and oral candidiasis (Takakura et al., 
2003; Valenti and Antonini, 2005). In a similar way, 
lactoferrin inactivates proteins required for the survival 
and colonisation of E.coli, H influenza, S.flexneri and 
others (Gomez et al., 2003; Ochoa et al., 2003; Plaut et 
al., 2000). In the case of viral infections, lactoferrin 
binds directly to glycosaminoglycan receptors, especially 
for heparin sulfate (HS) on viral surface (van der Strate 
et al., 2001). This binding prevents the contact between 
virus and host cell and thus prevents infection. This 
effect extends from human immunodeficiency virus and 
respiratory virus to hepatitis C and rotavirus (Groot et 
al., 2005; Seganti et al., 2004). Furthermore, treatment 
with bovine lactoferrin of guinea pigs that were infected 
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with the fungus Trichophyton mentagrophytes resulted in an 
apparent reduction of fungal infection on the skin of the 
back (tinea corpus) and limbs (tinea pedis) (Wakabayashi 
et al., 2000). Other studies show binding of human 
lactoferrin to the intracellular parasite Toxoplasma 
gondii and in this way, inhibiting the intracellular 
growth of the parasite within host cells (Dzitko et al., 
2007).  
Also, the bacteriostatic property of lactoferrin is 
enhanced by the anti-inflammatory effects of the protein 
and the stimulation of an immune response. For example, 
human lactoferrin transgenic mice displayed a better 
bacterial clearance than congenic littermates; something 
accompanied by inhibition of S.aureus growth as well as 
activation of the Th1 response (Guillen et al., 2002). The 
anti-inflammatory effect is mediated by changes in the 
cytokine profile expression as well as by promotion of T 
cell proliferation, as lactoferrin can act as an iron 
donor for maturing T cells. For instance, there was a 
marked upregulation in CD4 antigen expression following 
lactoferrin interactions with Jurkat T cells (Dhennin-
Duthille et al., 2000). Moreover, lactoferrin enhances 
phagocytosis against several bacteria and promotes the 
release of proinflammatory molecules such as TNF-α, IL-8 
and nitric oxide (Gahr et al., 1991; Kai et al., 2002; 
Shinoda et al., 1996; Sorimachi et al., 1997). It has also 
been shown to exert an adjuvant effect on delayed-type 
hypersensitivity as well as in the T cell response 
stimulated by BCG (Bacille Calmette-Gurein) vaccine (Hwang 
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et al., 2005; Zimecki et al., 2002). In herpes simplex 
virus I type infection in mice, lactoferrin enhances 
cytokine responses, whereas in hepatitis C infection 
lactoferrin stimulates Th1-response that favours the 
eradication of the infection based on IFN therapy 
(Wakabayashi et al., 2004).  
Lactoferrin as an Anti‐inflammatory Molecule 
A key question that arises is: given that lactoferrin is 
classically considered to be a marker of inflammation then 
how can it also be considered an anti-inflammatory 
effector molecue? In fact, lactoferrin secretion by 
neutrophils is a key event during an inflammatory response 
as well as in chronic inflammatory conditions. For 
example, in rheumatoid arthritis, there are increased 
lactoferrin levels in synovial fluid, whereas severe acute 
respiratory syndrome (SARS) infection is associated with a 
strong upregulation of lactoferrin gene expression 
(Caccavo et al., 1999; Reghunathan et al., 2005). Faecal 
lactoferrin is a marker of intestinal inflammation and 
therapeutic response in chronic inflammatory bowel disease 
and Crohn’s disease (Buderus et al., 2004; Kane et al., 
2003). Moreover, during neurodegenerative diseases that 
are linked to an activation of dopaminergic neurons, there 
is also an increased PMN degranulation and therefore, a 
dramatic increase in lactoferrin secretion (Kawamata et 
al., 1993; Leveugle et al., 1994).  
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However, the increase in lactoferrin levels is in parallel 
linked to the activation of an anti-inflammatory machinery 
that would eventually promote the resolution of the 
inflammatory condition. Indeed, lactoferrin has a 
suppressive effect on the synthesis of proinflammatory 
cytokines e.g TNF-α, IL-1 and IL-6 by resident activated 
monocytes or macrophages following LPS stimulation (Crouch 
et al., 1992; Mattsby-Baltzer et al., 1996). 
Simultaneously, lactoferrin stimulates the production of 
anti-inflammatory cytokines, such as IL-10 and IL-4 
(Togawa et al., 2002a). Interaction of lactoferrin with 
soluble CD14 inhibits IL-8 secretion (Elass et al., 2002), 
while suppression of TNF-α production further 
downregulates the secretion of the proinflammatory IL-6 
(Mattsby-Baltzer et al., 1996). For example, in adjuvant-
stimulated arthritis rat models, oral administration of 
lactoferrin inhibited TNF-α and stimulated IL-10 secretion 
(Hayashida et al., 2004). The interaction of lactoferrin 
with LPS and CD14 complex influences the activation of 
adhesion molecules on endothelial cells, such as E-
selectin, ICAM-1 and thus challenges neutrophil activation 
properties (Baveye et al., 2000). It has also been 
suggested that lactoferrin competes with IL-8 and other 
chemokines to bind to proteoglycans (Elass et al., 2002). 
On a similar basis, while lactoferrin is overexpressed in 
allergic patients, it can also inhibit an IgE-induced 
histamine release from human colon mast cells (He and Xie, 
2004). Other reported anti-inflammatory properties of 
lactoferrin involve NK cell activation, activation of 
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monocytes, activation of GM-CSF, stimulation of antibody-
dependent cell cytotoxicity and macrophage cytotoxicity as 
well as maturation of splenic B cells (Legrand et al., 
2005).  
Lactoferrin as a Growth Factor 
In normal tissues, lactoferrin expression is not organ-
specific, but in contrast, it is expressed by all organs. 
Its broad spectrum of secretion and its bacteriostatic 
activity place lactoferrin as a pivotal component of a 
homeostatic, anti-microbial mechanism. Indeed, lactoferrin 
is found in all tissues such as breast, stomach, pancreas, 
salivary gland, endometrium, spleen, prostate, liver and 
blood (Siebert and Huang, 1997). However, its expression 
is upregulated under specific conditions that are part of 
the normal function of a living organism and involve organ 
morphogenesis, lactation and involution of the mammary 
gland (Close et al., 1997; Masso-Welch et al., 2000; 
Rossiello et al., 1984; Wilde et al., 1997). 
The effect of lactoferrin on organ morphogenesis is 
illustrated by the regulatory role of lactoferrin in bone 
formation. More specifically, lactoferrin induces the 
development of osteoblast cells by promoting their 
proliferation and decreasing their apoptosis. This 
mitogenic effect of lactoferrin is mainly mediated via low 
density lipoprotein receptor related protein-1 (LRP-1) 
signalling (Cornish et al., 2004; Grey et al., 2004). In 
vivo, in mice in which lactoferrin (4 mg) had been 
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administered subcutaneously for 5 days, a marked 4-fold 
increase in bone mass was noted (Cornish et al., 2004). 
This mitogenic effect also implicates the p42/44 MAPK 
signalling pathway as an LRP-1 independent pathway and 
even extends to enterocyte formation, B and T lymphocyte 
expansion as well as macrophage development (Grey et al., 
2006). Although the physiological relevance of this 
mitogenic activity is still under investigation, it can be 
suggested that lactoferrin is an important contributor in 
terms of organ formation and bone development, based on 
its high levels of expression in a foetus.  
Lactoferrin and apoptosis 
 
During lactation, there is a variation of lactoferrin mRNA 
expression during the different lactation stages (Wang et 
al., 2005). On day 1 of lactation, lactoferrin is strongly 
expressed, whereas there is a gradual decrease in its 
expression from day 9 to day 17 of lactation. This is 
followed by a marked increase of lactoferrin expression on 
day 25. A cDNA microarray analysis on the expression of 
genes during the involution of bovine mammary gland 
further revealed a decreased mRNA expression of the milk 
protein genes of β-, κ-casein, α-lactalbumin and β-
lactoglobulin and a dramatic increase of the expression of 
lactoferrin 192 h post-milking (Singh et al., 2008). As 
the involution of the mammary tissue is dominantly 
characterised by elevated levels of apoptosis, the 
associated increase in the levels of lactoferrin provided 
initial insights that link lactoferrin to apoptosis. 
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Subsequent studies have demonstrated that lactoferrin 
induces apoptosis in hepatic epithelial cells via an iron-
dependent lysosomal death pathway in a process necessary 
for caspase-3 activation (Gorria et al., 2008). Similarly, 
in hepatocyte apoptosis induced by D-galactosamine, the 
levels of caspase-3 were elevated in the apoptotic liver 
cytoplasm and were accompanied by elevated serum 
transaminases (Katunuma et al., 2006). Although the 
involved molecular pathways are under investigation, it 
has been noted that the retinoid signalling cascade in 
cell growth and apoptosis in mammary cells upon 
lactoferrin treatment is implicated (Baumrucker et al., 
2006b).  
All these studies clearly demonstrate that lactoferrin is 
involved in the apoptotic process; however, they do not 
state that lactoferrin induces apoptosis. For example, in 
Jurkat T leukaemias, lactoferrin induced apoptosis via the 
regulation of c-Jun-N-terminal kinase (JNK) activity and 
via the activation of caspase-9 and caspase-3 (Lee et al., 
2009). An apoptosis-like cell death was also observed in 
Candida albicans that was characterised by PS 
externalisation, chromatin condensation, DNA degradation 
and increased ROS production (Andres et al., 2008). 
Similarly, lactoferrin peptides, like lactoferricin, exert 
a more potent effect as they promote apoptosis in 
oestrogen non-responsive MDA-MB-435 breast cancer cells 
(in association to C6 ceramide or tamoxifen) and in Jurkat 
T-leukaemic cells by sequential permeabilisation of the 
cell membrane and targeting of mitochondria. The observed 
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effect of lactoferricin was not attributed to the iron-
binding properties of the protein. This effect of 
lactoferricin extends to other human leukemias and 
carcinoma cell lines (Freiburghaus et al., 2009; Furlong 
et al., 2006; Iigo et al., 2004; Mader et al., 2007; Mader 
et al., 2005; Richardson et al., 2009). Also, the native 
Lf-B derived peptide (Pep1 –residues 17-34) that was 
highly cationic induced both apoptotic cell death and 
necrotic cell death in the leukemic cell line HL-60 
depending on its concentration (Onishi et al., 2008). 
Additional studies that support the role of lactoferrin in 
the induction of apoptosis include the apoptotic effect of 
pepsin-digested bovine lactoferrin in oral cancer cells 
via JNK/SAPK activation (Sakai et al., 2005) as well as 
the activation of the apoptosis-promoting Fas, Bid and Bax 
in the colon of azoxymethane-treated rats following 
lactoferrin treatment (Fujita et al., 2004a; Fujita et 
al., 2004b).   
Lactoferrin and tumour 
In comparison to healthy tissues, lactoferrin is also 
expressed in malignant tumours. Although its exact role in 
tumour development and metastasis is still under 
investigation, it is believed that it plays a key role in 
the regulation of the apoptosis levels observed in the 
tumour tissue, as well as in the proliferation of the 
tumour itself. For example, there is enhanced lactoferrin 
expression in human normal and neoplastic bone tissues, 
mainly in chondroblastomas, giant cell tumours (GCTs) and 
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osteoid osteomas (Ieni et al., 2009). Also, lactoferrin 
expression was observed in human sporadic renal cell 
carcinomas (Giuffre et al., 2007), in human astrocytomas 
and multiform glioblastomas (Tuccari et al., 1999), in 
colon carcinomas (Brock et al., 1994), in human breast 
cancer (Campbell et al., 1992), in Hodgkin’s disease and 
Burkitt’s lymphoma (Hoffer et al., 1979) and during the 
neoplastic transformation of the endometrium (Walmer et 
al., 1995) and of the endocervix (Giuffre et al., 2006); 
in the case of endocervix neoplasms, neoplastic formation 
correlates with downregulation of lactoferrin expression 
(Farley et al., 1997). Lactoferrin mRNA was also shown by 
RT-PCR analysis to be expressed by the promyelocytic 
leukaemia HL-60 cell line, T-lymphoblastic leukaemia 
Jurkat, breast tumour T41D, Burkitt’s lymphoma Raji, 
colorectal adenocarcinoma SW490 and erythroleukaemia K562 
cell lines (Hoffer et al., 1979; Siebert and Huang, 1997). 
Some forms of these tumour cells and tissues are 
characterised by a downregulation of lactoferrin levels 
and this is possibly attributable to differences in the 
methylation pattern of the lactoferrin gene and 
downregulation of its expression (Shaheduzzaman et al., 
2007; Teng et al., 2004). Moreover, its alternative splice 
variant, delta (Δ) lactoferrin, is not expressed in most of 
the tumours, implying in this way, that tumours evade host 
regulatory mechanisms in order to become established 
(Benaissa et al., 2005; Goldberg et al., 2005). The 
phenomenon of alternative splicing is also common in the 
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regulation of transcription factors such as c-Myc, GATA-1, 
prostate protein probastin and Pit1.  
The strong association of lactoferrin and development of 
normal and malignant tissues has given rise to the 
application of lactoferrin as a molecule that triggers 
anti-tumour responses. Indeed, oral administration of 
lactoferrin in a mouse intestinal mucosa inhibits 
carcinogenesis and metastasis (Iigo et al., 2004) as well 
as azoxymethane (AOM)-induced rat colon tumour formation 
and aberrant crypt foci development (Sekine et al., 1997a; 
Sekine et al., 1997b; Tsuda et al., 1998; Tsuda et al., 
2000). Specifically, when administered at doses of 100 or 
300 mg/kg/day, lactoferrin exerts an inhibitory effect on 
metastasis and tumour formation (Kuhara et al., 2000). 
Oral lactoferrin has also been widely reported to inhibit 
head and neck squamous cell carcinomas in vivo (McKeown et 
al., 2006; Wolf et al., 2007; Xiao et al., 2004). 
Injections of human lactoferrin were also found to inhibit 
the growth of solid tumours induced by v-ras transformed 
mice fibroblasts and methylcholanthrene-induced 
fibrosarcomas. Additionally, using B16-F10 melanoma cells, 
lactoferrin substantially reduced lung colonisation and 
experimental metastasis (Bezault et al., 1994). A similar 
effect was reported in vivo in colon carcinoma (Shimamura 
et al., 2004) and lung metastasis (Iigo et al., 1999) as 
well as in the Apc (Min) mouse model that is characterised 
by both familial adenomatous polyposis and sporadic colon 
cancer; in all cases, lactoferrin exerted an inhibitory 
effect on tumour growth (Ushida et al., 1998). 
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This effect of lactoferrin also extends to the stimulation 
of a chemopreventive effect. More specifically, iron-
saturated lactoferrin was found to be a potent natural 
adjuvant for augmenting cancer chemotherapy (Kanwar et 
al., 2008). Mice bearing EL-4 lymphoma, Lewis carcinoma or 
B16 melanomas that were fed with lactoferrin for 6 weeks 
prior to chemotherapy showed a complete rejection of 
tumours within 3 weeks following a single injection of the 
chemotherapeutic agent. On an analogous basis, in head and 
neck squamous cell carcinomas, combination therapy with 
oral recombinant human lactoferrin and cis-platinum 
resulted in a 79% growth inhibition of tumour; a 
statistically significant improvement compared to the use 
of each agent alone (Varadhachary et al., 2004). Moreover, 
lactoferrin was reported to reduce methotrexate-induced 
small intestinal damage.  
The anti-tumoural activity of lactoferrin is even 
conserved in the properties of lactoferrin-derived 
peptides. Treatment with lactoferricin resulted in an in 
vitro and in vivo decrease in the rate of cell 
proliferation of Caco-2 colon cancer cells as well as in a 
regression of MethA fibrosarcoma, B16 F10 melanoma and C26 
colon carcinomas. A similar effect was also observed by 
other lactoferrin-derived peptides such as L12 (Yang et 
al., 2004) that were active against the tumour cell lines 
MethA, HT-29 and MT-1 (Yang et al., 2002). Moreover, the 
intracellular delivery of the antimicrobial core of 
lactoferricin (RRWQWR –Lfcin B6) was reported to kill T-
leukemia cells (Richardson et al., 2009).  
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Despite the observed efficacy of lactoferrin and 
lactoferrin-derived peptides to trigger an anti-tumoural 
response in established tumours (Iigo et al., 2009; Yoo et 
al., 1998), there are attempts currently made to unravel 
the underlying molecular mechanisms. In most of the 
studies performed, lactoferrin activity has been shown to 
interfere with the cell cycle and induce a cell cycle 
arrest at the G1/S checkpoint. This negative effect on 
cellular proliferation mainly affects cell cycle 
regulatory proteins such as cyclin E, p21 and p27 Cdk 
inhibitory proteins that are associated with the Akt and 
MAPK pathways (Damiens et al., 1999; Xiao et al., 2004; 
Zhou et al., 2008). The apoptosis-promoting effect of 
lactoferrin might also molecularly account for its 
observed anti-tumoural effect by interfering for example 
with the Fas signalling pathway (Fujita et al., 2004a). 
Another recently identified mechanism for lactoferrin 
activity involves the activation of the NF-κB pathway and 
of the tumour suppressor p53, Mdm2 and p21 genes (Oh et 
al., 2004).  
Furthermore, the anti-tumoural efficacy of lactoferrin has 
broad implications on the activity of adaptive immune 
cells such as CD8+ and CD4+ T lymphocytes as well as NK 
cells; all of which become activated upon lactoferrin 
administration (Cao et al., 1999; Shau et al., 1992). For 
example, Balb/c mice transgenic for the rat neu (ErbB2) 
oncogene (BALB-neu T) showed tumour growth inhibition that 
was marked by an increase in intestinal mucosal IFN-γ 
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production along with an increase in Peyer’s patch 
cellularity. The overall effect was accompanied by an 
expansion of NK T cells and CD8+ lymphocytes and an 
enhancement of their cytotoxicity (Damiens et al., 1998; 
Spadaro et al., 2007; Wang et al., 2000b). This effect of 
lactoferrin is also mediated by IL-18, a key regulatory 
interleukin in tumour pathology, as lactoferrin 
upregulates IL-18 expression parallel to the activation of 
caspase-1 that is required to enzymatically cleave the 
active form of IL-18 (Cao et al., 1999; Iigo et al., 
2004). More importantly, the pepsin hydrolysate of bovine 
lactoferrin (bLfH) has been shown to upregulate IL-18 mRNA 
expression in mouse small intestine, which was also 
evident in the activity of bovine lactoferricin (bLfcin). 
In the same model, tumour growth and metastasis were 
inhibited by a simultaneous activation of the IFN-α/IL-7 
effector pathway (Iigo et al., 2009). Moreover, 
lactoferrin inhibits tumour-initiated angiogenesis both in 
vitro and in vivo; something that possibly accounts for 
the anti-angiogenic properties of IL-18 (Shimamura et al., 
2004). Specifically, in terms of the restriction of tumour 
angiogenesis, lactoferricin has been shown to inhibit 
basic fibroblast growth factor and vascular endothelial 
growth factor 165-induced angiogenesis by competing for 
heparin-like binding sites on human umbilical vein 





Lactoferrin is a highly cationic protein. Its cationic 
nature in combination with its high binding capacity as a 
protein, make lactoferrin receptors very difficult to 
identify definitely. Indeed, researchers over many years 
have attempted the detailed characterisation of 
lactoferrin receptors from various cell types with only 
partial success and many candidate receptors have been 
proposed for different cell types. In fact, different cell 
types or different tissues express their own lactoferrin 
receptors and their characteristics vary accordingly. 
Also, the involvement of “pseudo-receptors ” should not be 
excluded. Something that should be noted is that the 
molecular structure and function of these different 
lactoferrin receptors have not been elucidated yet. 
Elucidation of their characteristics would provide new 
insights on the exact role of lactoferrin in tissues. 
However, the lactoferrin receptors that have been 
characterised till now are expanded to the whole organism 
from brain to breast, small intestine, liver etc.  
Intestinal lactoferrin receptors 
Intestinal lactoferrin receptors (SI-LfRs) were first 
discovered in brush border membrane vesicles (BBMVs), to 
which human or bovine lactoferrin were found to bind in 
several organisms such as rats, rabbits and others with a 
dissociation constant (Kd) of 1 µM. Lactoferrin binding to 
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BBMVs was abrogated following addition of EGTA, whereas 
addition of Ca2+ enhanced the binding effect. Analogous 
studies on BBMVs in macacques showed that all forms of 
lactoferrin (apo, partial, holo lactoferrin) were able to 
bind to their specific receptor irrespective of its iron 
saturation however, holo-lactoferrin received a higher 
priority of binding. In mouse SI-LfR, the optimum pH for 
human lactoferrin binding was 5.5 and the binding process 
was Ca2+-dependent, while in human infant BBMVs, the 
binding of human lactoferrin had an optimum pH of 6.5-7.5 
and was saturable at protein concentrations of 0.2 to 16 
µM. Also, Kd was about 1 µM. Using HT-29 cell line as a 
model of human small intestine revealed a Kd of 60 nM (for 
high affinity binding sites) and 700 nM (for low affinity 
binding sites). Structurally, SI-mLfR had a molecular 
weight of 130 kDa, a pI of 5.8 and was composed of a 
single polypeptide chain with no subunits. On the 
contrary, human SI-LfR had a molecular weight of 114 kDa 
and several subunits of a molecular weight of 38 kDa. In 
terms of function, all SI-LfRs facilitate iron absorption 
by mediating the apical transport and not the basolateral 
transport of lactoferrin in the small intestine. In adult 
tissues, SI-LfRs are distributed in higher affinity in 
salivary glands, heart, adrenal glands, pancreas and 
skeletal muscle, whereas in fetal tissues, they are found 




Lactoferrin receptors in the liver (liver LfR1) were 
identified based on the rapid clearance of lactoferrin 
after an intravenous injection. In the liver, bound 
lactoferrin becomes internalised by hepatocytes and 
transported to lysosomes where it is degraded. Studies on 
rat parenchymal liver cells showed that the receptor in 
the liver for lactoferrin is LRP (LDL receptor-related 
protein) and is responsible for the binding of 
apolipoprotein E. Lactoferrin interacts with the 
extracellular domain of LRP via the arginine residues 
found in the sequence of lactoferrin. More specifically, 
LRP is comprised of an extracellular 515-kDa heavy chain 
and an 85-kDa light chain that passes through the cell 
membrane. The extracellular domain consists of four 
binding clusters (I-IV) and lactoferrin interacts with the 
second and fourth cluster. The binding of lactoferrin to 
LRP is Ca2+-independent and has also been implicated in 
bone formation and osteoclast survival. Apart from LRP, a 
Ca2+-dependent binding of lactoferrin also takes place; 
something that suggests the presence of a second 
lactoferrin receptor in the liver, the LV-LfR2, which was 
identified to be the RHL-1 subunit of the 
asialoglycoprotein receptor.  
Lymphocyte lactoferrin receptor 
Lymphocyte lactoferrin receptor (LC-LfR) was first 
identified in mitogen-activated lymphocytes and has a size 
of 105 kDa. The optimal binding pH was between pH 6.5 and 
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7.5 and its degree is irrespective of the iron saturation 
status of lactoferrin. The binding site is located in N-
terminal domain 1 and its function accounts for the effect 
of lactoferrin in B and T cell activation. A lactoferrin 
receptor is even characterised in megakaryocytes (PL-LfR) 
that was also involved in inhibition of platelet 
aggregation. Detailed characterisation proved that PL-LfR 
was identical to LC-LfR. 
Monocyte lactoferrin receptors 
Monocyte lactoferrin receptors (MC-LfRs) were first 
identified in mouse peritoneal macrophages and are 
implicated in iron turnover. The ability of lactoferrin to 
bind to soluble CD14 clearly proposed CD14, a 55-kDa 
glycoprotein, as an additional receptor on macrophages. 
Human lactoferrin binds to soluble CD14 with a high 
affinity (Kd: 16 ± 7 nM). The implication of CD14 possibly 
accounts for the anti-inflammatory effects of lactoferrin 
on monocytes. Moreover, using THP-1, a monocytic leukemia 
cell line as a model, four lactoferrin binding proteins 
were identified; 35 kDa, 35-37 kDa, 50 kDa and 80 kDa on 
the membrane of THP-1 cells; detailed structural 
characterisation of these proteins has not been carried 
out yet.  
In addition, the accumulation of high concentrations of 
human lactoferrin in neurons of Parkinson’s disease 
patients supported the involvement of a brain lactoferrin 
receptor that allows lactoferrin to pass the blood-brain 
barrier. Binding studies using bovine lactoferrin have 
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shown a high affinity binding site (Kd: 40 nM) and a low 
affinity one (Kd: 2 µM). Apart from brain capillary 
endothelial cells, lactoferrin receptors were also 
identified in human mammary epithelial cells from SV-40 
immortalised cell lines in non-malignant breast tissue, 
benign tumours and breast carcinomas as well as in the 
bovine mammary epithelial cell line MAC-T. Studies on 
BEAS-2B, a respiratory epithelial cell line of bronchial 
epithelium, also revealed the presence of lactoferrin 
receptors (BE-LfR). The upregulation of receptor 
expression by metals, such as iron, vanadium etc. 
supported the role of this receptor in reducing oxidative 
stress in the respiratory tract by forming complexes with 
the active, toxic metals.     
Neutrophil lactoferrin receptors 
In neutrophils, no distinct receptors for lactoferrin have 
been characterised so far. Scatchard analyses provided by 
Dr. Simon B. Brown (University of Edinburgh) confirmed 
previously published literature (Maneva et al., 1983; Spik 
et al., 1994) on the identification of two types of 
lactoferrin receptors on neutrophils. According to these 
results, it was evident that purified lactoferrin can 
directly associate with neutrophils, as scatchard binding 
analysis of 125I-labelled apo-lactoferrin indicated that 
lactoferrin binds to neutrophils via two classes of 
receptors that differ in affinity and number of binding 
sites per cell (Bournazou et al., 2009). The higher 
affinity receptors were determined to be expressed at a 
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density of 9,100 ± 2,500 binding sites per cell with an 
affinity of 350 ± 65 nM and the lower affinity receptors 
to be expressed at a density of 2.5x106 ± 0.7x106 per cell 
with an affinity of 20 ± 10 μM. Moreover, on eosinophils 
two classes of lactoferrin receptors were identified using 
125I-labelled lactoferrin with dissociation constants of 47 
nM and 260 nM (Thomas et al., 2002). However, in all 
cases, the detailed characterisation of the relative 
receptors as well as the molecular mechanisms underlying 
neutrophil and eosinophil inhibition by lactoferrin, 




Based on the characterisation of lactoferrin as a 
pleiotropic molecule, the aim of this thesis was to 
examine the effect of lactoferrin on granulocyte 
chemotaxis, how its expression is related to the 
proliferation of Burkitt’s lymphoma and how it is 
associated with apoptosis induction.  
Moreover, the next aim of this project was to place 
lactoferrin in an inflammatory context by linking its 
function to apoptotic and necrotic programs. The arising 
conclusions would provide clear insights on the role of 
lactoferrin in cellular proliferation and would allow the 







The following antibodies were used in this study: rabbit 
polyclonal anti–human lactoferrin IgG antibody (cat. no 
L3262; Sigma-Aldrich; Poole, Dorset, UK), mouse monoclonal 
anti–human lactoferrin antibodies (clone LF-2B8, murine 
IgG1, AbD Serotec, Kidlington, Oxford, UK; clone imab75, 
mIgG1, ImmunoSolv, Edinburgh, UK and clone imab77, mIgG1, 
ImmunoSolv), rabbit polyclonal IgG negative control (Dako 
Cytomation, Ely, Cambridgeshire, UK), mouse monoclonal 
IgG1 isotype control (MOPC21; Sigma-Aldrich), 
phycoerythrin (PE)-conjugated rat anti-mouse Ly-6G (GR1; 
RB6-8C5; eBioscience, Hatfield, UK), rat anti-mouse Ly-6G 
(GR1; rat IgG2b; eBioscience), PE-conjugated rat IgG2b 
isotype control (eBioscience), rat IgG2b isotype control 
(eBioscience), allophycocyanin (APC)-conjugated anti-human 
CD11b (ICRF44; BD Biosciences, Oxford, Oxfordshire, UK), 
fluorescein isothiocyanate (FITC)-conjugated anti-human 
CD62L (DREG56; BD Biosciences), APC-conjugated mouse IgG1 
negative control (MOPC21; BD Biosciences), FITC-conjugated 
mouse IgG1 negative control (AbD Serotec), mouse 
monoclonal anti-MAPK activated (diphosphorylated ERK1 and 
ERK2) antibody (MAPK-YT; Sigma-Aldrich), mouse monoclonal 
anti-human ERK2 (sc-81457; Santa Cruz Biotechnology, 
Heidelberg, Germany), horseradish peroxidase (HRP)-
conjugated goat anti-mouse immunoglobulin (Ig) 
(eBioscience) , rabbit monoclonal anti-human IκBα (E130; 
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Abcam, Cambridge, UK) and HRP-conjugated goat anti-rabbit 
Ig (Dako Cytomation).   
Unless otherwise stated, all reagents were obtained from 
Sigma-Aldrich. Nucleic acid extraction reagents were 
purchased from Qiagen (Crawley, West Sussex, UK) and 
magnetic separation reagents were from Miltenyi Biotech 
(Bergisch Gladbach, Germany) or from Qiagen. All SDS-PAGE 
reagents were purchased from Invitrogen, ECL and 
nitrocellulose membrane were from GE Healthcare (Bucks, 
Buckinghamshire, UK) and primers were obtained from MWG 
Biotech (Ebersberg, Germany). All PCR reagents were 
obtained from Promega (Southampton, Hampshire, UK) and 
reverse-transcription enzymes from Invitrogen. Unless 
otherwise stated, all reagents for immunohistochemistry 
were purchased from Dako Cytomation and Vector 
Laboratories (Orton Southgate, Peterborough, UK). 
Nucleocounter cassettes were from Chemometec (Epsom, 
Surrey, UK), Flow-Counter beads from Beckman Coulter (High 
Wycombe, Buckinghamshire, UK), Sepharose Fast FlowTM beads 
from Sigma-Aldrich, DNase I from Qiagen, FITC-conjugated 
recombinant human annexin V/propidium iodide (Anx/PI) from 
Arcus Biologicals (Modena, Italy), Fura 2/AM from 
Calbiochem (Beeston, Nottingham, UK) and Lipofectamine™ 
from Invitrogen. For leukocyte chemotaxis and activation, 
the following reagents were used: purified formyl-
methionyl-leucyl-phenylalanine (fMLP), recombinant human 
complement 5a (C5a), recombinant human interleukin 8 (IL-
8), phorbol myristate acetate (PMA) and leukotriene B4 
(LTB4) from Sigma-Aldrich, recombinant human eotaxin from 
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PeproTech (London, UK) and human TNF-α from R&D Bioscience 
(Abingdon, Oxfordshire, UK).  
Purified milk-derived human lactoferrin, recombinant human 
lactoferrin (partially iron saturated), purified bovine 
lactoferrin and purified human transferrin were all 
purchased from Sigma-Aldrich, purified neutrophil-derived 
human lactoferrin from Athens Research and Technology 
(Athens, Georgia, USA), while recombinant human apo-
lactoferrin (0.05 mg iron per g of protein) and 
recombinant holo-lactoferrin (1.4 mg iron per g of 
protein) were purchased from ProSpec Bio (Rehovot, 
Israel).    
Cell culture media and reagents were from Gibco Invitrogen 
(Paisley, Renfrewshire, UK) and PAA Laboratories 
(Pasching, Austria). X-vivo 20™ medium was purchased from 
BioWhittaker Cambrex (Cambridge, UK) and foetal bovine 
serum (FBS) from BioWest (West Sussex, UK). For bacterial 
cell culture, terrific broth (TB) and selection 
antibiotics were obtained from Sigma Aldrich. Luria 
Bertani (LB) media were prepared in house using reagents 
from Sigma Aldrich. 
Cell Isolation and Culture 
Cell lines and culture 
Unless otherwise stated, all cell lines were cultured at 
37oC (5% CO2) in a humidified atmosphere. The EBV-positive 
BL lines, Mutu and Wan, the EBV-negative BL lines, BL2 and 
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L3055 as well as the lactoferrin shRNA-expressing BL2 cell 
line and its shRNA negative control were cultured in RPMI 
1640 growth medium supplemented with 2 mM L-glutamine, 100 
IU ml-1 penicillin, 100 µg ml-1 streptomycin and 10% FBS. 
These cell lines retain the features of the parental 
tumour cells and display a characteristic cell surface 
phenotype of CD10+ CD77+ CD23- CD39-. Also, they lack Bcl-2 
protein expression and display a high apoptosis rate. 
BL2/bcl-2 cell line is a cell line stably transfected to 
express Bcl-2 protein and therefore displays a reduced 
apoptosis rate; however it was cultured in the same mode 
as the Mutu and BL2 cell lines. 
For proliferation assays, the EBV-positive BL cell lines 
Mutu and Wan and the EBV-negative BL cell lines BL2 and 
L3055 were used and were cultured in serum-free medium 
(1:1 X-vivo™ 20/RPMI 1640) supplemented with 2 mM L-
glutamine, 100 IU ml-1 penicillin and 100 µg ml-1 
streptomycin. Culture in serum-free medium (1:1 X-vivo™ 
20/RPMI 1640) occurred gradually by increasing its ratio 
vs. RPMI supplemented with 10% FBS.  
MCF7-caspase-3 (MCF7-C3) is an adherent breast cancer cell 
line transfected with caspase-3, so as cells to be able to 
undergo classical apoptosis. MCF7-C3 cell line was 
cultured in high-glucose DMEM (Dulbecco’s modified Eagle 
medium) supplemented with 2 mM L-glutamine, 100 IU ml-1 
penicillin, 100 µg ml-1 streptomycin and 10% FBS until 75-
80% confluent. Jurkat cell line is a T lymphoblastic 
leukaemia cell line cultured in RPMI 1640 growth medium 
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supplemented with 2 mM L-glutamine, 100 IU ml-1 penicillin, 
100 µg ml-1 streptomycin and 10% FBS.  
A549 lung cancer cell line is an adherent cell line 
cultured in high-glucose DMEM supplemented with 2 mM L-
glutamine, 100 IU ml-1 penicillin, 100 µg ml-1 streptomycin 
and 10% FBS until 75-80% confluent.  
293FT cell line used for the generation of lentiviral 
particles was cultured in high-glucose DMEM supplemented 
with 2 mM L-glutamine, 100 IU ml-1 penicillin, 100 µg ml-1 
streptomycin and 10% FBS. 
Neutrophil isolation 
Leukocytes were isolated according to the Royal Infirmary 
of Edinburgh (Scotland) Lothian Local Research Ethics 
Committee (approval 1702/95/3111 and 08/S1103/38). All 
volunteers were healthy and provided oral or written 
informed consent. Peripheral venous blood was drawn using 
a 19-gauge needle from an antecubital vein, immediately 
transferred to polypropylene tubes containing 12.9 mM 
sodium citrate and gently mixed. Citrated blood was 
centrifuged at 350g for 20 min in order to separate blood 
plasma from the cellular component. Platelet-rich plasma 
was then removed and used to prepare autologous serum in 
sterile glass tubes by recalcification of the plasma (CaCl2 
22 mM final concentration) and 1 h incubation at 37oC. 




Leukocytes in the remaining plasma-free blood component 
were then separated from erythrocytes by dextran 
sedimentation (0.6% w/v) (Pharmacia, Buckinghamshire, UK). 
After a 20-min incubation at room temperature, two 
separate layers were formed. The upper layer (leukocyte-
rich) was collected and cells were pelleted by 
centrifugation at 350g for 6 min. Three isotonic PercollTM 
gradient fractions (50%, 61%, 73%, Pharmacia) were 
prepared in phosphate buffered saline (PBS) (Ca2+/Mg2+-free) 
and once complete, the leukocyte-rich pellet was 
resuspended in the 50% Percoll gradient fraction and added 
on top of the two other isotonic gradients 61% and 73%. 
Following a 20-min centrifugation at 720g, mononuclear 
leukocytes were harvested from the 50%/ 61% interface, 
whereas the PMN leukocytes from the 61% /73% interface and 
washed twice in PBS (230g; 6 min). Cells were >99% viable, 
as assessed by trypan blue exclusion and unless otherwise 
stated, isolated cells were immediately used.  
Neutrophils represented >95% of isolated PMN cells, as 
assessed routinely by flow cytometry and cytospin 
analysis.  
Eosinophil isolation 
For eosinophil isolation, eosinophils (about 2-15% of 
total PMN population) were separated from freshly-isolated 
PMN leukocytes by negative selection using an 
immunomagnetic separation step with sheep anti-mouse IgG-
Dynabeads (Dynabeads M-450™, Invitrogen, UK) coated with 
the human CD16 antibody (clone 3G8), as described by 
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(Rossi et al., 1998). Dynabeads were coupled with the 
anti-CD16 antibody following incubation with the 
supernatant from 3G8 hybridoma cells (8x106 beads ml-1 of 
supernatant) at 4oC for 14 h. Unbound antibody was removed 
by washing the beads with ice-cold PBS (Ca2+/Mg2+-free). 
Freshly-isolated PMN leukocytes co-incubated with anti-
CD16 coupled beads were washed with PBS (Ca2+/Mg2+-free) 
three times. Isolated eosinophils were >98% pure and >99% 
viable, as assessed by cytospin analysis and trypan blue 
staining. 
Monocyte isolation 
Monocytes (>90% CD14+ cells) were positively selected from 
freshly-isolated mononuclear leukocytes using CD14 
magnetic beads (Miltenyi Biotec). In detail, mononuclear 
cell suspension was centrifuged at 300g for 10 min. Cell 
pellet was resuspended in PBS pH 7.2 containing 0.5% (w/v) 
bovine serum albumin (BSA) and 2 mM EDTA. CD14 MicroBeads 
were added and incubated for 15 min on ice. Cells were 
washed with PBS containing 0.5% (w/v) BSA and 2 mM EDTA 
and CD14+ cells were separated using the MACS magnetic 
column. Isolated cells were >90% CD14+ monocytes, as 
assessed by flow cytometry. Cell viability was >98%, as 
assessed by trypan blue exclusion. Isolated cells were 
used immediately for subsequent experiments.  
Generation of human monocyte‐derived macrophages (HMDMs) 
In order to obtain human monocyte-derived macrophages, 
mononuclear leukocytes (8-25% monocytes) were suspended at 
4x106 ml-1 in IMDM and incubated at 37oC for 1 h. Non-
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adherent cells were removed by vigorous washing with 
Hanks’ buffered salt solution (HBSS) (with Ca2+/Mg2+) 
medium. Adherent cells were cultured in IMDM containing 
10% autologous serum at 37oC for 6 days. Culture medium was 
replaced every 48 h. Monocyte-derived macrophages were 
phenotypically assessed by microscopy and/or by flow 
cytometry (CD14+ cells).  
Biochemical Analysis 
Size fractionation 
To determine the molecular weight of the inhibitory 
factor(s), size fractionation of the BL supernatant was 
performed using filters with specific molecular weight 
cut-off sizes [Amicon Bioseparations Centriplus 
Centrifugal filters YM-50 (50 kDa cut-off point) and YM-
100 (100 kDa cut-off point) Millipore (Watford, 
Hertfordshire, UK)]. The BL conditioned medium was 
obtained from BL2 cells (2x106ml-1) that were incubated in 
assay medium for 12 h at 37oC. Once incubation complete, BL 
cells were centrifuged at 400g for 10 min. For the size 
fractionation analysis, the BL conditioned medium was 
placed on the sample reservoir of the filtration unit and 
centrifuged at 3000g for 15 min. Filtrate (supernatant 
that passed through the filter, i.e. proteins that had 
lower MW size than filter) and retentate (supernatant that 
remained on top of the filter, i.e. higher MW size than 





To determine the pI of the inhibitory factor(s), an ion 
exchange chromatography was carried out using Sepharose 
Fast Flow beads (Sigma-Aldrich) with either positive (Q 
beads) or negative (S beads) charge. Prior to use, each 
bead type was washed with PBS and neutralising buffer (10 
mM Tris; pH 7.0) four times. BL supernatant or control 
medium (RPMI 1640 supplemented with 2 mM L-glutamine, 100 
IU ml-1 penicillin, 100 µg ml-1 streptomycin) was mixed with 
the beads and incubated at room temperature for 5 min 
under continuous agitation so as anionic or cationic 
proteins to stick to the surface of the corresponding 
beads (Q and S, respectively). Then, samples were 
centrifuged (300g, 5 min) and resulting supernatants were 
kept. Bound proteins were then eluted by adding the 
corresponding elution buffer (for S beads: 10 mM Tris, 0.5 
M NaCl; pH 10; for Q beads: 10 mM sodium acetate, 0.5 M 
NaCl; pH 4). Following a 5-min incubation at room 
temperature, beads were centrifuged (300g, 5 min) and 
supernatants were collected and analysed. Prior to 
chemotaxis analysis, the supernatants were diluted (1:100) 
and pH was adjusted to 7.0.   
MALDI‐TOF Analysis 
Supernatants from BL2 cells that were incubated in serum-
free medium (RPMI 1640, 2 mM L-glutamine, 100 IU ml-1 
penicillin, 100 μg ml-1 streptomycin) for 12 h were 
collected, centrifuged at 400g for 10 min and their 
protein content was precipitated using trichloroacetic 
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acid (TCA). TCA (100% w/v; 100 µl) was added in 1 ml 
conditioned medium at 4oC. Samples were centrifuged at 
20,000g and the pellets washed in ice-cold acetone. The 
pellet was resuspended in sample buffer (25 µl; non-
reducing conditions –NuPAGE, Invitrogen). Proteins were 
resolved by SDS-PAGE electrophoresis and selected proteins 
were identified by peptide mass fingerprinting using 
MALDI-TOF mass spectrometry. The procedure was carried out 
by the Scottish Instrumentation and Resource Centre for 
Advanced Mass Spectrometry (SIRCAMS), School of Chemistry, 
University of Edinburgh. 
In vitro Chemotaxis Assay 
In vitro leukocyte chemotaxis was determined based on a 
well-established transfilter migration assay using 
polyvinyl uncoated TranswellTM inserts (5 µm pore size, 
Costar Corning, Lutterworth, Leicestershire) (Truman et 
al., 2004). Leukocytes (1x105 cells -except for monocytes, 
2x105 cells) were added on top of the transwell filter and 
stimulated to migrate towards BL cells (at the indicated 
concentrations), conditioned cell media or lactoferrin (10 
µg ml-1, unless otherwise stated) that were placed in the 
lower chamber of the well (600 µl) in the presence or 
absence of a chemoattractant. Chemotactic agents used in 
the study, included fMLP (100 nM; Sigma-Aldrich), C5a 
(6.25 ng ml-1; Sigma-Aldrich), IL-8 (100 nM; Sigma-Aldrich), 
LTB4 (100 nM; Sigma-Aldrich) and eotaxin (100 nM; 
PeproTech). Time of incubation (37°C; 5% CO2) varied for 
cell type (neutrophils: 60 min; eosinophils: 60 min; 
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monocytes: 90 min; macrophages: 4 h). For neutralisation 
experiments, rabbit polyclonal anti–human lactoferrin IgG 
antibody or mouse monoclonal anti–human lactoferrin 
antibodies, rabbit polyclonal IgG negative control and 
mouse monoclonal IgG1 isotype control were used. Cells 
that had migrated through the filter were fixed in 
methanol and stained with Diff-Quick II (Dade, Germany). 
The number of migrated cells was determined by counting 
ten random high-power fields (magnification 400x) using an 
inverted microscope (Axiovert 25, Zeiss, Welwyn Garden 
City, Hertfordshire, UK) attached to a JVC KYF55B camera. 
Lactoferrin Absorption Experiments 
For lactoferrin absorption experiments, each 
chemoattractant [fMLP (100 nM), C5a (6.25 ng ml-1), IL-8 
(100 nM)] was incubated with purified human milk-derived 
lactoferrin (10 µg ml-1) in assay medium at 37oC for 15 min. 
A mouse monoclonal anti-human lactoferrin antibody (10 µg 
ml-1; LF-2B8; AbD Serotec) or isotype control [mouse 
monoclonal IgG1 isotype control (MOPC21; Sigma-Aldrich)] 
was added and samples were incubated at 4oC for 20-30 min. 
Samples were then added to the BioMag goat anti-mouse IgG 
particles (Qiagen) to completely remove the antibody. It 
should be noted that prior to use, BioMag particles were 
washed 2-3 times in assay medium. Samples were incubated 
at 4oC for 15 min under continuous agitation. Tubes were 
then applied to the magnetic separator for 5-10 min. Once 
separation was complete, the supernatant was carefully 
removed without disturbing the pellet and used in a 
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chemotaxis assay. The efficiency of antibody removal was 
assessed by analysing the pre-absorbed chemoattractants by 




The following shRNA MISSION lentiviral vectors (pLKO.1-
puro vectors; ampicillin- and puromycin-resistant; Sigma-
Aldrich) were used in this study so as to downregulate 
lactoferrin expression: TRCN0000047028 –Recognising 




CCCTACAAACTGCGACCTGTA-3’. Also, the plasmids pLP1, pLP2, 
pLP/VSV-G (ViraPower™ Lentiviral packaging mix; 
Invitrogen) were included for the generation of lentiviral 
particles. All plasmid maps and sequences are presented in 
the Appendix. 
Plasmid Extraction 
Plasmid extraction was performed using Qiagen Plasmid Maxi 
kit™ (Qiagen), based on manufacturer’s instructions. In 
detail, a single E.coli colony was inoculated in LB medium 
(5 ml; 37oC) that contained carbenicillin (100 µg ml-1) as a 
plasmid selection antibiotic. Cultures were incubated for 
8 h (37oC; 250 rpm) and further diluted (1:500) into 
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selective LB medium containing carbenicillin (100 µg ml-1). 
After a 15-h incubation at 37oC (250 rpm), culture was 
centrifuged (6000g; 15 min; 4oC) and bacterial pellets were 
resuspended in ice-cold Buffer P1 (10 ml containing RNase 
A). Buffer P2 (10 ml; Lysis buffer) was further added and 
cells mixed well several times by inversion. After a 5-min 
incubation at room temperature, ice-cold Buffer P3 (10 ml) 
was added in order to neutralise the lysis reaction. 
Lysates were incubated on ice for 20 min and then 
centrifuged (6000g; 30 min; 4oC) to remove cell debris. 
Supernatant was carefully transferred to new polypropylene 
tubes and further centrifuged (3400g; 15 min; 4oC) to 
remove any remaining cell debris completely.  
Supernatant was further applied onto a Qiagen-tip™ 500 
column. Prior to use, the column was equilibrated by 
adding Buffer QBT (10 ml). Once supernatant applied, the 
column was thoroughly washed by applying Buffer QC (60 
ml). Buffer QF (elution buffer) was further applied to 
elute the plasmid DNA. Isopropanol (10 ml) was added to 
the eluate and mixed thoroughly. Isopropanol-containing 
plasmid DNA was centrifuged (4000g; 30 min; 4oC), the 
pellet was resuspended in 70% (v/v) ethanol (5 ml) and 
further centrifuged for 10 min (4000g; 4oC). Supernatant 
was decanted and the DNA pellet air-dried and gently 
resuspended with sterile, nuclease-free water. Plasmid DNA 
was quantified spectrophotometrically and the OD260/OD280 
ratio was used to assess purity. Plasmid quality was 
further assessed by 1% (w/v) agarose gel electrophoresis 
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(UltraPureTM agarose; Invitrogen). Values of 1.9 were 
considered optimal. DNA was stored at -20oC.   
Generation of lentiviral particles 
The production of lentiviral stocks was performed 
following an optimised transfection protocol, as suggested 
by the manufacturer (Invitrogen). In detail, the day 
before transfection (Day 1), 293FT cells (5x106 cells in 10 
ml of DMEM growth medium containing 10% FBS) were plated 
in a 10 cm tissue culture plate so as to achieve 90-95% 
confluency on the day of transfection. No antibiotics were 
included in the medium. 
The following day (Day 2), the culture medium was removed 
from the 293FT cells and replaced with 5 ml of Opti-MEM 
ITMmedium containing serum, but no antibiotics. For each 
shRNA transfection sample, a separate pDNA-Lipofectamine™ 
LTX complex was prepared as follows: In a sterile 5 ml 
tube, 9 µg of the ViraPower™ Packaging Mix and 3 µg of 
shRNA plasmid DNA were diluted in 1.5 ml of serum-free 
Opti-MEM I medium and mixed gently. In a separate sterile 
5 ml tube, Lipofectamine™ LTX (36 µl) was diluted in 1.5 
ml of serum-free Opti-MEM I medium. Sample was mixed 
gently and incubated for 5 min at room temperature. Then, 
the diluted DNA and the diluted Lipofectamine™ LTX samples 
were combined, mixed gently and incubated for 20 min at 
room temperature to allow the DNA-Lipofectamine™ LTX 
complexes to form. The DNA-Lipofectamine™ LTX complexes 
were then added dropwise to each plate of cells and mixed 
gently by rocking the plate back and forth. Cells were 
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incubated overnight at 37oC in a humidified 5% CO2 
incubator.  
The next day (Day 3), the medium containing the DNA-
Lipofectamine™ LTX complexes were removed and replaced 
with 10 ml complete culture medium (without antibiotics). 
After 48 h post-transfection (Day 4), the virus-containing 
supernatants were harvested and placed into a 15 ml 
sterile tube. Supernatants were centrifuged (400g; 15 min; 
4oC) and stored in aliquots at -80oC. 
Lentiviral infection of BL2 cells 
BL2 cells were removed from culture, washed twice in PBS 
and resuspended in culture medium (RPMI 1640 growth medium 
supplemented with 2 mM L-glutamine, 10% FBS, 100 IU ml-1 
penicillin and 100 µg ml-1 streptomycin) at a concentration 
of 2x106 cells ml-1. Then, BL2 cells were plated on a 48-
well plate (2x105 BL2 cells per well). The supernatant 
containing the lentiviral particles was then added to the 
BL2 cells at a dilution of 2:1 (200 µl of supernatant) and 
1:1 (100 µl of supernatant). Infected BL2 cells were then 
incubated at 37oC (5% CO2). Stable cell lines were then 




Total RNA was extracted by using the RNeasy™ Mini-Kit 
(Qiagen), following manufacturer’s instructions. In 
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detail, 1x107 cells in suspension, as in the case of BL2, 
BL2/bcl-2 and Jurkat cells, were centrifuged at 300g for 5 
min, supernatant was removed by aspiration and pellet was 
disrupted by adding 350 µl of RLT Buffer [+ 1% β-
mercaptoethanol (β-ME)]. In adherent cells (A549 and MCF7-
C3; 5x106 cells), cell culture medium was aspirated, cells 
washed twice with PBS and disrupted by adding 600 µl of 
RLT Buffer (+1% β-ME) directly to the cell culture flask.  
In all types of cells, the resulting lysate was 
homogenised by passing the lysate at least five times 
through a 20-gauge needle (0.9 mm diameter) fitted to an 
RNase-free syringe. Ethanol (70% v/v) was added to the 
homogenised lysate (350 µl for cells in suspension; 600 µl 
for adherent cells) and mixed well by pipetting. Sample 
was transferred to an RNeasy spin column and centrifuged 
at 14,000g for 15 s. To increase RNA purity and eliminate 
genomic DNA contamination, an on-column DNase digestion 
process was carried out. Buffer RW1 (350 µl) was added to 
the RNeasy spin column and column was centrifuged for 15 s 
at 14,000g to wash the spin column membrane. DNase I stock 
solution (10 µl) was added to 70 µl Buffer RDD and mixed 
by gently inverting the tube. This DNase I incubation mix 
(80 µl) was then added directly to the RNeasy spin column 
membrane and samples were incubated for 15 min at room 
temperature. After 10 min, column was washed with Buffer 
RW1 (350 µl) and further centrifuged for 15 s at 14,000g. 
Column was subsequently washed with Buffer RPE (500 µl) 
twice. RNA was eluted from the column by the addition of 
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RNase-free water (50 µl) and a further centrifugation at 
14,000g for 1 min. Resulting RNA was quantified 
spectrophotometrically and the OD260/OD280 ratio was 
calculated. Values of 1.9-2.0 were considered optimal. RNA 
was stored at -70oC.   
RNA reverse‐transcription 
RNA (2 µg) was reverse-transcribed using SuperscriptTM III 
Reverse Transcriptase (Invitrogen) by the following 
reaction: 2 µg of RNA was added along with 3.8 mM oligodT 
(Promega, Southampton, Hampshire, UK), 0.78 mM dNTP mix 
(dATP, dTTP, dCTP, dGTP; Promega) and nuclease-free water 
to make a final reaction amount of 13 µl. Samples were 
incubated at 65oC for 5 min and immediately transferred on 
ice and incubated for at least 1 min. After a brief 
centrifugation, RNA was reverse-transcribed using 
Superscript III reverse transcriptase (Invitrogen), 
following manufacturer’s instructions. In each 13-µl 
sample, the following components were added: 5x First 
Strand Buffer, 7.6 mM DTT, RNase OUT recombinant RNase 
inhibitor and Superscript III reverse transcriptase (200 U 
µl-1). Reactions were mixed gently and incubated at 50oC for 
75 min. Reaction was terminated by heat-inactivation of 
the enzyme by incubating at 90oC for 10 min. Samples were 
stored at -20oC until used for PCR amplification analysis.  
PCR amplification 
Resulting cDNAs were used as template in PCR experiments 
in 50 µl (for GAPDH) or 25 µl (for lactoferrin) PCR 
amplification reactions. For GAPDH, the following primer 
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pair sequence was used: forward primer (5′-
CGACAGTCAGCCGCATCTTCTTTTGCGTCG-3′); reverse primer (5′-
GGACTGTGGTCATGAGTCCTTCCACGATAC-3′). For lactoferrin: 
forward primer (5′-TGTCTTCCTCGTCCTGCTGTTCCTCG-3′); reverse 
primer (5′-CTGCCTCGTATATGAAACCACCATCAA-3′). PCR 
amplification reactions for GAPDH were performed in 50 µl 
reaction volume containing: 1x GoTaq® Flexi Buffer, 1.5 mM 
MgCl2, 0.2 mM dNTP mix, cDNA (2 µl), 0.2 µM of each forward 
and reverse primer pair and GoTaq® Flexi DNA polymerase 
(2.5 U µl-1). PCR amplification reactions for lactoferrin 
were performed in 25 µl reaction volume containing: 1x 
GoTaq Flexi Buffer, 1.5 mM MgCl2 (1.5 µl), 0.2 mM dNTP mix, 
cDNA (2 µl), 0.4 µM of each forward and reverse primer 
pair and GoTaq Flexi DNA polymerase (2.5 U µl-1). Cycle 
parameters (for lactoferrin: 40 cycles; GAPDH: 28 cycles) 
involved a primer annealing temperature at 67°C 
(lactoferrin) or 50°C (GAPDH) for 1 minute, and extension 
at 72°C for 45 s. All PCR amplification conditions 
included an initial denaturation step at 94°C for 7 
minutes and a final extension step at 72°C for 5 minutes. 
PCR reactions were run on an MJ Thermal Cycler (Bio-Rad 
Laboratories, Hemel Hempstead, Hertfordshire, UK). PCR 
products were then analysed by agarose (2% w/v) gel 
electrophoresis. Gels were stained with ethidium bromide 
and visualised by UV illumination.   
DNA sequencing 
PCR products were purified using QIAquick™ gel extraction 
kit (Qiagen), according to manufacturer’s instructions. In 
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detail, the DNA fragment was excised from agarose gel with 
a clean, sharp scalpel. Excised gel fragments were 
dissolved by incubation at 50oC for 10 min in the presence 
of Buffer QG (3 volumes of buffer for 1 volume of gel). 
Isopropanol was then added (1:1 volume). Samples were 
mixed thoroughly and applied to a QIAquick column. Column 
was sequentially washed with Buffer QG (0.5 ml) and Buffer 
PE (0.75 ml) and centrifuged for an additional 1 min at 
14,000g to completely remove residual wash buffer. DNA was 
eluted with nuclease-free sterile water and incubated at 
room temperature for 1 min before centrifugation (14,000g; 
1 min). Purified PCR products were then sequenced by the 
Sequencing Service of the School of Life Sciences, 
University of Dundee, using Applied Biosystems BigDye 3.1 
chemistry on an Applied Biosystems model 3730 automated 
capillary DNA sequence analyser. For sequencing, the same 
set of primer pairs were used as those used for PCR 
amplification, i.e.forward primer (5′-
TGTCTTCCTCGTCCTGCTGTTCCTCG-3′); reverse primer (5′-
CTGCCTCGTATATGAAACCACCATCAA-3′). Chromatograph files were 
viewed and analysed using the Sequence Scanner Software 
v.1.0 (Applied Biosystems). 
In vivo BL Tumour Xenografts  
All animal procedures were carried out under a UK Home 
Office Animals (Scientific Procedures) Act 1986 project 
licence. For the BL tumour xenografts, six- to 10-week-old 
BALB/c SCID mice were injected i.p. with 107 BL2 cells. 
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Tumours developed i.p. within 2 months of injection. Mice 
were sacrificed and tumours excised. 
Immunohistochemistry 
An immunohistochemical staining to detect the presence of 
neutrophils on frozen slides of BL2 tumours in SCID mice 
(GR1+ cells) was carried out. In detail, the following 
protocol was carried out: slides (stored at -20oC) were 
allowed to reach room temperature for approximately 1 h 
prior to staining. Then, sections were washed in PBS and 
incubated in 0.1% (v/v) H2O2 for 30 s. Once loaded to the 
chamber, 3 drops of Vector Avidin Block were added per 
slide for 10 min followed by a PBS-wash and a further 
addition of 3 drops of Vector Biotin Block for 10 min. 
Dako serum-free Protein Block (3 drops) was further added 
followed by the addition of the primary antibody affinity 
purified rat anti-mouse Ly-6G (1:100; GR1; RB6-8C5; 
eBioscience) or affinity purified rat IgG2b isotype 
control (eBioscience) and a subsequent incubation for 12 h 
at 4oC. Slides were then washed twice with PBS and anti-rat 
biotin vector secondary antibody (125 µl) diluted in Dako 
ChemMate Antibody Diluent was added at a 1:200 
concentration and slides were incubated for 30 min at room 
temperature. Slides were then washed twice in PBS, 3 drops 
of Vector RTU Vectastain Elite ABC reagent were added and 
slides were further incubated for 30 min. After two wash 
steps with PBS, 125 µl of Dako DAB chromagen were added 
per slide and once complete, slides were removed from the 
chamber and counterstained with haematoxylin for 30 s. 
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Three wash steps with PBS were then carried out followed 
by a last step with distilled H2O. Tumour sections were 
dehydrated through incubation in alcohol (70%, 90%, 100%; 
5 min each) and finally soaked in histoclear (10 min) and 
mounting histoclear (10 min). Slides were mounted and 
allowed to dry for 12 h prior to their analysis by 
microscopy (Zeiss Axioskop 2 microscope).   
In vivo Model of Peritonitis 
For the peritonitis model, 8- to 12-week-old female 
C57BL/6 mice (n = 7 per group) were injected i.p. with 
purified human lactoferrin or transferrin (500 ng in 
saline/0.1% (w/v) BSA; Sigma Aldrich) or saline/0.1% BSA 
alone followed by a second i.p. injection with 1% 
thioglycollate (500 μl) or saline/0.1% (w/v) BSA after 20 
min. Recruited leukocytes were harvested after 4 h by 
peritoneal lavage with ice-cold saline containing 2 mM 
EDTA. Harvested cells were counted using a NucleoCounter™ 
(ChemoMetec), which excluded non-nucleated cells. Counting 
results were also confirmed using Flow-Count beads™ 
(Beckman Coulter). Red blood cells were lysed under 
hypotonic conditions. Harvested cells were suspended in 
PBS to the original lavage volume, mixed with pre-defined 
numbers of flow-count beads and analysed by flow 
cytometry. Cytospin slides were also prepared and the 
number of neutrophils was assessed microscopically. In 
addition, the percentage (%) of recruited mouse 
neutrophils was determined by GR1 immunolabelling. 
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Harvested cells were pelleted by centrifugation at 300g 
for 5 min and pellet was resuspended in PBS (Ca2+/Mg2+-free) 
containing 1% FBS and either PE-conjugated rat anti-mouse 
Ly-6G (GR1; RB6-8C5; eBioscience) or PE-conjugated rat 
IgG2b isotype control (eBioscience) was added. After a 20-
min incubation on ice, the number of GR1+ cells was 
recorded from the % of total cells by flow cytometry 
analysis (BD FACSCalibur). Data were analysed by CellQuest 
(BD Biosciences) or FlowJow (Treestar, Ashland, Oregon, 
USA).  
Time‐lapse Video Microscopy 
For video microscopy, freshly isolated neutrophils (106 ml-
1) were suspended in assay medium (RPMI 1640, 2 mM L-
glutamine, 100 IU ml-1 penicillin, 100 μg ml-1 streptomycin, 
0.1% bovine serum albumin) and incubated in the presence 
or absence of purified milk-derived human lactoferrin (10 
µg ml-1; Sigma-Aldrich) for 40 min at 37oC under continuous 
agitation. Prior to video microscopy analysis, fMLP (1 µM) 
was added and neutrophils were incubated at 37oC for 10 
min. Images were captured every 5 s over a 1-h time 
course. During the time of video microscopy analysis, room 
temperature was stable at 37oC. Videos were created and 
analysed by QuickTime player. Criteria for neutrophil 
activation included the increased locomotion of 
neutrophils around the substratum, increased movement as 
well as changes in neutrophil morphology as activated 




Measurement of [Ca2+]i was performed according to the 
published protocol (McMeekin et al., 2006). Freshly 
isolated neutrophils were suspended (107 ml-1) in HBSS 
(Ca2+/Mg2+-free) and were incubated with 2 μM Fura2/AM 
(Calbiochem) at 37°C for 30 minutes. The cells were washed 
twice, resuspended at 2×106 ml-1 in HBSS (with Ca2+/Mg2+), 
incubated for an additional 30 min at 37°C in the presence 
of lactoferrin (10 μg ml-1), and then stimulated with fMLP 
(1 nM or 10 nM). [Ca2+]i levels were determined based on 
340:380 nm dual wavelength excitation in a PerkinElmer 
luminescence spectrometer at 37°C with constant stirring. 
Calibration was performed after each experiment using 
Triton X (Rmax) and EGTA (Rmin) (Rmax and Rmin are the maximum 
and minimum 340:380 fluorescence ratios, respectively). 
[Ca2+]i was calculated based on the 340:380 nm fluorescence 
ratio.  
Immunolabelling and Flow Cytometry 
Neutrophil activation status was assessed by quantifying 
the expression levels of two activation markers, CD11b and 
CD62L by flow cytometry. Neutrophils (5x106 per condition) 
were centrifuged at 300g for 5 min and incubated in the 
presence or absence of purified milk-derived human 
lactoferrin (10 µg ml-1) in PBS (Ca2+/Mg2+) for 40 min at 37oC 
under continuous agitation. Agonists were then added, 
samples were mixed gently and further incubated at 37oC for 
30 min. Agonists used included fMLP (Sigma-Aldrich), TNF-α 
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(R&D Bioscience, Abingdon, Oxfordshire, UK) and PMA 
(Sigma-Aldrich) at the indicated concentrations. Cells 
were immunolabelled with APC-conjugated anti-human CD11b 
(ICRF44; BD Biosciences) or FITC-conjugated anti-human 
CD62L (DREG56; BD Biosciences) and incubated for 30 min on 
ice. APC-conjugated mouse IgG1 negative control (MOPC-21; 
BD Biosciences) and FITC-conjugated mouse IgG1 negative 
control (AbD Serotec) were used as isotype controls. 
Samples were analysed by flow cytometry (BD FACSCalibur) 
and data analysis was performed using CellQuest (BD 
Biosciences) or FlowJow (Treestar). 
Proliferation Assay 
To determine BL cell proliferation, BL cells (control, 
shRNA-transfected for lactoferrin, shRNA-transfected 
negative control) were suspended in serum-free medium (1:1 
X-vivo 20/RPMI 1640) at a concentration of 0.5x106 ml-1 and 
incubated at 37oC (5% CO2) for 48 h. Unless otherwise 
stated, rabbit polyclonal anti-human lactoferrin IgG 
antibody, mouse monoclonal anti-human lactoferrin antibody 
(clone LF-2B8; mIgG1; AbD Serotec), rabbit polyclonal IgG 
negative control, mouse monoclonal IgG1 isotype control or 
purified milk-derived human lactoferrin were added at a 
final concentration of 10 µg ml-1. Cells were counted using 




A direct ELISA specific for lactoferrin was carried out by 
plating purified milk-derived human lactoferrin, purified 
bovine lactoferrin or purified human transferrin (Sigma-
Aldrich) at standard concentrations of 1.5 ng ml-1 to 200 
ng ml-1 in a 96-well plate (100 µl per well). Plate was 
incubated for 14 h at 4oC and washed twice with PBS 
(Ca2+/Mg2+-free) containing 0.1% (v/v) Tween-20TM and further 
blocked with 0.5% (w/v) BSA/0.5% (v/v) Tween-20TM for 1 h 
at room temperature. A variety of monoclonal mouse anti-
human lactoferrin antibodies were added per well and the 
plate was incubated for 1 h at room temperature. The plate 
was then washed twice with PBS (Ca2+/Mg2+-free) containing 
0.1% (v/v) Tween-20TM. HRP-conjugated goat anti-mouse IgG 
(eBioscience) was then added (1:1000 dilution) for 30 min 
at room temperature. Plate was then washed twice and 
developed with 3,3’5,5’ tetramethylbenzidine (TMB) 
containing 3% (v/v) H2O2 solution was added. Reaction was 
stopped with 1 M KCl and absorbance values (OD450) were 
recorded.   
Immunoblot Analysis 
To prepare neutrophil lysates, neutrophils (5x106 cells ml-
1) were incubated in the presence or absence of purified 
milk-derived human lactoferrin (10 µg ml-1) for 40 min at 
37oC, prior to their activation with fMLP (100 nM). 
Neutrophils were further incubated at 37oC under continuous 
agitation at the indicated time points. Neutrophils were 
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then centrifuged at 14,000g for 1 min and lysed with Tris 
buffered saline (TBS) containing protease inhibitor 
cocktail (Sigma-Aldrich), aprotinin, leupeptin, pepstatin 
A, 4-(2-aminoethyl)benzenesulfonyl fluoride, sodium 
orthovanadate, benzamidine, levamisole, and β-
glycerophosphate for 10 min on ice. After 10 min, NP-40 
was added to a final concentration of 1% (v/v) and samples 
were further incubated for 10 min on ice. Samples were 
then centrifuged (13,000g; 4oC, 20 min) and supernatants 
resuspended in 25 µl sample buffer (NuPAGE™, Invitrogen) 
and denatured under reducing conditions at 95oC for 10 min. 
Samples were then stored at 4oC and were used within 24 h. 
For TCA-precipitation of conditioned cell media, 
trichloroacetic acid (TCA; 100% w/v; 100 µl) was added in 
1 ml conditioned medium and samples were centrifuged for 
10 min at 13,000g; 4oC. Pellets were washed in ice-cold 
acetone and finally suspended in sample buffer (25 µl; 
non-reducing conditions –NuPAGE™, Invitrogen). 
For immunoblotting, samples were resolved by SDS-PAGE 
using 4-12% Bis-Tris gels (NuPAGE™; Invitrogen) and 
proteins were then electroblotted onto a nitrocellulose 
membrane (NuPAGE™; Invitrogen), blocked with 3% (w/v) BSA 
in PBS containing Tween-20 (0.1% v/v) for 1 h at room 
temperature and probed with mouse monoclonal anti-MAPK 
activated (diphosphorylated ERK1 and ERK2) antibody 
(1:1000; Sigma-Aldrich), polyclonal mouse ERK2 (1:1000, 
Santa-Cruz Biotechnology) or mouse monoclonal anti-human 
lactoferrin antibody (1:100; LF-2B8, AbD Serotec) in 0.5% 
(w/v) BSA/0.5% (v/v) Tween-20 overnight at 4oC. Membrane 
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was further washed with PBS containing 0.1% (v/v) Tween-20 
for 30 min at room temperature and incubated with 
secondary antibody (HRP-conjugated goat anti-mouse Ig 
1:2000 in 0.5% (w/v) BSA/0.5% (v/v) Tween-20 (Amersham, 
Little Chalfont, Buckinghamshire, UK) for 1 h at room 
temperature. After subsequent wash-up steps for 30 min, 
membrane was visualised using enhanced chemiluminescence 
(ECL, GE Healthcare). 
For IκB immunoblot analysis, same protocol was followed; 
however, rabbit monoclonal anti-IκBα (1:2,500; E130; Abcam) 
was used as a primary antibody followed by HRP-conjugated 
goat anti-rabbit Ig (1:2,500; Dako Cytomation).  
Induction of Apoptosis and Primary Necrosis 
Cell lines were induced to undergo classical apoptosis, 
according to the following protocol: Staurosporine (1 µM; 
Sigma-Aldrich) was added to BL2, BL2/bcl-2 and Jurkat 
cells that were suspended at a concentration of 1x106 cells 
ml-1 in serum-free medium (RPMI 1640 supplemented with 2 mM 
L-glutamine, 100 IU ml-1 penicillin and 100 µg ml-1 
streptomycin). Cells were gently mixed and incubated at 
37oC (5% CO2) for the indicated time points. In MCF7-C3 and 
A549 cells (60-70% confluent), apoptosis was induced by 
suspending the cells into serum-free high glucose DMEM 
medium (containing 2 mM L-glutamine, 100 IU ml-1 penicillin 
and 100 µg ml-1 streptomycin) and by adding etoposide (100 
µM; Sigma-Aldrich) or staurosporine (1 µM). Cells were 
incubated at 37oC (5% CO2) for 20 h (etoposide-induced) or 
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1 h (staurosporine-induced apoptosis). In order to prevent 
apoptosis in A549 cells, the pan-caspase inhibitor zVAD-
fmk (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- 
fluoromethylketone; Sigma-Aldrich) was added in serum-free 
high glucose DMEM medium (containing 2 mM L-glutamine, 100 
IU ml-1 penicillin and 100 µg ml-1 streptomycin) at a 
concentration of 100 µg ml-1. Cells were then incubated at 
37oC (5% CO2) at the indicated time points.  
BL2 cells were induced to become necrotic by suspending 
them (1x106 cells ml-1) in serum-free medium and incubating 
them at 56oC for 1 h. Apoptosis or necrosis were assessed 
by trypan blue exclusion and/or annexin V/propidium iodide 
(Anx/PI) staining.  
Quantification of Apoptosis and Cell Cycle Analysis 
Apoptosis in leukocytes or cell lines used in this study 
was determined by annexin V/propidium iodide (Anx/PI) 
staining. Cells (1x105) were centrifuged at 400g for 10 min 
and pellet resuspended in the Anx/PI buffer provided by 
Arcus Biologicals. Annexin V was added to the cell 
suspension and incubated for 10 min on ice. Anx/PI buffer 
(0.5 ml) was then added to the cell suspension and 
propidium iodide (PI; 10 µl) was added prior to flow 
analysis (BD FACSCalibur). 
For cell cycle analysis, harvested cells were washed twice 
with PBS (Ca2+/Mg2+-free) and pellets were fixed in cold 70% 
(v/v) ethanol that was added dropwise to the cell pellet 
to minimise clumping. Cells were fixed for 30 min at 4oC or 
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stored for 2-3 days in the cold room. At the day of the 
cell cycle analysis, cells were washed twice in PBS 
(Ca2+/Mg2+-free) and further treated with ribonuclease by 
adding 50 µl of RNase (100 µg ml-1; Sigma-Aldrich) to 
ensure that only DNA was stained. Before flow analysis, 
200 µl of propidium iodide (50 µg ml-1; Sigma-Aldrich) was 
added to each sample. Samples were analysed by flow 
cytometry and data were analysed by CellQuest (BD 
Biosciences) or FlowJow (Treestar).  
Statistical Analysis 
Unless otherwise stated, results from multiple experiments 
are presented as mean ± standard error of the mean (SEM). 
One-way analysis of variance (ANOVA) was performed to test 
for differences in the mean values of quantitative data 
and where statistically significant effects were observed, 
Bonferroni post-hoc test was performed. In all cases, p 
values of 0.05 or less were considered statistically 
significant. Data analysis was performed with GraphPad 






The initial aim of this work was to address whether 
apoptotic cells influence the migratory activity of 
neutrophils, based on the observation that neutrophils are 
absent from sites where homeostatic apoptosis rates are 
high accounting in this way for the anti-inflammatory 
nature of the apoptotic program (Kerr et al., 1972; Serhan 
and Savill, 2005). To this end, a series of in vitro 
Boyden-type chemotaxis assays were carried out in order to 
investigate neutrophil migration towards Burkitt’s 
lymphoma cells. As already mentioned, Burkitt’s lymphoma 
was initially employed as a model tissue for apoptosis, as 
this class of tumour cell population displays high levels 
of apoptosis, a property that is retained constitutively 
in the tumour-derived cell lines (Frost et al., 2004; 
Gregory et al., 1991; Soini et al., 1998b). As at all 
sites where homeostatic apoptosis rates are high, in 
Burkitt’s lymphoma, there is a marked infiltration of 
macrophages that engulf the apoptotic cells, giving rise 
to the typical “ starry sky ” histological appearance of 
this tumour (Truman et al., 2004). Macrophage infiltration 
is marked by the synthesis and secretion of cytokines that 
are commonly expressed by sites where homeostatic 
apoptosis rates are high and include fractalkine, IL-10 
and others (Ogden et al., 2005; Truman et al., 2008). 
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However, as evidenced by an immunohistochemical staining 
for the detection of GR1 granulocytic marker in Figure 7, 
no neutrophils are present in the BL stroma.  
In order to assess the effects of BL cells on the 
migratory activity of neutrophils in vitro, chemotaxis 
assays were carried out (Figure 8A), in which neutrophils 
were added to the top compartment of a transwell filter 
and stimulated to migrate towards the lower chamber 
containing BL cells (Mutu that are EBV+ or BL2 that are 
EBV-) at a concentration of 2x106 ml-1 in the presence of the 
powerful neutrophil chemoattractant formyl-methionyl-
leucyl-phenylalanine (fMLP -100 nM) (mean number of 
migrated neutrophils: 8.1 ± 1.68 towards Mutu cells, mean 
number of migrated neutrophils: 9.4 ± 1.31 towards BL2 vs. 
97.1 ± 6.68 towards fMLP control) (Figures 8B and 8C). 
Also as shown in Figure 8D, neutrophil chemotaxis was 
significantly inhibited in a concentration-dependent 
manner towards BL2 cells that were placed at the lower 
chamber of the filter at varying concentrations (0.5x106 
cells ml-1, 1x106 cells ml-1 and 2x106 cells ml-1). In all 
cases, 100 nM of fMLP were added to stimulate neutrophil 
migration (36.8% inhibition in neutrophil migration 
towards 0.5x106 cells ml-1; 50.8% towards 1x106 cells; 63.8% 
towards 2x106 cells).  
Subsequent chemotaxis assays were carried out using BL-
conditioned medium. In detail, BL2 or Mutu cells (2x106 
cells ml-1) were washed in PBS, resuspended in chemotaxis 
assay (serum-free) medium and incubated at 37oC (5% CO2) 
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for 12 h. Cells were then centrifuged at 400g for 10 min 
and supernatant was collected and used in chemotaxis 
assays. It was found that fMLP-stimulated neutrophils 
failed to migrate towards both types of BL supernatants at 
levels comparable to fMLP positive control (mean number of 
migrated neutrophils: 28.8 ± 1.6 towards BL2 medium; 27.6 
± 1.62 towards Mutu medium vs. 102.9 ± 3.6 towards fMLP) 
(Figure 9A). Similarly, a marked inhibition in neutrophil 
migration was also evident in further chemotaxis assays 
using supernatants obtained from BL2 cells over a 7-hour 
time course (17.4% inhibition in neutrophil migration (1 
h), 32.2% inhibition (3 h), 45.2% (5 h), 50.4% (7 h)) 
(Figure 9B). The release of the inhibitory factor appeared 
to be linked to the levels of apoptosis in the BL cell 
population, since the inhibitory activity was 
significantly lower in further chemotaxis assays using BL-
conditioned medium derived from cells overexpressing the 
apoptosis inhibitor Bcl-2, as compared with that of 
parental cells (Figure 9C). In detail, at the 5 h time 
point, the mean number of migrated neutrophils was 62 ± 
2.5 towards BL2 conditioned medium vs. 111.5 ± 3.7 
migrated neutrophils towards BL2/bcl-2 conditioned medium. 
In summary, it was evident that neutrophils are absent 
from the BL stroma due to an active mechanism and in 
particular, due to factors released by BL cells. The 
release of such factors seems to be related to the 

















Immunohistochemical analysis of neutrophils in (A) BL and 
(B) spleen (positive control) sections. Slides were 
stained to detect the presence of GR1 (granulocyte marker; 
affinity purified rat anti-mouse Ly-6G). Inset images 
represent isotype control (rat IgG2b isotype control). 
Original magnification: x400. It was revealed that 





(A) In a chemotaxis assay, neutrophils are added on top of 
a transwell filter and stimulated to migrate towards a 
chemoattractant or medium alone added on the bottom well 
of the assay (B) Representative images of stained 
Transwell filters (C) Neutrophil chemotaxis towards Mutu 
(EBV+ cell line; 2x106 cells ml-1) and BL2 (EBV- cell line; 
2x106 cells ml-1) assessed in the presence of fMLP (100 nM) 
n=3; *p<0.01 vs. fMLP control. (D) Neutrophil chemotaxis 
towards increasing concentrations of BL cells (0.5x106 
cells ml-1; 1x106; 2x106) assessed in the presence of fMLP 
(100 nM) n=3; *p<0.05 vs. concentration 0. Original 































(A) Neutrophil chemotaxis towards conditioned media 
obtained from BL2 and Mutu cells [2x106 cells ml-1 cultured 
in serum-free medium; 12 h; 37oC (5% CO2)]. n=3; *p<0.05 
vs. fMLP control. (B) Neutrophil chemotaxis towards 
conditioned media obtained from BL2 cells (2x106 cells ml-1) 
at the indicated time points n=3; *p<0.05 vs. fMLP (C) 
Neutrophil chemotaxis towards fMLP was analysed in the 
presence of conditioned media from BL2 control or BCL2-
transfected BL2 cells obtained following a 0- and 5-h 
incubation at 37oC (5% CO2) n=3; *p<0.05 vs. BL2 0 h; 
NS=non-significant vs. BL2/bcl-2 0 h; fMLP, formyl-
methionyl-leucyl-phenylalanine; hpf, high power field. 






Having established that BL cells actively release 
factor(s) that inhibit neutrophil chemotaxis, a series of 
assays were performed in order to biochemically 
characterise the inhibitory factor(s). Initially, it was 
determined whether the neutrophil migration inhibitory 
factor was heat-labile. In detail, BL2-conditioned medium 
(2x106 cells; 12 h incubation) was heat-treated (incubation 
at 100oC for 30 min) and subsequently used in a chemotaxis 
assay to determine neutrophil migration. As shown in 
Figure 10, heat inactivation completely abrogated all 
chemotaxis inhibitory activity in BL cell-conditioned 
medium, suggesting that the inhibitory factor(s) were most 
likely protein or heat-sensitive lipid mediators in 
nature. In an attempt to gain further insight into the 
biochemical nature of the factor(s) that BL cells secrete 
in order to exclude neutrophils from their environment, we 
then estimated the molecular weight range of the 
inhibitory factor(s) by using filters with molecular 
weight cut-off points of approximately 3, 10, 30, 50, and 
100 kDa. BL-conditioned media obtained after 24-hour 
incubation were fractionated and each fraction was 
examined in vitro using the neutrophil chemotaxis assay 
described above. The results revealed that fractions 
containing molecules of less than 50 kDa failed to display 
any inhibitory effect on neutrophil migration (Figure 
11A). In fact, the >50 kDa fraction retained the ability 
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to inhibit neutrophil migration (3.44 ± 1.31 mean number 
of migrated neutrophils; 56.52 ± 3.87 for fMLP control) 
and thus, it makes it clear that at least one factor had a 
molecular weight that ranged between 50 and 100 kDa. 
However, the use of 100 kDa filters revealed that both 
fractions (>100 kDa and <100 kDa) displayed an inhibitory 
effect on neutrophil migration (<100 kDa fraction: 32.6 ± 
1.5 migrated neutrophils; >100 kDa 11.2 ± migrated 
neutrophils vs. 62.3 ± 2.6 towards fMLP control; 82.0% 
inhibition for >100 kDa; 52.6% inhibition for <100 kDa) 
(Figure 11B), indicating that at least one factor has a 
molecular weight that ranges between 50 and 100 kDa. The 
presence of inhibitory activity in the filtrate of the 100 
kDa cut-off membrane is likely to result from (a) 
imprecise molecular weight cut-off of molecules in the 50–
100 kDa range, (b) complex formation through 
multimerisation of the 50–100 kDa factor or through 
interaction with other molecules, or (c) the existence of 
a distinct inhibitory activity of greater than 100 kDa. It 
should be noted that the selected isolation approach is 
skewed in favour of proteins and that additional low 
molecular weight (for example, lipid) mediators of 
neutrophil migration inhibition would not be identified by 
these procedures. 
To investigate further the biochemical properties of the 
retentate and filtrate of the 100 kDa cut-off membrane, 
the charge (pI value) of the migration-inhibitory activity 
was first determined by means of an ion exchange analysis 
of BL-conditioned media. In detail, specialised ion-
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exchange beads were used that were either positively (Q 
Sepharose beads) or negatively (S Sepharose beads) 
charged. In this way, proteins found in the BL supernatant 
were distinguished according to their charge, based on 
their ability to become bound to the oppositively charged 
beads.  
At a first stage, supernatants of BL cells cultured for 24 
h were analysed using negatively charged beads (S beads). 
Two fractions of the BL supernatants were obtained; S1: 
negative charged fraction that failed to become bound to S 
beads and S2: positively charged fraction of molecules 
bound to and eluted from the beads. These two fractions 
were used in neutrophil chemotaxis assays and it was 
revealed that neutrophil migration was significantly 
reduced compared to their corresponding control (43.5% 
inhibition for S1; 50.0% for S2) (Figure 12A). In summary, 
these findings clearly indicated the presence of a 
positively charged (cationic) or a negatively charged 
(anionic) inhibitory factor present in the BL supernatant. 
However, the possibility of an inhibitory factor of a 
neutral charge (pI about 7.0 –8.0) could not be excluded.  
At a second stage, based also on these observations, 
subsequent ion-exchange analyses of both fractions of the 
100-kDa filter were carried out. More specifically, 
positively charged beads were used (Q beads) in this case 
and analyses of the <100 kDa fraction presented an 
inhibitory effect in both the supernatant (positive 
charge) and the eluant (negative charge) of the Q beads. 
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In detail, the cationic fraction (Q1) showed a 50.3% 
inhibition, whereas the inhibition in the anionic one (Q2) 
was 29.0% compared to their corresponding controls (Figure 
12B). By contrast, analyses of the retentate (>100 kDa 
fraction) revealed that only the negatively charged eluant 
displayed significant activity in inhibiting neutrophil 
migration (51.5%), clearly indicating in this way that the 
inhibitory factor in the >100 kDa fraction possesses a 
negative charge.  
Collectively, these results indicate that at least two 
moieties with neutrophil migration-inhibitory activity 
were present in BL-conditioned medium: one of 50-100 kDa 
with positive pI and a second of 100 kDa or more and 
negatively charged. We then analysed the proteins released 
from BL cells in viable and apoptotic states by protein 
fingerprinting. Polypeptide bands of greater than 50 kDa 
were excised from a 10% SDS polyacrylamide gel. Tryptic 
peptides were gel extracted and a matrix-assisted laser 
desorption ionisation–time of flight (MALDI-TOF) mass 
spectrometric analysis was carried out (Figure 13 and 
Table 11). Also, given the crude biochemical 
characteristics described above, a candidate approach was 
then undertaken based on the proteins released from 
apoptotic BL cells. The factor released by BL cells that 
prevented neutrophil chemotaxis was identified to be 
lactoferrin. The identification of lactoferrin supported 
the findings of the biochemical approach carried out in 
this study, as lactoferrin is heat-sensitive, has a 
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molecular weight of 80 kDa, which is over 50 kDa, and is 















Chemotaxis assay of neutrophils towards BL-conditioned 
medium (2x106 BL2 cells ml-1; 12 h incubation in serum-free 
medium) that was heat-inactivated (100oC; 30 min). Results 
showed that no inhibition in neutrophil migration was 
evident towards heat-inactivated BL medium, compared to 
non-heat-inactivated control. n=3; NS vs. fMLP control; 
fMLP, formyl-methionyl-leucyl-phenylalanine; H-I, heat-









Conditioned media from BL2 cells cultured for 12 h were 
size fractionated using filters with (A) 50 kDa and (B) 100 
kDa molecular weight cut-off sizes. Unfiltered medium was 
included as control. The >50 kDa fraction retained the 
ability to inhibit neutrophil migration n=3 *p<0.001 vs. 
fMLP; fMLP, formyl-methionyl-leucyl-phenylalanine; hpf, 













Ion exchange analysis included the use of (A) S 
(negatively charged) and (B) Q Sepharose beads (positively 
charged) in order to distinguish positively and negatively 
charged molecules in the whole BL medium and in the <100 
kDa fraction respectively. Unbound molecules (S1 and Q1 
fraction) were collected, whereas bound molecules (S2 and 
Q2 fraction) were eluted from the beads. Neutrophil 
migration toward these fractions in the presence of fMLP 
(100 nM) was assessed. S and/or Q fractions of serum-free 
medium (no BL) were included as control n=2 for both A and 
B, *p<0.05 compared with the corresponding control; ANOVA 
was performed based on the mean number of migrating 
neutrophils per hpf for each condition; fMLP, formyl-
methionyl-leucyl-phenylalanine; hpf, high power field. 














MALDI-TOF mass spectrum for the tryptic digest of the 
peptide bands released from BL cells that were induced to 
become apoptotic (1 μM staurosporine). MALDI-TOF analysis 
was performed by Scottish Instrumentation and Resource 










































































Lactoferrin is a glycoprotein of approximately 75-80 kDa 
that belongs to the transferrin family of proteins due to 
its iron-binding properties (Ward et al., 2005). It is a 
well-characterised component of neutrophil secondary 
granules, lacrimal fluid, colostrum, saliva and mucosal 
secretions, in which it confers antibacterial activity. 
Apart from its role in iron metabolism, lactoferrin is a 
pleiotropic molecule, whose properties range from anti-
inflammatory to anti-microbial and anti-tumoural.  
In this study, lactoferrin was identified as a factor that 
inhibits neutrophil migration, as evidenced by chemotaxis 
assays, in which anti-human lactoferrin antibody was added 
to conditioned media from BL2 and/or from MCF7-C3, a 
breast cancer cell line, which is a caspase-3 transfectant 
of MCF7, known to constitutively express lactoferrin 
(Turner et al., 2003). In detail, addition of rabbit 
polyclonal anti-human lactoferrin IgG antibody abrogated 
the inhibitory effect compared to isotype control (mean 
number of migrated neutrophils towards BL medium+antibody: 
78.1 ± 1.32 vs. 8 ± 0.21 mean number of migrated 
neutrophils towards BL medium+isotype control in the 
presence of fMLP (100 nM); 92 ± 1.28 towards fMLP control) 
(Figure 14A). BL-conditioned medium was obtained following 
incubation of 2x106 cells ml-1 under serum-free conditions 
for 12 h. An analogous effect was also observed using 
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conditioned media from MCF7-C3 cells (2x106 cells incubated 
in 3 ml serum-free medium -mean number of migrated 
neutrophils: 98.1 ± 2.21 towards MCF7-C3 +antibody vs. 
30.3 ± 0.01 mean number of migrated neutrophils towards 
MCF7-C3 medium+isotype control in the presence of fMLP 
(100 nM); 110.8 ± 1.36 towards fMLP control), indicating 
in this way that the neutrophil migration-inhibitory 
activity is not restricted to BL cell-derived lactoferrin 
(Figure 16A).  
Moreover, subsequent chemotaxis assays were carried out 
using mouse monoclonal anti-human lactoferrin antibodies 
(LF-2B.8; AbD Serotec) as well as imab75 and imab77 
(Immunosolv), which also abrogated the inhibitory effect 
on neutrophil migration towards BL-conditioned medium. For 
LF-2B.8: mean number of migrated neutrophils towards BL 
medium + LF-2B.8 antibody: 72.1 ± 3.1 vs. 8.5 ± 0.21 mean 
number of migrated neutrophils towards BL medium + isotype 
control in the presence of fMLP (100 nM); 93.7 ± 4.2 
towards fMLP control (Figure 14B). When LF-2B.8 monoclonal 
antibody was added to MCF7-C3 medium: mean number of 
migrated neutrophils towards MCF7-C3 medium + LF-2B.8 
antibody was 109 ± 2.9 vs. 38 ± 1.2 mean number of 
migrated neutrophils towards MCF7-C3 medium+isotype 
control in the presence of fMLP (100 nM); 115 ± 2.6 
towards fMLP control (Figure 16B).  
A similar effect was observed using imab75 and imab77 
antibodies that were provided by ImmunoSolv and selected 
from a panel of monoclonal mouse anti-human lactoferrin 
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antibodies, based on their specificity to human 
lactoferrin in comparison to human transferrin and bovine 
lactoferrin, as assessed by a direct ELISA assay (Table 
12). For imab 75: mean number of migrated neutrophils 
towards BL medium + imab75 antibody: 88.8 ± 5.60 vs. 22.1 
± 1.21 mean number of migrated neutrophils towards BL 
medium+isotype control in the presence of fMLP (100 nM); 
88.3 ± 4.12 towards fMLP control (Figure 15A). For imab 
77: mean number of migrated neutrophils towards BL medium+ 
imab77 antibody: 102.3 ± 1.26 vs. 21 ± 0.81 mean number of 
migrated neutrophils towards BL medium+isotype control in 
the presence of fMLP (100 nM); 118.7 ± 6.3 towards fMLP 
control (Figure 15B). Therefore, when imab75 or imab77 
were added to the BL-conditioned medium, an abrogation of 
the inhibitory effect in neutrophil chemotaxis was 
observed vs. BL-medium control in the presence of fMLP.  
In order to provide additional support for the specificity 
of the observed lactoferrin effect, MCF7-C3 and BL2 cell 
lines were created that were transfected with a shRNA 
vector specific for human lactoferrin or with a mismatch 
control (Figures 17A and 17B). Thus, it was found that 
neutrophil chemotaxis towards supernatants obtained from 
BL2 cells transfected with shRNA vectors targeted against 
lactoferrin [2x106 cells ml-1; serum-free conditions for 12 
h at 37oC (5 % CO2)] was higher (mean number of migrated 
neutrophils: 87 ± 2.6 towards supernatants from LTF shRNA 
BL2 cells; mean number of migrated neutrophils: 53 ± 2.8 
towards shRNA mismatch (mm) control; 108 ± 2.3 towards 
fMLP control) (Figure 17C). A similar effect was observed 
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in chemotaxis assay towards conditioned medium obtained 
from shRNA MCF7-C3 cells transfected for lactoferrin (mean 
number of migrated neutrophils: 108 ± 1.2 towards 
supernatants from LTF shRNA BL2 cells; mean number of 
migrated neutrophils: 49 ± 2.8 towards shRNA mm control; 
119 ± 1.2 towards fMLP control) (Figure 17D).   
In an additional attempt to verify these results and 
provide further evidence on the role of lactoferrin in the 
regulation of neutrophil chemotaxis, the effect of 
purified milk-derived human lactoferrin towards fMLP-
induced neutrophil migration was in vitro assessed. In 
detail, varying concentrations of human lactoferrin were 
used ranging from 10 pg ml-1 to 100 μg ml-1 and neutrophil 
migration towards them was measured. It was observed that 
lactoferrin inhibited neutrophil chemotaxis in a bell-
shaped manner. Maximum neutrophil inhibition was observed 
at 10 μg ml-1 (84.8% inhibition), but even at a 106-fold 
lower concentration (10 pg ml-1), an inhibition in 
neutrophil chemotaxis was also evident (Figure 18A).  
Apart from milk, lactoferrin is also found in the 
secondary granules of polymorphonuclear neutrophils. 
Although both types of lactoferrin (milk-derived and 
neutrophil-derived) have been reported to possess no 
difference in terms of their functional properties, 
neutrophil-derived lactoferrin structurally lacks terminal 
fucose residues in the glycal chains necessary for binding 
to macrophages. In chemotaxis assays, it was found that 
the neutrophil migration-inhibitory effect was also 
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displayed by lactoferrin purified from human neutrophils 
(mean number of migrated neutrophils: 18.3 ± 0.12 towards 
neutrophil-derived lactoferrin; 17.2 ± 0.1 towards milk-
derived lactoferrin in the presence of fMLP vs. 119.2 ± 
2.1 migrated neutrophils towards fMLP control) (Figure 
18B). It should be noted that both types of purified 
lactoferrin used in this study were free of endotoxin 
contamination, as assessed by Limulus assay, and the 
observed inhibitory effect did not appear to be due to any 
lactoferrin-associated molecules such as LPS. Furthermore, 
the inhibitory effect in neutrophil migration by shRNA-
transfected BL cells- further supports the specificity of 
lactoferrin in promoting this inhibitory effect on 
neutrophils. In addition, lactoferrin exerted no toxic 
effects on neutrophils, as assessed by Anx/PI staining of 
control and lactoferrin-treated neutrophils (> 98% cell 
viability). 
Iron and iron-associated molecules have been previously 
shown to play an important role in many immunomodulatory 
functions. Indeed, suppression of IL-1 release by 
monocytes is observed by purified iron-saturated 
lactoferrin, whereas an inhibition of GM-CSF activity 
production by monocytes and macrophages correlated with 
the iron saturation status of lactoferrin (Broxmeyer et 
al., 1978; Broxmeyer et al., 1986; Zucali et al., 1989). 
Therefore, it was further examined whether differences in 
the iron saturation profile of lactoferrin affect its 
ability to inhibit neutrophil migration. Chemotaxis assays 
to determine neutrophil migration towards iron-depleted 
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(apo-form), partially iron-saturated, or fully iron-
saturated (holo-form) lactoferrin revealed that the level 
of iron saturation was not responsible for the observed 
inhibition in neutrophil migration, as in all cases, an 
inhibition of neutrophil chemotaxis was noted (Figure 19). 
Also, as lactoferrin belongs to the transferrin family of 
proteins sharing 74% sequence homology with transferrin 
(both of them are ~80 kDa cationic iron-binding 
glycoproteins) (Harrington, 1992; Metz-Boutigue et al., 
1984; Park et al., 1985), it was reasoned that, if the 
underlying neutrophil migration–inhibitory mechanism of 
lactoferrin was rooted in its ability to chelate iron, 
transferrin might show similar effects on neutrophil 
migration. To explore this possibility, chemotaxis assays 
were performed in which neutrophils were induced to 
migrate toward fMLP in the presence of partially iron-
saturated transferrin. The results showed that 
transferrin, unlike lactoferrin, had no effect on fMLP-
induced neutrophil chemotaxis (mean number of migrated 
neutrophils: 19.2 ± 0.8 towards purified lactoferrin + 
fMLP vs. 152 ± 1.8 towards purified transferring + fMLP) 
(Figure 19). These findings support the conclusion that 
the observed neutrophil migration–inhibitory effect is 
both lactoferrin specific and not related to the iron-
binding properties of the protein.    
Having established the inhibitory effects of lactoferrin 
on neutrophil chemotaxis in vitro, a murine peritonitis 
model was then used to assess the effect of lactoferrin on 
leukocyte recruitment in vivo. Lactoferrin and transferrin 
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were tested for their ability to affect thioglycollate-
induced leukocyte recruitment to the peritoneal cavity. At 
a first stage, the peritonitis model was optimised in 
terms of the concentration of thioglycollate to be used. 
For this reason, the effect of 1%, 2.5%, 5% and 10% 
thioglycollate was checked by injecting C57BL/6 mice with 
thioglycollate at 500 µl final volume. As shown in Figure 
20, thioglycollate caused a rapid recruitment of 
leukocytes following a dose-dependent mode compared to 
negative control and the recruited leukocytes were 
predominantly neutrophils (88.0%), as assessed by GR1 
marker expression. To test the ability of lactoferrin in 
this in vivo model, mice were injected with human 
lactoferrin (10 µg ml-1), human transferrin (10 µg ml-1) or 
saline alone, followed by a second injection with 1% 
thioglycollate, 20 min after the first injection. In the 
presence of lactoferrin, the total number of neutrophils 
recruited to the peritoneal cavity was reduced by 52.0% 
compared with control, whereas transferrin had no effect 
(3.6x106 ± 2.5 recruited cells harvested from lactoferrin-
treated mice; 8.3x106 ± 5.1 recruited cells from 
transferrin-treated vs. 7.2x106 ± 3.8 recruited cells in 
thioglycollate control) (Figure 21A). Lactoferrin reduced 
specifically the proportion and number of neutrophils 
migrating into the cavity but did not affect recruitment 
of other types of leukocytes in response to thioglycollate 
(2.1x106 ± 1.8 recruited GR1+ cells harvested from 
lactoferrin-treated mice; 6.1x106 ± 5.3 recruited GR1+ 
cells from transferrin-treated vs. 4.7x106 ± 2.2 GR1+ cells 
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in thioglycollate control) (Figures 21B and 22). These 
results demonstrate that, similar to its effect on 
neutrophil chemoattraction in vitro, lactoferrin is a 
potent inhibitor of neutrophil migration in vivo. 
It has been recently demonstrated that chemokines or 
factors that are known to attract neutrophils, like IL-8, 
also exert a chemorepulsive effect on them when used at 
low concentrations (Tharp et al., 2006). In order to 
investigate whether lactoferrin is one of such factors 
that promote neutrophil repulsion or acts by inhibiting 
neutrophil migration, chemotaxis assays were further 
carried out, in which lactoferrin (10 µg ml-1) was added to 
the upper chamber along with neutrophils. It was revealed 
that when added with neutrophils, neutrophils failed to 
migrate towards fMLP (100 nM) or even control medium at 
significantly lower levels, compared to neutrophils 
stimulated to migrate in the absence of lactoferrin 
(Figure 23A). This result also suggested that lactoferrin 
exerts a direct effect on neutrophils by inhibiting their 
migratory ability and not forcing them to migrate in all 
directions away from the chemoattractant; an activity that 
would have been predicted to result in a statistically 
higher number of migrated neutrophils in this assay.  
Moreover, pre-treatment of neutrophils with 10 µg ml-1 
lactoferrin (serum-free medium; 20 min; 37oC) followed by 
removal of lactoferrin via washing with PBS, resulted in 
the maintenance of the inhibitory effect of lactoferrin, 
despite its absence, and thus, a reduced number of 
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migrating neutrophils towards fMLP, compared to non-
lactoferrin treated control cells (mean number of migrated 
neutrophils: 31 ± 1.5 towards fMLP following lactoferrin-
pre-incubation; vs. 118.2 ± 3.9 mean number of migrated 
neutrophils towards fMLP, pre-incubated in the absence of 
lactoferrin) (Figure 23B). The fact that the inhibitory 
effect on neutrophil migration was evident after 20 min 
suggests that lactoferrin possibly acts on the 
intracellular signalling cascade of the cell by affecting 
NF-κB pathway or stimulating new protein synthesis.  
In summary, it was found that lactoferrin specifically 
inhibited neutrophil migration both in vivo and in vitro, 
as evidenced by neutralisation experiments, by shRNA-
mediated knockdown of lactoferrin expression in BL2 and 
MCF7-C3 cells as well as by experiments on a murine model 
of peritonitis.  





 Neutralisation experiments to determine neutrophil 
chemotaxis in the presence of (A) rabbit polyclonal anti-
human lactoferrin IgG antibody; n=3; *p<0.05 vs. isotype 
control; NS vs. fMLP anti-lactoferrin control (B) mouse 
monoclonal anti-human lactoferrin IgG1 antibody (clone LF-
2B8); or isotype control [rabbit polyclonal IgG negative 
control or mouse monoclonal IgG1 (MOPC21) isotype control] 
using media from BL2 cells [serum free-medium; 12 h 
incubation at 37oC (5% CO2)]; n=3; *p<0.05 vs. isotype 
control; NS vs. fMLP anti-lactoferrin control. In all 
cases, addition of anti-human lactoferrin antibody 
201 
 
abrogated the inhibitory effect on neutrophil migration. 
fMLP, formyl-methionyl-leucyl-phenylalanine; hpf, high 





Clone No  Human Lactoferrin  Bovine Lactoferrin  Human Transferrin 
1  +  +  + 
2  +  ‐  ‐ 
3  ‐  ‐  ‐ 
4  ‐  ‐  ‐ 
5  ‐  ‐  ‐ 
6  +  ‐  ‐ 
7  ‐  ‐  ‐ 
8  +  ‐  ‐ 
9  ‐  ‐  ‐ 
10  ‐  ‐  ‐ 
11  ‐  ‐  ‐ 
12  +  ‐  + 
13  ‐  ‐  ‐ 
15  ‐  ‐  ‐ 
16  ‐  ‐  ‐ 
17  ‐  ‐  ‐ 
18  ‐  +  ‐ 
19  ‐  ‐  ‐ 
20  +  +  + 
21  +  +  + 
22  +  +  ‐ 
23  +  +  ‐ 
24  +  ‐  ‐ 
25  +  +  + 
26  ‐  ‐  ‐ 
27  ‐  ‐  ‐ 
28  ‐  +  ‐ 
29  +  ‐  ‐ 
30  ‐  ‐  ‐ 
31  +  ‐  ‐ 
32  +  ‐  ‐ 
33  +  ‐  ‐ 
34  +  ‐  ‐ 
35  +  ‐  ‐ 
36  +  ‐  ‐ 
37  +  ‐  ‐ 
38  +  ‐  ‐ 
39  +  ‐  ‐ 
40  +  ‐  ‐ 
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41  +  ‐  ‐ 
42  ‐  ‐  ‐ 
43  ‐  ‐  ‐ 
44  +  ‐  ‐ 
45  +  +  + 
46  +  ‐  ‐ 
47  ‐  ‐  ‐ 
48  ‐  ‐  ‐ 
49  ‐  ‐  ‐ 
50  ‐  ‐  ‐ 
51  +  ‐  ‐ 
52  ‐  ‐  ‐ 
53  +  ‐  ‐ 
54  +  ‐  ‐ 
55  ‐  ‐  ‐ 
56  ‐  ‐  ‐ 
57  +  ‐  ‐ 
58  +  ‐  ‐ 
59  +  ‐  ‐ 
60  ‐  ‐  ‐ 
61  +  ‐  ‐ 
62  ‐  ‐  ‐ 
63  ‐  ‐  ‐ 
64  ‐  +  ‐ 
65  ‐  ‐  ‐ 
66  ‐  ‐  ‐ 
67  +  ‐  ‐ 
68  ‐  ‐  ‐ 
69  +  ‐  + 
70  ‐  ‐  ‐ 
71  ‐  ‐  ‐ 
72  +  +  + 
73  ‐  ‐  ‐ 
74  +  +  ‐ 
76  +  +  + 
77  ‐  ‐  ‐ 
78  ‐  ‐  ‐ 
79  +  +  + 
80  ‐  ‐  ‐ 







Νeutralisation experiments to determine neutrophil 
chemotaxis in the presence of (A) monoclonal anti-human 
imab75; n=3; *p<0.05 vs. isotype control; NS vs. fMLP 
anti-lactoferrin control and (B) imab77 IgG1 (in house 
prepared antibodies) or isotype control [mouse monoclonal 
IgG1 (MOPC21) isotype control] using media from BL2 cells 
[serum free-medium; 12 h incubation at 37oC (5% CO2)]; n=3; 
*p<0.05 vs. isotype control; NS vs. fMLP anti-lactoferrin 
control. In all cases, addition of anti-human lactoferrin 





migration fMLP, formyl-methionyl-leucyl-phenylalanine; 






Neutralisation experiments to determine neutrophil 
chemotaxis in the presence of (A) rabbit polyclonal anti-
human lactoferrin IgG antibody; n=3; *p<0.001 vs. 
fMLP/isotype control; NS vs. fMLP/anti-lactoferrin control 
(B) mouse monoclonal anti-human lactoferrin IgG1 antibody 
(clone LF-2B8) or isotype control [rabbit polyclonal IgG 
negative control or mouse monoclonal IgG1 (MOPC21) isotype 
control] using media from MCF7-C3 cells [serum free-
medium; 12 h incubation at 37oC (5% CO2)]; n=4; *p<0.001 
vs. fMLP/isotype control; NS vs. fMLP/anti-lactoferrin 
control. In all cases, addition of anti-human lactoferrin 
antibody (10 µg ml-1) abrogated the inhibitory effect on 





phenylalanine; LTF, lactoferrin; hpf, high power field. 













RT-PCR analysis to assess lactoferrin expression in BL 
cells (A) and MCF7-C3 (B) stably expressing lactoferrin 
shRNA and mock-transfected (mm) cells that were induced to 
become apoptotic (BL2: 1 µM staurosporine; MCF7-C3: 100 μM 
etoposide; 37oC). Images are representative of three 
independent experiments. (C) Chemotaxis assay to determine 
neutrophil migration towards conditioned media obtained 
from control, lactoferrin shRNA and mock-transfected BL 
cells (88.7 ± 1.2 migrated neutrophils towards LTF-shRNA 
vs. 53.7 ± 1.8 towards mm-shRNA control) n=3, **p<0.05 
compared with fMLP; NS=non-significant compared with fMLP 
control. (D) Chemotaxis assay to determine neutrophil 
migration toward conditioned media obtained from control, 
lactoferrin shRNA and mock-transfected MCF7-C3 cells n=3, 
**p<0.05 compared with fMLP; NS=non-significant compared 
with fMLP control; It was revealed that depletion of 
lactoferrin by an shRNA-mediated approach in both BL2 and 
MCF7- C3 cell line resulted in an abrogation of the 
observed inhibitory effect on neutrophil migration. fMLP, 
formyl-methionyl-leucyl-phenylalanine; LTF, lactoferrin; 








(A) Dose-response analysis of purified milk-derived human 
lactoferrin n=3 *p<0.05 vs. 0 g ml-1 purified lactoferrin 
+fMLP. (B) Neutrophil chemotaxis towards milk-derived or 
neutrophil-derived purified lactoferrin (10 µg ml-1), 
assessed in the presence of fMLP n=3 **p<0.001 vs. fMLP; 
fMLP, formyl-methionyl-leucyl-phenylalanine; LTF, 

















Chemotaxis assay to determine neutrophil migration towards 
purified recombinant iron-depleted (apo-), partially iron-
saturated and fully iron-saturated (holo-) recombinant 
lactoferrin (10 µg ml-1). Milk-purified lactoferrin and 
partially iron-saturated transferrin (10 µg ml-1) were used 
as control. In all cases, neutrophil chemotaxis was 
inhibited towards lactoferrin in the presence of fMLP, 
despite its iron saturation status. However, neutrophil 
migration towards transferrin, a homologous protein, was 
not inhibited. n=4; *p<0.001 compared to fMLP control; 
fMLP, formyl-methionyl-leucyl-phenylalanine; LTF, 
213 
 





















Total cell number harvested from peritoneal lavage after 
stimulation with different doses of thioglycollate (1%, 
2.5%, 5% and 10%). Mice (n=2 per thioglycollate dose) were 
injected with the indicated doses of thioglycollate and 
recruited leukocytes were harvested after 4 h by 
peritoneal lavage. (A) Total cell number was determined 
using a NucleoCounter™, which excluded non-nucleated cells 
and results were confirmed using Flow-Count beads™; n=1 
(B) Neutrophil number (GR1+) was determined by cytospin 
staining and GR1 immunolabelling (PE-conjugated rat anti-
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(A) Total cell or (B) neutrophil number (GR1+) obtained 
from peritoneal lavage following pre-treatment with 
lactoferrin. In detail, mice (n=7 mice per group) were 
injected with human lactoferrin (10 µg ml-1), human 
transferrin (10 µg ml-1) or saline alone (control), 
followed by a second injection with 1% thioglycollate 20 
min after the first injection. Recruited leukocytes were 
harvested after 4 h by peritoneal lavage. Lactoferrin 
reduced specifically the proportion and number of 
neutrophils (GR1+) migrating into the peritoneal cavity *p 
< 0.05 vs. transferrin; **p < 0.01 vs. transferrin 
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control. TG, thioglycollate; LTF, lactoferrin; TF, 















Characteristic cytospin images obtained from peritoneal 
lavage. Mice (n=7 mice per group) were injected with human 
lactoferrin (10 µg ml-1), human transferrin (10 µg ml-1) or 
saline alone (control), followed by a second injection 
with 1% thioglycollate 20 min after the first injection. 
Lactoferrin reduced specifically the proportion and number 
of neutrophils migrating into the peritoneal cavity but 
did not affect recruitment of other types of leukocytes in 
response to thioglycollate. TG, thioglycollate; LTF, 
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lactoferrin; TF, transferrin. Original magnification, 
















(A) Chemotaxis assay to determine neutrophil migration in 
the presence of lactoferrin (10 µg ml-1) in the top or 
bottom compartment of the Transwell insert n=3; NS vs. 
corresponding lactoferrin (bottom+) controls. (B) 
Chemotaxis assay towards fMLP or negative control to 
determine the migration of neutrophils that were pre-
incubated in the presence (dashed columns) or absence of 
milk-derived lactoferrin (10 µg ml-1; 40 min; 37oC) and 
washed with PBS prior to use in the assay n=3 *p<0.001 vs. 
fMLP. Results revealed that lactoferrin did not exert a 
chemorepulsive effect on neutrophils and the observed 
inhibitory effect was maintained in lactoferrin pre-
treated neutrophils following the removal of lactoferrin. 
fMLP, formyl-methionyl-leucyl-phenylalanine; LTF, 
lactoferrin; hpf, high power field. hpf, high power field. 






Till now, the results of this study suggested that 
lactoferrin binds to neutrophils and inhibits their 
ability to undergo chemotaxis. To exclude the possibility 
that the observed inhibitory activity of lactoferrin was 
due to its ability to bind to chemoattractants modulating 
their activity, additional chemotaxis assays were 
performed to assess the effect of lactoferrin on 
neutrophil migration in the presence of other 
chemoattractants such as C5a, IL-8 and LTB4. It was 
revealed that with all these chemoattractants, lactoferrin 
inhibited neutrophil migration, strongly suggesting that 
it does not directly interfere with the chemoattractant 
activity (Figure 24A). Moreover, to examine whether 
lactoferrin functionally neutralises the chemoattractant 
efficiency, additional chemotaxis assays were performed 
using chemoattractants (fMLP, C5a, IL-8) that were 
preabsorbed with lactoferrin. To achieve this, 
chemoattractants were pre-incubated with lactoferrin for 
30 min at 37oC in serum-free chemotaxis medium. 
Subsequently, anti-lactoferrin antibody was used to remove 
the lactoferrin with the aid of IgG-coated magnetic beads 
that capture lactoferrin. As shown in Figure 24B, no 
difference in neutrophil chemotactic activity was observed 
between the control and lactoferrin-absorbed 
chemoattractants, which excludes the possibility that 
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(A) Neutrophil chemotaxis towards different 
chemoattractants: C5a (726 nM), IL-8 (100 nM), LTB4 (50 nM). 
n = 3; *p< 0.05. (B) Neutrophil chemotaxis toward 
chemoattractants (control) or chemoattractants that were 
incubated with lactoferrin (10 μg ml-1) followed by the 
addition of isotype or anti-lactoferrin monoclonal antibody 
(10 μg ml-1). Antibodies were removed using magnetic IgG 
beads. n = 3; *p < 0.05, NS= non-significant vs. 
chemoattractant control; fMLP, formyl-methionyl-leucyl-
phenylalanine; C5a, complement 5a; IL-8, interleukin-8; 
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LTB4, leukotriene B4; LTF, lactoferrin; hpf, high power 




To determine whether the migration-inhibitory effects of 
lactoferrin were specific to neutrophils among 
professional phagocytes, its effects on monocyte and 
macrophage migration in vitro was analysed. As shown in 
Figures 25A and 25B, C5a-induced chemotaxis of mononuclear 
phagocytes was unimpaired by lactoferrin. However, in 
terms of eosinophil migration, lactoferrin exerted a 
significant inhibitory effect on eosinophil chemotaxis.  
In detail, the migration of eosinophils towards milk-
derived purified or towards neutrophil-derived lactoferrin 
was first determined and it was found that both milk-
derived and neutrophil-derived lactoferrin exerted 
inhibitory effects on eotaxin-induced eosinophil migration 
(mean number of migrated eosinophils: 21.7 ± 1.07 towards 
neutrophil-derived lactoferrin; 27.6 ± 1.65 towards milk-
derived lactoferrin in the presence of eotaxin (100 nM) 
vs. 50.8 ± 2.06 towards eotaxin control) (Figure 26A). 
Furthermore, lactoferrin purified from human milk 
displayed a concentration-dependent inhibitory activity 
toward eosinophil migration in response to eotaxin as well 
as towards other chemoattractants such as fMLP, C5a and 
LTB4 to similar levels (Figures 26B and 27A). Moreover, as 
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in neutrophils, lactoferrin exerted no toxic effects on 
eosinophils, as assessed by Anx/PI staining of control and 
lactoferrin-treated eosinophils. In addition, lactoferrin 
(10 µg ml-1) did not promote neutrophil or eosinophil 
apoptosis when the cells were cultured over a 24- or 48-h 
period (Figure 28). Whether lactoferrin acted by 
inhibiting eosinophil migration directly or by promoting 
eosinophil repulsion was next investigated. In chemotaxis 
assays, in which lactoferrin was added to the upper 
chamber along with eosinophils, an inhibition of 
eosinophil migration towards eotaxin and control medium 
was observed, suggesting that lactoferrin, similar to 
neutrophils, exerts a direct effect on eosinophils by 
inhibiting their migratory ability and not by forcing them 
to migrate in all directions away from the chemoattractant 
(Figure 27B).  
Furthermore, subsequent chemotaxis assays were performed 
in which the inhibitory activities of iron-depleted (apo-
form), partially iron-saturated or fully iron-saturated 
lactoferrin (holo-form) were compared. It was found that 
the levels of iron saturation were not related to the 
levels of inhibition in eosinophil migration (Figure 29A). 
Eosinophils were also induced to migrate towards eotaxin 
in the presence of transferrin and it was clearly 
demonstrated that transferrin, in stark contrast to 
lactoferrin, displayed no inhibitory effect on eosinophil 
chemotaxis, providing in this way strong evidence that the 
observed inhibition is lactoferrin-specific and does not 
require iron-chelating activity [mean number of migrated 
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eosinophils: 31.3 ± 1.8 towards lactoferrin in the 
presence of eotaxin (100 nM); 48.2 ± 1.9 towards 
transferrin vs. 50.3 ± 2.3 mean number of migrated 
eosinophils towards eotaxin control (Figure 29B). 
In summary, it was found that lactoferrin specifically 
exerts an inhibitory effect on granulocyte migration. This 
effect was irrespective of the source of lactoferrin 
(milk- or neutrophil-derived), as both types presented a 
significant inhibition in neutrophil migration. Also, it 
was found to be irrespective of the iron-binding 






Chemotaxis assays to determine the migration of (A) 
monocytes; n=3; NS=non-significant vs. C5a control or (B) 
macrophages towards C5a (6.25 ng ml-1) in the presence of 
lactoferrin (10 µg ml-1); n=3; NS=non-significant vs. C5a 
control. Results showed that lactoferrin exerted no 
inhibitory effect on the chemotaxis of these cell types. ; 
C5a, complement 5a; LTF, lactoferrin; hpf, high power 








 (A) Chemotaxis assay to determine eosinophil migration 
towards milk-derived or neutrophil-derived lactoferrin (10 
µg ml-1) in the presence of eotaxin (100 nM) n=4, *p<0.05 
vs. eotaxin control (B) Eosinophil chemotaxis towards 
eotaxin (100 nM) in the presence of varying concentrations 
of purified human lactoferrin; n=3; *p<0.05 vs. eotaxin 
control. Results showed an inhibition in the eotaxin-
induced migration of eosinophils towards lactoferrin. LTF, 
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(A) Chemotaxis assay to determine eosinophil migration 
towards the chemoattractants fMLP (100 nM), C5a (726 nM) 
and LTB4 (50 nM) in the presence of milk-purified 
lactoferrin (10 µg ml-1) n=3; *p<0.05 vs. corresponding 
positive control. (B) Eotaxin-induced chemotaxis assay in 
the presence of lactoferrin (10 µg ml-1) in the top or 
bottom compartment of the Transwell insert n=3; NS=non-
significant vs. corresponding lactoferrin (bottom +) 
controls; fMLP, formyl-methionyl-leucyl-phenylalanine; 
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C5a, complement 5a; LTB4, leukotriene B4; LTF, lactoferrin; 











Measurement of apoptosis levels in neutrophils after 24 h 
(A) or eosinophils after 24 h (B) and after 48 h cultured 
in the presence (Control + LTF) or absence (Control) of 
purified human lactoferrin (10 µg ml-1), as assessed by 
Anx/PI staining; n=3 for A, B and C; NS=non-significant 
compared to control cells (no lactoferrin); LTF, 














Chemotaxis assay to determine (A) eosinophil migration 
towards eotaxin (100 nM) in the presence of recombinant 
iron-depleted (Apo-), partially iron saturated and fully 
iron-saturated (Holo-) recombinant lactoferrin (10 µg ml-
1); n=3 *p<0.05 vs. eotaxin control and (B) eosinophil 
migration towards eotaxin (100 nM) in the presence of 
purified human lactoferrin (10 µg ml-1) or purified human 
transferrin (TF, 10 µg ml-1); n=3 *p<0.05 and NS, non-
significant vs. eotaxin control. Results showed that the 
inhibitory effect exerted by lactoferrin on eosinophil 
migration was irrespective of the iron-saturation status 











Neutrophil migration involves activation, adhesion and 
extravasation; processes that are accompanied by gross 
changes in cell morphology (Servant et al., 2000). While 
non-activated neutrophils are rounded, activated 
neutrophils acquire a polarised morphology with spreading 
and adhesion to the available substratum. In order to 
initially assess the effects of lactoferrin on the 
acquisition of neutrophil activation a time-lapse video 
microscopy of neutrophils was performed and recorded 
directly their activation morphology, cell spreading and 
locomotion. During a 1-h time course, lactoferrin pre-
treated neutrophil populations (10 µg ml-1; 40 min at 37oC) 
stimulated with fMLP (1 µM) displayed a greater proportion 
of non-adherent cells with a rounded, non-activated 
morphology as compared with neutrophils treated with fMLP 
alone (Figure 30A). These quantitative differences between 
lactoferrin-treated and untreated neutrophils stimulated 
with fMLP were reflected in the locomotion of the cells 
around the substratum, with lactoferrin-treated cells 
displaying markedly reduced movement (for example, at 30 
min: about 25.0% non-polarised neutrophils after 
lactoferrin pre-treatment, 49.0% non-polarised neutrophils 
without lactoferrin pre-treatment; -at 60 min: 36.0% non-
polarised neutrophils after lactoferrin pre-treatment, 
68.0% non-polarised neutrophils without lactoferrin pre-
treatment) (Figure 30B). 
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Changes in cell morphology following stimulation with fMLP 
or other neutrophil agonists are characterised by a rapid 
increase in intracellular cytoplasmic calcium levels 
through mobilisation of calcium from ER stores and 
activation of calcium influx channels of the plasma 
membrane, mediated by the inositol triphosphate (IP3) and 
diacylglycerol/phospholipase C (DAG/PLC) pathways (Lew et 
al., 1984; Nigam et al., 1992; Pozzan et al., 1983). In 
order to further determine whether the observed cell shape 
alterations following lactoferrin treatment are related to 
changes in intracellular calcium concentrations ([Ca2+]i), 
the levels of [Ca2+]i in control and lactoferrin-treated 
cells were measured in response to fMLP stimulation (1 nM 
or 10 nM). No changes were observed in the fMLP-mediated 
[Ca2+]i response between control and lactoferrin-treated 
neutrophils, as in both cases, a maximum [Ca2+]i increase of 
300 nM at approximately 55 s was noted after stimulation 
with 10 nM fMLP. These findings suggest that lactoferrin 
acts downstream or independently of the mechanisms 
involved in intracellular calcium flux (Figure 31). In 
general, it was found that the inhibitory effect of 
lactoferrin on neutrophil migration was linked to the 
impaired activation morphology of neutrophils, providing 







 (A) Time-lapse video microscopy frames of control or 
lactoferrin pre-treated neutrophils (10 μg ml-1; 40 min at 
37°C) stimulated with 1 μM fMLP over a 1-h incubation time 
course. n=2; Original magnification ×400. (B) 
Quantification of neutrophils (non-polarised) counted from 
five different fields n=2; *p < 0.05, **p< 0.01 vs. 
corresponding +LTF control. Results showed that 
lactoferrin acted by impairing the acquisition of the 
activation morphology of neutrophils. fMLP, formyl-
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methionyl-leucyl-phenylalanine; LTF, lactoferrin. Error 
















Representative plot (n=3) showing measurement of [Ca2+]i 
levels in neutrophils incubated in the presence or absence 
of lactoferrin (10 μg ml-1; 30 min at 37°C) followed by 
stimulation with fMLP (10 nM). Results revealed that 
lactoferrin did not alter the [Ca2+]i levels in neutrophils 





As lactoferrin was demonstrated to prevent neutrophil 
migration and the acquisition of polarised activation 
morphology, it was next explored whether lactoferrin could 
also affect the neutrophil activation state. To this end, 
the expression of two known neutrophil activation–
associated markers, CD62L (L-selectin) and CD11b, was 
measured using two-colour flow cytometry. Upon activation, 
CD62L is cleaved from the neutrophil surface, whereas 
CD11b expression is upregulated following translocation 
from cytoplasmic granules to the cell membrane. Freshly 
isolated neutrophils were pre-treated with lactoferrin and 
then exposed to the activation stimuli fMLP (100 nM), TNF-
α (1 ng ml-1) and PMA (100 nM). As shown in Figures 32 and 
33, it was found that, in lactoferrin-treated neutrophils 
compared with control cells, CD62L expression was 
significantly higher, whereas CD11b levels were lower. 
These effects were common to all activation stimuli used. 
Transferrin-treated neutrophils were also included but 
showed no significant differences compared with control 
cells. It is noteworthy that the lactoferrin effect was 
also evident when PMA, a specific PKC activator, was used 
as an agonist, indicating that lactoferrin acts downstream 
of PKC and not on pathways involved in PKC activation and 
[Ca2+]i  responses, such as the IP3 and DAG/PLC pathways.  
242 
 
This finding prompted to investigate putative downstream 
targets of PKC involved in the late signalling cascades 
following neutrophil activation that also regulate cell 
motility and actin reorganisation. Such cascades involve 
the activation of MAP family kinases (Szczur et al., 2006) 
and the phosphorylation status of p44/42 (ERK1 and ERK2) 
MAPKs was therefore examined. Whereas in untreated 
neutrophils, ERK1 and ERK2 were phosphorylated following 
fMLP stimulation (100 nM), lower levels of phosphorylated 
ERK1/2 were observed in neutrophils that had been pre-
treated with lactoferrin prior to stimulation with fMLP 
(Figure 34A). Collectively, these data suggest that 
lactoferrin has a clear impact on neutrophil activation, 
including impairment of neutrophil degranulation, 
inhibition of expression of β2 integrins and reduction of 
activation of intracellular kinases with profound effects 
on cell migration and motility. 
Lactoferrin has been shown previously to bind to receptors 
on mononuclear phagocytes and to inhibit proinflammatory 
responses via NF-κB (Birgens et al., 1983; Haversen et 
al., 2002; Van Snick and Masson, 1976). However, the 
involvement of the NF-κB pathway in the inhibition of 
neutrophil migration seems unlikely, since lactoferrin 
also exerted an inhibitory effect on the chemotaxis of 
neutrophils treated with gliotoxin (2 ng ml-1), a specific 
NF-κB inhibitor (Figure 34B). In addition, no changes in 
the levels of IκB, an inhibitor of NF-κB that is degraded 
following NF-κB activation, were observed in Western blot 
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analysis of fMLP-stimulated neutrophils treated with or 
without lactoferrin (Figure 34C). In general terms, it was 
found that the inhibitory effect of lactoferrin on 
neutrophil migration was linked to the impairments in the 
activation status of neutrophils and in particular, in 
downstream signalling molecules involved in neutrophil 














The expression of CD11b was assessed in fMLP- (100 nM), 
TNF-α– (1 ng ml-1), or PMA-stimulated (100 nM) neutrophils 
(30 min at 37°C) that were pre-incubated (40 min at 37°C) 
in the presence or absence of lactoferrin (10 μg ml-1) n=3. 
(A) Representative flow cytometry overlays of CD11b 
expression in control (gray) and stimulated neutrophils 
(lactoferrin-treated: red; untreated: blue). n = 3. (B) 
Flow cytometry results showed lower levels of CD11b 
expressed i.e. lower activation status, in neutrophils 
pre-incubated with lactoferrin followed by agonist 
stimulation, compared to control activated neutrophils n = 
3; *p < 0.05,              **p < 0.01. fMLP, formyl-
methionyl-leucyl-phenylalanine; TNF-α, tumour necrosis 
factor-α, PMA, phorbol myristate acetate; LTF, 











The expression of CD62L was assessed in fMLP- (100 nM), 
TNF-α– (1 ng ml-1) or PMA-stimulated (100 nM) neutrophils 
(30 min at 37°C) that were pre-incubated (40 min at 37°C) 
in the presence or absence of lactoferrin (10 μg ml-1). (A) 
Representative flow cytometry overlays of CD62L expression 
in control (gray) and stimulated neutrophils (lactoferrin-
treated: red; untreated: blue). n = 3. (B) Flow cytometry 
results showed higher levels of CD62L expressed i.e. lower 
activation status in neutrophils pre-incubated with 
lactoferrin followed by agonist stimulation, compared to 
control activated neutrophils n=3. fMLP, formyl-methionyl-
leucyl-phenylalanine; TNF-α, tumour necrosis factor-α, PMA, 



























Immunoblot analysis to determine levels of (A) ERK1/2 
phosphorylation and of (C) IκBα. Neutrophils were incubated 
with lactoferrin (10 μg ml-1; 40 min at 37°C), followed by 
stimulation with fMLP (100 nM) for the indicated times. 
Membrane was stripped and reprobed for total ERK2 and IκBα. 
Results are representative of three independent 
experiments. Results showed that neutrophils treated with 
lactoferrin presented a reduced ERK1/2 phosphorylation 
status following fMLP stimulation; however no effect on 
IκBα levels was evident. Results are representative of 
three (for ERK1/2) or two (for IκBα) independent 
experiments. (B) Chemotaxis assay to determine the effect 
of gliotoxin (2 ng ml-1) on neutrophil migration towards 
lactoferrin. Chemotaxis of neutrophils was determined 
after being pre-incubated in the presence of gliotoxin 
(black columns; 40 min; 37oC) and washed with PBS prior to 
use in the assay. Gliotoxin pre-treatment was found to 
have no effect on the inhibitory activity of lactoferrin 






Pursuing the early observations that the inhibition of 
neutrophil migration by BL cells was correlated with BL 
cell apoptosis (Figure 4C), lactoferrin expression was 
assessed following induction of apoptosis in a panel of 
cells of diverse lineages. By transcriptional analysis 
using RT-PCR, lactoferrin was found to be expressed, as 
reported previously, by MCF7-C3 breast cancer epithelial 
cells in their viable state but not by the T leukemic cell 
line Jurkat, the epithelial lung cancer A549 cells or BL2 
cells. Upon apoptosis induction, lactoferrin expression 
was shown to be upregulated in MCF7-C3 cells and expressed 
de novo in Jurkat, BL2, and A549 cells (Figure 35). More 
specifically, lactoferrin was transcribed de novo early 
after induction of apoptosis in A549 cells by either 100 
nM etoposide or 1 μM staurosporine and its expression 
levels were relevant to the levels of apoptosis (Figure 
36A). The RT-PCR results also revealed that the levels of 
lactoferrin induced by etoposide were reduced in A549 
cells treated in the presence of the broad-spectrum 
caspase inhibitor zVAD-fmk (carbobenzoxy-valyl-alanyl-
aspartyl-[O-methyl]- fluoromethylketone), which prevented 
apoptosis induction (Figure 36B). The link between 
lactoferrin expression and apoptosis induction was further 
supported by the effects of the apoptosis inhibitor, Bcl-
2. BL cells expressing exogenous Bcl-2 that provided 
protection from apoptosis expressed lower levels of 
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lactoferrin upon exposure to staurosporine than did their 
parental counterparts (Figures 9C and 35).  
Not only was apoptosis-related lactoferrin expression 
demonstrated at the transcriptional level, lactoferrin 
protein was also recovered from supernatants of BL2 and 
A549 cells undergoing apoptosis. Similarly, an analogous 
effect was also evident from supernatants obtained from 
primary lymphocytes induced to become apoptotic in the 
presence of 1 μM staurosporine, showing in this way that 
the release of lactoferrin extends to all cells undergoing 
apoptosis used in this study (Figure 37A). Moreover, as 
shown in Figure 37B, treatment of A549 cells with 
brefeldin A (1 µg ml-1), which interferes with 
intracellular transport of newly synthesised proteins, 
resulted in inhibition of apoptosis-induced lactoferrin 
release, providing further evidence for the de novo 
synthesis and secretion of lactoferrin by cells undergoing 
apoptosis. Finally, the release of lactoferrin is not 
linked to necrosis but lactoferrin is expressed and 
actively released from cells as a consequence of 
activation of their apoptosis program, as evidenced by 
immunoblotting analyses and chemotaxis assays using 
supernatants of BL cells undergoing primary necrosis (1x106 
ml-1 BL cells stimulated to become necrotic by incubation 
at 56oC for 1 h) (Figures 38A and 38B). In summary, it was 
evident that lactoferrin was actively expressed and 
released upon apoptosis induction in diverse cell types. 
The release of lactoferrin is a characteristic of 
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apoptosis, enabling in this way, the anti-inflammatory 






RT-PCR analysis in cell lines stimulated to undergo 
apoptosis (A) and unstimulated controls (V). The cell 
lines included MCF7 cells transfected with caspase-3 
(25.4% apoptosis; 100 μM etoposide, 20 h), Jurkat (18.4% 
apoptosis; 1 μM staurosporine, 3 h), BL2 (12.5% 
apoptosis), and BL2/bcl-2 (7.4% apoptosis; 1 μM 








(A) Lactoferrin expression in A549 cells at defined time 
points (h) following stimulation with 100 μM etoposide or 
1 μM staurosporine. (B) Addition of pan-caspase inhibitor 
zVAD-fmk (100 μg ml-1) for 12 h in order to prevent 
etoposide-induced apoptosis in A549 cells. It was revealed 
that lactoferrin expression was linked to and upregulated 
by the apoptosis levels of the cells. Results (A and B) 






(A) Immunoblot analysis of cell supernatants from: BL2 and 
primary lymphocytes in the presence (+) or absence (–) of 
staurosporine (1 μM) in serum-free conditions for 1 h. 
A549 cells were stimulated with (+) or without (–) 100 μM 
etoposide for 5 h. (B) A549 cells were induced to become 
apoptotic (100 μM etoposide; 20 h) in the presence or 
absence of brefeldin A (1 μg ml-1), a protein release 
inhibitor. Treatment with brefeldin A reduced the amount 
of lactoferrin released from apoptotic A549 cells. Results 
(A and B) are representative of three independent 







(A) Immunoblot analysis of conditioned media from apoptotic 
and/or necrotic BL2 cells (1x106 cells ml-1) to detect 
lactoferrin. Image is representative of three independent 
experiments; proteins run on the same gel. (B) Chemotaxis 
assay to determine neutrophil migration towards conditioned 
media from BL2 cells (2x106 cells ml-1) stimulated to undergo 
apoptosis (1 µM staurosporine; 1 h; 37oC) or primary 
necrosis (56oC; 1 h) in serum-free conditions n=3; *p<0.001 
compared to fMLP control; **p<0.05 vs. apoptotic control; 
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NS= non-significant vs. fMLP control; hpf, high power 




These studies indicate that lactoferrin is expressed by a 
great diversity of cell lineages and it is upregulated 
upon apoptosis as a feedback mechanism to prevent 
neutrophil infiltration and stimulate a variety of anti-
inflammatory immune effector activities. The next goal was 
to identify what is the role of lactoferrin in a 
proliferating tumour cell line. In other words, examine 
whether the expressed lactoferrin also plays a role in 
tumour establishment and growth.  
Using BL as a model, the EBV+ (Mutu, Wan) and EBV- (BL2, 
L3055) BL cell lines were cultured at a starting number of 
0.3x106 cells in X-vivo culture medium (lactoferrin-free). 
Their cell number was then determined in the presence of 
monoclonal anti-human lactoferrin antibody (10 µg ml-1) or 
isotype control and in all cases, it was noted that 
depletion of lactoferrin significantly inhibited BL cell 
proliferation over a 48-h time course, suggesting in this 
way that lactoferrin is an important determinant of cell 
growth. Indeed, the addition of lactoferrin antibody (10 
µg ml-1) resulted in a reduction of the proliferation rate 
of all the cell lines examined (Figures 39 and 40). In 
detail, after a 48-h incubation, the number of BL2 cells 
in control conditions was 9.14x105 ± 0.7 cells, whereas in 
the presence of lactoferrin antibody or isotype control, 
it was 5.61x105 ± 0.7 and 8.14x105 ± 0.4 BL2 cells 
respectively. In terms of Mutu cell proliferation after 48 
h culture in X-vivo, in control conditions, 7.69x105 ± 0.8 
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Mutu cells were counted, while 5.32x105 ± 0.5 and 8.51x105 
± 0.6 cells in the presence of anti-lactoferrin antibody 
or isotype control, respectively. Similarly, in Wan and 
L3055 culture in control conditions, 8.53x105 ± 0.9 Wan 
cells and 7.56x105 ± 1.2 L3055 cells were counted in 
control conditions at the 48 h time point. This number was 
reduced to 7.20x105 ± 0.5 and 5.20x105 ± 0.3 respectively 
after the addition of anti-lactoferrin antibody. The 
isotype control numbers were 8.49x105 ± 1.8 Wan and 
7.85x105 ± 0.8 L3055 cells. This result supports earlier 
studies that have reported the presence of lactoferrin in 
BL tissue scans as well as studies that proposed the role 
of endogenously expressed lactoferrin as a growth factor. 
It should be noted that addition of polyclonal anti-
lactoferrin antibody to the BL cells did not stimulate 
such an effect (Figure 41). 
Additional experiments were carried out, in which the 
proliferation of BL2 cells and BL2 cells transfected with 
shRNA vector for lactoferrin was examined. As a control, 
shRNA BL2 cells transfected with a negative control vector 
were included. Although the starting number of all three 
cell types was 0.3x106 cells, the lactoferrin shRNA-
transfected cells were proliferating at a slower rate than 
their respective control cells over a 48-h time course 
(Figure 42). In detail, after 48 h, the number of parental 
control BL2 cells was 8.20x105 ± 0.9 cells, whereas that of 
the lactoferrin shRNA-transfectant ones was 5.10x105 ± 1.2 
cells and of the negative shRNA control BL2 cells was 
9.30x105 ± 1.1 cells. Moreover, despite the fact that 
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purified lactoferrin when added to cells at a 
concentration of 10 µg ml-1 had no effect, it promoted the 
proliferation of lactoferrin shRNA-transfected cells at 
analogous levels to their negative control counterparts 
when added at concentrations of 100 pg ml-1 or 1 ng ml-1; 
therefore increasing cell number to 7.60x105 ± 0.6 and 
8.10x105 ± 0.8 cells, respectively. In general terms, these 
results revealed that lactoferrin promotes BL 
proliferation, based on proliferation experiments, in 
which lactoferrin was depleted via the use of an anti-
lactoferrin antibody or via an shRNA-mediated knockdown 
approach. These findings provide a first line of evidence 
that lactoferrin is a determinant of BL cell proliferation 
and further experiments should be carried out to examine 






Proliferation assay to determine the proliferation rate of 
the EBV- BL cell lines (A) BL2 and (B) L3055 under 
conditions, in which lactoferrin was depleted via the use 
of mouse monoclonal anti-human lactoferrin antibody (clone 
LF-2B8; 10 µg ml-1). Cells were plated at an initial 
concentration of 0.3x106 cells and their proliferation 
(relative number) was recorded for 48 h. An isotype 
control (mouse monoclonal IgG1 isotype control –MOPC21) 











Proliferation assay to determine the proliferation rate of 
the EBV+ BL cell lines (A) Mutu and (B) Wan under 
conditions, in which lactoferrin was depleted via the use 
of mouse monoclonal anti-human lactoferrin antibody (clone 
LF-2B8; 10 µg ml-1). Cells were plated at an initial 
concentration of 0.3x106 cells and their proliferation 
(relative number) was recorded for 48 h. An isotype 




was also included (10 µg ml-1; n=6 for each cell line; 






Determination of the proliferation rate of (A) BL2 and (B) 
Mutu under conditions, in which lactoferrin was depleted 
via the use of polyclonal anti-human lactoferrin IgG 
antibody. Cells were plated at an initial concentration of 
0.3x106 cells and their proliferation (relative number) was 
recorded for 48 h. An isotype control (rabbit polyclonal 
IgG negative control) was also included (10 µg ml-1; n=3; 












Proliferation assay to determine the proliferation of the 
BL2 parental cell line, of lactoferrin shRNA-transfected 
BL2 cell line and of shRNA-negative control BL2 cell line. 
As a control, purified lactoferrin (100 pg ml-1 and 1 ng ml-
1) was added to lactoferrin shRNA-transfected BL2 cells. 
All cells were plated at an initial concentration of 
0.3x106 cells and their proliferation (relative number) was 
recorded for 48 h n=5; *p<0.05 vs. negative shRNA control, 









There are many studies that support that exogenous 
administration of lactoferrin has potent apoptosis-
inducing and anti-tumoural effects. However, such studies 
had not reported possible limitations concerning the 
origin and quantity of the administered lactoferrin; 
something that might possibly trigger toxic effects. In 
this study, it was shown for the first time, that 
lactoferrin is endogenously expressed and its expression 
is linked to BL cell proliferation. As Burkitt’s lymphoma 
displays a high apoptosis rate as a tumour, whether 
lactoferrin expression is related to the rate of cell 
apoptosis was further examined.  
Indeed, by carrying out analogous proliferation 
experiments in BL2 cells, the addition of the monoclonal 
anti-lactoferrin antibody was found to promote the 
induction of apoptosis, as over a 48-h time course, 
addition of anti-lactoferrin antibody resulted in an 
increase in the number of necrotic (Anx+/PI+) BL cells 
(Figure 43). Also, addition of purified lactoferrin 
resulted in a lower proportion of cells undergoing 
apoptosis. 
This effect on apoptosis rates was also prominent in the 
measurement of the cell cycle status of these cells. Cells 
incubated in the presence of the anti-lactoferrin antibody 
presented a classical cell cycle profile of cells 
undergoing apoptosis that was marked by the inefficiency 
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of cells to enter the G2 phase (Figure 44). As an 
analogous effect was not evident in shRNA-transfected BL2 
cells (Figure 45), it could be proposed that the addition 
of the anti-lactoferrin antibody to BL cells induces 
cellular death via an antibody-dependent cytotoxicity. 
Moreover, the possibility that the use of antibody causes 
a rapid deprivation of lactoferrin in these cells, 
promoting their cellular death shall not be excluded, as 
the shRNA transfected ones were used to survive in a 
lactoferrin-deficient environment. Also, in shRNA-
transfected cells, lactoferrin was knocked down and not 
completely neutralised, and therefore, low levels of 
lactoferrin could have been present.  
To better elucidate the effect of lactoferrin on 
apoptosis, BL cells were cultured in X-vivo medium (serum-
free) at a concentration of 1x106 cells ml-1 over a 24 h 
time course in the presence or absence of 1 ng ml-1, 100 ng 
ml-1, 1 µg ml-1 and 10 µg ml-1 of purified lactoferrin. We 
observed that lactoferrin did not stimulate BL cells to 
become apoptotic at all concentrations. Also, when BL2 
cells were induced to become apoptotic following 
staurosporine treatment (1 µM; 1 h at 37oC) or in serum-
free conditions (24 h), the addition of purified 
lactoferrin (1 µg ml-1) did not promote or inhibit 
apoptosis induction (Figure 46).  
In summary, it has been clearly shown that lactoferrin is 
an endogenous and tumour cell autonomous component of 
Burkitt’s lymphoma and acts both by regulating the type of 
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immune cells infiltrating the tumour stroma as well as the 
proliferation of the tumour cells. Distortion of the 
expression of lactoferrin –if not genetically redundant- 
might possibly elicit devastating anti-tumour effects. In 
support to this, very promising preliminary findings on 
the in vivo growth of lactoferrin shRNA-BL cell lines in 
SCID xenografts showed a reduction in BL tumour 
establishment and growth compared to shRNA negative BL2 
control xenografts (Figure 47). However, due to technical 
problems and time constraints, the number of mice in each 
group is not comparable and analogous experiments cannot 
unfortunately be carried out in the context of this 





Measurement of apoptosis levels in BL2 cells cultured in 
the presence or absence of mouse monoclonal anti-human 
lactoferrin antibody (LF-2B8; 10 µg ml-1), as assessed by 
Anx/PI staining. An isotype control (mouse monoclonal IgG1 
isotype control –MOPC21) was also included (10 µg ml-1). It 
was evident that the antibody-mediated depletion of 
lactoferrin resulted to an increase in the percentage of 









Analysis of the cell cycle profile of BL2 cells cultured 
in the (B) presence or (A) absence of mouse monoclonal 
anti-human lactoferrin antibody (LF-2B8; 10 µg ml-1 ). (C) 
An isotype control (mouse monoclonal IgG1 isotype control 
–MOPC21) was also included (10 µg ml-1). Results are 
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representative of six (n=6) independent experiments; 
*p<0.05 vs. respective control. Results indicated that BL2 
cells incubated in the presence of the anti-lactoferrin 






Determination of apoptosis levels in lactoferrin shRNA-
transfected BL2 cells and their control counterparts, as 
assessed by Anx/PI staining. As a transfection control, a 
negative shRNA-transfected BL2 cell line was included. No 




three cell lines. n=6 for 24 h and 48 h; NS=non-







Determination of apoptosis levels in BL2 cells that were 
induced to become apoptotic following staurosporine 
treatment (1 µM; 1 h at 37oC) or in serum-free conditions 
(24 h) in the presence or absence of purified lactoferrin 
(1 µg ml-1), as assessed by Anx/PI staining. It was 
revealed that lactoferrin neither stimulated BL2 cells to 
become apoptotic nor promoted or inhibited apoptosis 








Lactoferrin depletion seemed to result to decreased 
xenograft tumour growth. The BL2 LTF-shRNA and the BL2-
shRNA negative control xenograft tumours were grown for 8 
weeks and tumour size was determined after the appearance 
of visible tumours. The rate of tumour growth was 
determined by averaging the tumour size in each cell line 





Apoptosis is an intrinsically non-phlogistic process that 
regulates many physiological, homeostatic processes of an 
organism, such as organ morphogenesis, limb development 
and immune responses (Kerr et al., 1972; Majno and Joris, 
1995). Unlike necrosis, which has proinflammatory 
consequences, apoptosis is an anti-inflammatory process 
(Kerr et al., 1994; Leist and Nicotera, 1997). For this 
reason, defining the properties of apoptotic cells that 
contribute to the non-inflammatory or anti-inflammatory 
nature of the apoptosis program is critical to the 
understanding of this fundamental biological process 
(Savill et al., 1993; Vaux, 1993). Failure to control 
apoptosis, can result to detrimental effects to the host 
such as inflammation and autoimmunity (Ekert and Vaux, 
1997). In this study, lactoferrin was identified as a 
cell-autonomous, anti-inflammatory mediator that inhibits 
granulocyte migration. Lactoferrin is a pleiotropic 
protein widely known mainly for its iron-binding 
properties and is a member of the transferrin family of 
proteins (Baker and Baker, 2005; Ward and Conneely, 2004). 
It is mainly found in the specific granules of neutrophils 
and mucosal secretions and is expressed by the epithelial 
cells of the digestive and respiratory tracts (Bennett and 
Kokocinski, 1978; Ward et al., 2005). Apart from the 
bacteriostatic properties of lactoferrin that are 
attributable mostly due to its iron-binding ability, the 
anti-inflammatory activities of lactoferrin are ever 
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increasing (Legrand et al., 2005). The ability of 
lactoferrin to inhibit granulocyte migration, as described 
here, is an additional anti-inflammatory feature of this 
molecule, independent of its iron-chelating activity.  
Although its exact involvement in the apoptotic process 
and its relations to other immune cell types has not been 
clearly determined yet, in this study, lactoferrin was 
found to inhibit neutrophil chemotaxis both in vitro and 
in vivo with no consequences on neutrophil survival, pose 
it as a key regulatory molecule in inflammation. In 
detail, in this study, Burkitt’s lymphoma (BL) cells, like 
all other apoptotic cell types, were demonstrated to 
actively release lactoferrin so as to inhibit neutrophil 
recruitment. This effect of BL cells on neutrophils is a 
possible homeostatic mechanism so as to prevent the 
cytostatic effects arising from neutrophil infiltration. 
Indeed, as evidenced from preliminary experiments, when 
neutrophils were co-cultured with BL cells at different 
ratios, a decrease in the total viable cell population was 
noted (I. Bournazou, unpublished data).  
The identification of lactoferrin as an inhibitor of 
neutrophil migration released from BL cells was validated 
by neutralisation experiments using both monoclonal and 
polyclonal antibodies specific for human lactoferrin. 
Moreover, in subsequent chemotaxis experiments, it was 
demonstrated that purified human lactoferrin inhibited 
neutrophil migration in a bell-shaped mode. It should be 
noted that lactoferrin prevented neutrophil recruitment 
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with no toxic effects on neutrophil survival, as assessed 
by Anx/PI staining. This inhibitory effect was 
irrespective of its source (neutrophil-derived or milk-
derived), showing in this way that differences in the 
glycosylation profile of lactoferrin do not seem to 
account for its described anti-inflammatory activity on 
neutrophils. In fact, although there are no differences 
reported until now in terms of their biological activity, 
the only difference between milk and neutrophil-derived 
lactoferrin is that lactoferrin from neutrophils lacks 
terminal fucose residues in the glycan chain that are 
required for binding to macrophages (Martins et al., 
1995); however, this difference has no effect in terms of 
its activity on neutrophils, as both these types of 
lactoferrin were shown to inhibit neutrophil chemotaxis at 
similar levels.  
The observed in vitro effect on neutrophil chemotaxis was 
supported by in vivo findings, which demonstrated that 
lactoferrin inhibited neutrophil recruitment in a 
thioglycollate-induced mouse model. In that model, it was 
also examined whether transferrin inhibits neutrophil 
recruitment or the described inhibitory effect was 
specifically exerted by lactoferrin. Although transferrin 
is another member of the transferrin family of proteins 
and highly homologous to lactoferrin (Harrington, 1992; 
Masson and Heremans, 1971; Metz-Boutigue et al., 1984), it 
failed to exert an analogous inhibitory effect on 
neutrophil chemotaxis, showing in this way that 
lactoferrin specifically inhibits neutrophil chemotaxis 
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independent of its iron-binding properties. This provided 
a first clue in attempts to identify the region of 
lactoferrin that is responsible for this inhibitory 
activity. Although more detailed investigation for the 
identification of this specific region is required, mainly 
employing techniques such as site-directed mutagenesis, it 
can be suggested that the region of lactoferrin that 
specifically inhibits neutrophil migration is not its 
iron-binding site. However, it can be speculated that this 
region is possibly found in the N lobe of lactoferrin, as 
this lobe has been demonstrated to account for all the 
described anti-inflammatory effects of lactoferrin (Baveye 
et al., 1999; Brock, 2002; Velliyagounder et al., 2003). 
The fact that iron plays no role in the effect of 
lactoferrin on neutrophil chemotaxis, as described in this 
study, was further supported by the finding that 
lactoferrin exerts the same level of inhibition in 
neutrophil migration irrespective of its iron saturation 
status. Indeed, although iron and iron-associated 
molecules have been previously shown to play an important 
role in many immunomodulatory functions, when three 
different iron-saturation variants of lactoferrin (apo, 
partial and fully-iron saturated) were used in this study, 
no difference was observed in terms of their efficiency to 
inhibit neutrophil migration. This result is in contrast 
to other studies, in which the level of iron saturation 
plays a key role in the anti-inflammatory response. For 
example, purified iron-saturated lactoferrin was shown to 
suppress IL-1 release by monocytes, whereas an inhibition 
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of GM-CSF activity production by monocytes and macrophages 
was found to be correlated with the iron saturation status 
of lactoferrin (Broxmeyer et al., 1978; Broxmeyer et al., 
1986; Zucali et al., 1989).   
In this study, it was also found that lactoferrin, apart 
from neutrophils, exerted an inhibitory effect on 
eosinophil migration. However, unlike other chemorepellent 
stimulants (Jutila et al., 1991; Tharp et al., 2006), it 
had no chemorepulsive activities on either neutrophils or 
eosinophils. This result complemented earlier findings 
that described the ability of lactoferrin to reduce 
allergic airway inflammation in in vivo models (Elrod et 
al., 1997; Kruzel et al., 2006) and the inability of 
soluble, contrary to immobilised, lactoferrin to activate 
eosinophils (Thomas et al., 2002). It should be emphasised 
that the inhibitory effect of lactoferrin was restricted 
to granulocyte migration, as subsequent chemotaxis 
experiments to determine monocyte or macrophage chemotaxis 
displayed no difference in the C5a-induced chemotaxis of 
these cells, despite the presence of lactoferrin. However, 
it cannot be excluded that lactoferrin exerts multiple 
effects on the resident monocytes or macrophages by 
regulating their activation status and promoting 
functional activities such as phagocytosis. Indeed, it has 
been reported that lactoferrin has a suppressive effect on 
the synthesis of proinflammatory cytokines e.g TNF-α, IL-1 
and IL-6 by resident, activated monocytes or macrophages 
following LPS stimulation (Crouch et al., 1992; Mattsby-
Baltzer et al., 1996). Other reported properties of 
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lactoferrin involve NK cell activation, activation of 
monocytes, activation of GM-CSF, stimulation of antibody-
dependent cell cytotoxicity and macrophage cytotoxicity as 
well as maturation of splenic B cells (Baveye et al., 
1999; Legrand et al., 2005). 
This diversity in the anti-inflammatory activity of 
lactoferrin on immune and endothelial cells is evidenced 
by the presence of lactoferrin-specific receptors on the 
cell surface (Suzuki and Lonnerdal, 2002; Suzuki et al., 
2005). It should be noted that the cationic nature of 
lactoferrin in combination with its high binding capacity 
as a protein, make lactoferrin receptors very difficult to 
identify. Also, the involvement of pseudo-receptors shall 
not be excluded. For all these reasons, the detailed 
characterisation of lactoferrin receptors from various 
cell types had partial success and many candidate 
receptors have been proposed for various cell types 
(Suzuki and Lonnerdal, 2002). The lactoferrin receptors 
that have been characterised till now are expanded to the 
whole organism and include intestinal lactoferrin 
receptors, liver lactoferrin receptors such as LRP (LDL 
receptor-related protein) as well as lactoferrin receptors 
in the brain and the bronchial epithelial cells (Davidson 
and Lonnerdal, 1988; Ghio et al., 1999; Herz and 
Strickland, 2001; Kawakami et al., 1990; Kawakami and 
Lonnerdal, 1991). Other cell types that display 
lactoferrin receptors are lymphocytes, megakaryocytes and 
monocytes (Nillesse et al., 1994; Suzuki et al., 2005). In 
neutrophils, no distinct receptors for lactoferrin have 
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been characterised so far. Scatchard binding analysis of 
125I-labelled apo-lactoferrin indicated that lactoferrin 
bound to neutrophils via two classes of receptors that 
differ in the affinity and the number of binding sites per 
cell (Bournazou et al., 2009). The higher affinity 
receptors were determined to be expressed at a density of 
9,100 ± 2,500 binding sites per cell with an affinity of 
350 ± 65 nM and the lower affinity receptors to be 
expressed at a density of 2.50x106 ± 0.7x106 per cell with 
an affinity of 20 ± 10 μM. This finding was supported by 
previously published literature on the identification of 
two types of lactoferrin receptors on neutrophils (Maneva 
et al., 1983; Spik et al., 1994). Moreover, published 
evidence on eosinophils, presented two classes of 
lactoferrin receptors using 125I-labelled lactoferrin with 
dissociation constants of 47 nM and 260 nM (Thomas et al., 
2002). However, in all cases, the detailed 
characterisation of the relative receptors and the 
molecular mechanisms underlying neutrophil and eosinophil 
inhibition by lactoferrin require extensive further work.    
Another point that should be mentioned in terms of the 
recognition of receptors on neutrophil surface by 
lactoferrin is the finding that lactoferrin does not 
directly associate with chemoattractants and 
chemoattractant receptors. The absence of association with 
chemoattractants is evident since the efficiency of the 
chemoattractant molecules remained intact following 
treatment and antibody-based removal of lactoferrin in 
lactoferrin absorption experiments. Also, lactoferrin 
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reduced the activation status of neutrophils treated with 
PMA, an intracellular PKC agonist, showing in this way 
that its inhibitory effect does not arise due to its 
interactions with chemoattractant receptors on neutrophil 
surface. It should also be mentioned that the observed 
effect of lactoferrin was not due to any association with 
LPS, as the lactoferrin used was endotoxin-free and the 





Till now, the effect of lactoferrin on neutrophils had not 
been unravelled, apart from early observations, in which 
orally administered bovine lactoferrin in influenza virus 
infected mice reduced the number of infiltrating 
leukocytes in bronchoalveolar lavage fluid (Yamauchi et 
al., 2006). Also, the administration of recombinant human 
lactoferrin prevented injury of non-steroidal anti-
inflammatory drugs in the intestine of rats; an effect 
linked to attenuation of neutrophil migration (Dial et 
al., 2005).  
The results of this study support these findings and 
further suggest that lactoferrin is one of the few till 
now identified molecules, along with lipoxins and annexin-
1, which are endogenously expressed to inhibit granulocyte 
migration (Lim and Pervaiz, 2007; Perretti and D'Acquisto, 
2009; Schwab et al., 2007). Furthermore, according to 
results from time-lapse video microscopy of neutrophils, 
it was demonstrated that lactoferrin prevents neutrophils 
from attaining classical polarisation morphology. This was 
confirmed by subsequent findings that lactoferrin prevents 
neutrophil migration by affecting the acquisition of 
particular neutrophil activation states, as assessed by 
the levels of two known activation markers, CD62L and 
CD11b in response to the activation stimuli of fMLP, TNF-α 
and PMA. It is noteworthy that the lactoferrin effect was 
also evident when PMA, a specific PKC activator, was used 
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as an agonist, also indicating that lactoferrin acts 
downstream of PKC and not on pathways involved in PKC 
activation and [Ca2+]i responses, such as the IP3 and 
DAG/PLC pathways. This was validated by the fact that 
lactoferrin did not influence intracellular calcium levels 
[Ca2+]i. Following lactoferrin treatment, no differences 
were noted in intracellular calcium concentrations ([Ca2+]i) 
in response to fMLP stimulation. Based on these findings, 
putative downstream targets of PKC were examined that were 
involved in the late signalling cascades following 
neutrophil activation and also regulate cell motility and 
actin reorganisation (Szczur et al., 2006). Such cascades 
involve the activation of MAP family kinases and 
therefore, the phosphorylation of p44/42 (ERK1 and ERK2) 
MAPKs was next examined. Indeed, following fMLP 
stimulation, lower levels of phosphorylated ERK1/2 were 
observed in neutrophils that had been pre-treated with 
lactoferrin.  
The arising data clearly suggest that the observed 
lactoferrin-mediated inhibitory effects on neutrophil 
chemotaxis could be attributed to modulation of molecules 
other than those involved in the [Ca2+]i response following 
agonist stimulation. In addition, analysis of the 
expression of early activation markers such as CD62L and 
CD11b following stimulation with diverse neutrophil 
agonists, including PMA, a specific synthetic 
intracellular activator of PKC, further suggested that 
lactoferrin acts downstream or independently of the PKC 
pathway, affecting signalling cascade components of the 
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later phases of neutrophil activation. This notion was 
strengthened by the observation that lactoferrin inhibited 
the phosphorylation of p44/42 (ERK1 and ERK2) MAPKs, 
indicating that its action is mediated, at least in part, 
via the MAPK pathway, a key pathway downstream of PKC with 
a crucial role in the regulation of cytoskeletal 
rearrangement and cell adhesion (Thompson et al., 1994; 
Thompson et al., 1993; Van Lint et al., 1993).  
Although the exact molecular mechanism of lactoferrin 
concerning neutrophil chemotaxis requires further more 
detailed investigation, a model of lactoferrin activity 
can be proposed (Figure 48). According to this model, it 
can be speculated that the previously reported specific 
interaction of lactoferrin with the calcium-calmodulin 
complex (Ca2+/CaM) might also be a potential intracellular 
signalling target of lactoferrin (de Lillo et al., 1992). 
The Ca2+/CaM complex is formed following the increase in 
[Ca2+]i and PKC activation, and regulates the activity of a 
number of pathways involved in cell adhesion and migration 
including the ERK1/2 kinases (Gaines et al., 2008; Schmitt 
et al., 2004; Verploegen et al., 2005; Verploegen et al., 
2002). Indeed, the use of specific inhibitors of 
calmodulin activity has been demonstrated to mimic the 
effect of lactoferrin, i.e. inhibition of neutrophil 
migration as reported in this study (Downey et al., 1996; 




At a molecular level, it was further investigated whether 
the described effect of lactoferrin on neutrophils is NF-
κB-associated. Indeed, it has been previously shown that 
lactoferrin binds to receptors on mononuclear phagocytes 
and inhibits proinflammatory responses via NF-κB (Birgens 
et al., 1983; Haversen et al., 2002; Van Snick and Masson, 
1976). Also, on a rat model of trinitrobenzensulfonic acid 
(TNBS)-induced colitis, administration of lactoferrin has 
resulted in a significant reduction in the proinflammatory 
cytokines, TNF-α and IL-1β, a downregulation of the NF-κB 
pathway and an upregulation of the anti-inflammatory IL-4 
and IL-10 (Togawa et al., 2002a; Togawa et al., 2002b). 
However, the involvement of the NF-κB pathway in the 
inhibition of neutrophil migration seems unlikely, since 
the lactoferrin-mediated inhibition of chemotaxis of 
neutrophils treated with gliotoxin, a specific NF-κB 
inhibitor, was found to be identical to that of untreated 
cells. In addition, no changes in the levels of IκB, an 
inhibitor of NF-κB that is degraded following NF-κB 
activation, were observed in Western blot analysis of 
fMLP-stimulated neutrophils treated with or without 
lactoferrin.  
In general, the identification of lactoferrin is of 
particular importance, as it is one of the few 
physiological mediators that have been characterised so 
far to negatively regulate neutrophil migration. In this 
way, insights on the way that the other negative 
regulators act can prove beneficial so as to identify the 
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signalling pathway or the molecules affected by 
lactoferrin. For instance, lipoxins, mainly lipoxin A4 
(LXA4), have been reported to inhibit neutrophil 
recruitment by inhibiting integrin clustering and mobility 
and by inhibiting TNF-α secretion via a block in ERK 
activation (Filep et al., 1999; Serhan, 1997). Also, it 
stimulates the uptake of apoptotic neutrophils by 
macrophages (Godson et al., 2000). Recently, it was found 
that LXA4 associates with polyisoprenyl phosphate (PIPP) 
signalling pathway leading to accumulation of presqualene 
disphosphate (PSDP), a potent negative intracellular 
signal in neutrophils that acts by inhibiting superoxide 
generation and recombinant PLP (Jozsef et al., 2002; Levy 
et al., 1999; Maderna et al., 2002; Ohira et al., 2004). 
LXA4 intracellular activity has also been demonstrated to 
involve a block in the phosphorylation and activation of 
leukocyte-specific protein-1 and of several other 
components of the p38 MAPK pathway. In terms of the 
recognition receptor for LXA4, it has been shown that LXA4 
acts via an identified lipoxin A4 receptor (ALX), which is 
a seven-transmembrane G-protein-coupled receptor (Chiang 
et al., 2006). Annexin-1, which is also another negative 
regulator of neutrophil migration, acts via the same 
receptor (ALX), proposing in this way a similar mode of 
activity (Babbin et al., 2006; Chiang et al., 2006; 
Perretti, 2003). Moreover, ALX was found to share a 
conserved homology to ChemR23 that is a receptor for 
resolvin E1 (RvE1) (Arita et al., 2005; Flower and 
Perretti, 2005). Whether lactoferrin binds or associates 
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with ALX is something that needs to be investigated. Also, 
whether lactoferrin modulates the expression of cytokines 
or related adhesion molecules on neutrophils so as to 
elicit its inhibitory effect is till now not known.  
It should also be highlighted that lactoferrin was 
reported to be linked to an upregulation in IL-10 levels 
(Hwang et al., 2007). This is a common characteristic with 
annexin-1 activity, as exposure of macrophages to annexin-
1-derived peptides was demonstrated to induce IL-10 
secretion; an effect also mimicking glucocorticoid 
activity (Clark, 2007; Ferlazzo et al., 2003; Parente and 
Solito, 2004; Perretti et al., 2002; Perretti and 
D'Acquisto, 2009; Souza et al., 2007). In this way, 
comparison of annexin-1 or glucocorticoid effects with the 
anti-inflammatory effects of lactoferrin would be 
interesting to examine.  
At this stage, a useful tool to study the molecular 
effects of lactoferrin would be the generation of 
lactoferrin knock-out mice (LTF-/-). Unfortunately, LTF-/- 
mice are not commercially available. However, one study 
has reported the generation of such a knock-out strain, 
but there is controversy as to whether this model is 
successful, as these mice were presented to be viable and 
fertile and displayed a normal development. Also, the iron 
status of these mice was normal (Ward et al., 2003). This 
is quite unexpected, based on the crucial role of 
lactoferrin in development, reproduction and as an iron-
binding protein. Other reported evidence of a LTF-/- mouse 
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model presented a different phenotype, confirming the 
assumption that the generation of such a knock-out model 
is not feasible. Indeed, that LTF-/- model was lethal at the 
pre-implantation stage of the embryo (Spik, 1998). The 
embryo appeared normal until 8-cell stage, but failed to 
reach the 16-cell stage. The validity of this model was 
confirmed when the embryos were rescued following addition 
of recombinant mouse lactoferrin to the culture medium, 
showing in this way, that lactoferrin is involved in fetal 
haemopoiesis as well.  
Therefore, based on these reported studies, several 
attempts should be made in order to generate a successful 
LTF-/- model. If such a model is made experimentally 
possible, then many insights would be gained in terms of 
the molecular effect of lactoferrin on neutrophil 
chemotaxis and the identification of the underlying 
factors and mechanisms. Also, using this LTF-/- model, the 
role of lactoferrin on the expression of cytokines could 
be easily determined. The factors that promote or regulate 
lactoferrin expression will be therefore better 
characterised, as till now there is restricted evidence as 
the ERE (estrogen response element) region is the only 
till now characterised regulatory molecule located in the 
5’ flanking region of the gene that controls the 
expression of the lactoferrin gene (Liu and Teng, 1992). 
The location and expression of ERE overlaps the binding 
site of the COUP transcription factor that acts as a 
negative regulator of oestrogen. Lactoferrin gene activity 
was also found to be dependent on prolactin expression 
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within a species’ mammary gland (Green and Pastewka, 
1978), whereas the uterine lactoferrin gene expression was 
highly dependent on 17β-oestradiol treatment (Pentecost 
and Teng, 1987; Teng et al., 1989). In this way, the 
identification of the exact pattern of the molecular 
activity of lactoferrin will prove to be beneficial in 


















It is speculated that lactoferrin acts intracellularly and 
more specifically, it interacts and inhibits the activity 
of calcium-calmodulin (Ca2+/CaM) complex. The Ca2+/CaM 
complex is formed following PKC activation and [Ca2+]i 
increase and regulates the activity of cell adhesion and 
migration pathways including ERK1/2 phosphorylation. 
Inhibitors of calmodulin activity mimic the inhibitory 




The identification of lactoferrin, apart from its anti-
microbial properties, bears strong implications in the 
therapeutic potential of many inflammatory disorders that 
are marked by aberrant neutrophil infiltration. Such 
disorders include glomerulonephritis, interstitial lung 
disease, rheumatoid arthritis etc. (Weiss, 1989). This is 
even supported by the finding that the presence of 
significant numbers of neutrophils found in the pulmonary 
fluid from infants with hyaline membrane disease (HMD) and 
bronchopulmonary dysplasia (BPD) are linked to lactoferrin 
and lysozyme deficiency in the airway secretion of the 
affected individuals (Revenis and Kaliner, 1992). Thus, 
although lactoferrin represents a major protein in 
respiratory epithelial lining fluid, its deficiency may 
lead to predisposition of altered host defense towards 
lung injuries and result to neutrophil accumulation. 
Moreover, the identification of the anti-inflammatory 
properties of lactoferrin enabled to gain better insights 
on its role in disorders that are marked by the presence 
of anti-lactoferrin antibodies, especially ulcerative 
colitis, primary sclerosing cholangitis, Crohn’s disease 
and SLE (Audrain et al., 1996; Caccavo et al., 2005; 
Roozendaal et al., 1998).  
Due to its broad role in inflammation, many attempts have 
been carried out to obtain large amounts of the protein. 
In detail, a recombinant form has been available and was 
established using various expression systems such as 
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filaments of Aspergillus fungus (Ward et al., 1992), yeast 
and other bacteria (Kim et al., 2006; Tian et al., 2007). 
Also recently, transgenic Bombyx mori insects were 
created, each expressing 205 µg of lactoferrin per 
infected pupa (Liu et al., 2005b). This was followed by 
the generation of transgenic animals that produce 
lactoferrin in goats, mice, rabbits (levels up to 2 g of 
human lactoferrin per litre of milk) (Nuijens et al., 
1997; Zhang et al., 2008). The development of lactoferrin 
peptides with highly efficient bacteriostatic, anti-
microbial and apoptotic properties has also yielded 
tremendous applications (Elass et al., 2002; Roy et al., 
2002; Ward and Conneely, 2004). The surprising fact is 
that the physical and biological characteristics of the 
recombinant protein are indistinguishable from the native 
one; however, in both cases, the possibility of LPS 
contamination shall not be excluded that might account for 
experimental variations among groups. Despite this 
limitation, it should be emphasised that lactoferrin is a 
commercially attractive molecule that is a natural 
component of the immune system with an ever-increasing 
list of properties. It can be readily supplied in large 
quantities and is one of the few physiological, endogenous 
expressed molecules characterised so far that negatively 
regulate neutrophil infiltration. 
The inhibitory effect of lactoferrin on eosinophil 
migration should also be highlighted, as it can be 
therapeutically beneficial in allergic inflammatory 
conditions, including allergic rhinitis and asthma, which 
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are characterised by excessive eosinophil infiltration. 
Many modes of lactoferrin administration have been 
characterised and involve oral administration, 
subcutaneous or inhaled (Ward et al., 2005). Another 
described mode involves the use of liposomes as carriers 
for lactoferrin (Chen et al., 2010a; Roseanu et al., 
2010). Liposomes are prepared from biodegradable, non-
toxic lipids and are used for the local delivery of 
therapeutic agents. A study by Trif et al. (2001), has 
introduced the application of human lactoferrin entrapped 
in positively charged liposomes in the inflamed joint in a 
model of collagen-induced arthritis. Therefore, the use of 
lactoferrin-entrapped liposomes can be a good candidate in 
inflammatory conditions to prevent their exacerbation. 
Also, the effect of lactoferrin on the activity of 
disease-specific anti-inflammatory drugs or whether the 
application of lactoferrin could enable the resolution and 
eradication of the inflammatory responses are two points 
that would be interesting to examine.  
Despite its therapeutic potential, the identification of 
lactoferrin also reveals novel insights on the processes 
that take place during the resolution of an inflammatory 
response. What could therefore be proposed is that, based 
on the findings of this study, in inflammatory conditions, 
recruited, activated neutrophils arrive at the site of 
inflammation and release lactoferrin. Secreted lactoferrin 
creates a concentration gradient that stops neutrophil 
movement, while inhibiting the chemotaxis of other 
neutrophils that arrive from circulation (Figure 49). In 
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fact, it is the same protein that is released by 
neutrophils, as a means of their effector activities, 
while it prevents their further recruitment. This response 
triggers the creation of an anti-inflammatory environment 
that marks the later phases of a response, which in 
parallel is also a homeostatic mechanism that promotes the 
initiation of the resolution phase of inflammation. 
Indeed, the local concentration of lactoferrin at sites of 
inflammation or infection was found to be up to 200 μg ml-1 
maximum; a concentration that was demonstrated in this 
study to be able to inhibit neutrophil migration in vitro.  
Furthermore, in sites where homeostatic apoptosis rates 
are high, which are characterised by an anti-inflammatory 
environment, it can be suggested that the constitutive 
production of lactoferrin accounts for the absence of 
neutrophils from such sites and therefore, it contributes 
to the non-inflammatory nature of apoptosis. In general 
terms, the anti-inflammatory nature of the apoptotic 
program is stimulated mainly by the release of anti-
inflammatory cytokines, such as IL-10, TGF-β by 
macrophages or epithelial cells as well as by possible 
till now unidentified molecular mechanisms that prevent 
neutrophil recruitment. Also, in professional phagocytes, 
sensing mechanisms that are not yet well defined allow 
these cells to navigate to apoptotic cells through 
chemotactic processes involving lipid signalling 
molecules, such as lipoxins and classical chemokine 
mechanisms. It is noteworthy that of the two categories of 
300 
 
professional phagocytes, mononuclear and polymorphonuclear 
cells, apoptotic cells attract mononuclear phagocytes 
selectively (Kerr et al., 1972; Ravichandran and Lorenz, 
2007). Indeed, the lack of recruitment of granulocytes to 
apoptotic zones is a hallmark of the non-phlogistic 
apoptosis program, distinguishing normal areas of cell 
death from sites of accidental or pathological tissue 
damage or infection.  
Recent evidence suggests that certain recombinant 
preparations of lactoferrin have the potential to 
chemoattract monocytes (de la Rosa et al., 2008). Although 
monocyte attraction to milk-derived lactoferrin failed to 
be observed in this study, these results indicate that 
lactoferrin has the potential to function in the selective 
attraction of monocytes by excluding granulocytes from 
sites where homeostatic apoptosis rates are high. 
Furthermore, a point that should be examined is whether 
lactoferrin interacts or regulates the expression of 
“ find-me”  molecules that are exposed on the surface of 
apoptotic cells or macrophages to promote cell clearance. 
It can be speculated that lactoferrin, secreted by 
neutrophils or by cells at the early stages of their 
apoptosis, as demonstrated in this study, promotes the 
expression of macrophage chemoattractants or recognition 
molecules, such as thrombospondin, PS exposure and 
nucleotides that will enable phagocytic clearance.   
In summary, it can be proposed from the results of this 
study that lactoferrin arising from the secondary granules 
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of neutrophils and from apoptotic cells constitutes a 
negative feedback component that limits the influx of 
neutrophils. On this basis, it could be speculated that 
neutrophils undergoing apoptosis en route to resolution of 
inflammation would release lactoferrin as do other 
apoptotic cells but would be unlikely to be required to 
synthesise the protein de novo. Also, this could be a 
mechanism by which granulocytes are retained at the 
inflammatory site, as lactoferrin prevents them from 
moving. Lactoferrin is therefore a constitutive anti-
inflammatory component of apoptotic cells that, in 
addition to its known anti-inflammatory properties, 
militates against the proinflammatory recruitment of 
granulocytes to sites where homeostatic apoptosis rates 
















Based on the results of this study, in an inflammatory 
site, lactoferrin is secreted by the recruited neutrophils 
and by resident apoptotic cells. Secreted lactoferrin 
creates a concentration gradient that (a) stops further 
neutrophil recruitment, (b) immobilises resident  
neutrophils allowing them to exert their effector 
functions, (c) chemoattracts monocytes (based on de la 
Rosa et al., 2008), (d) activates resident macrophages 
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(based on Curran et al., 2006) and (e) promotes 
phagocytosis (based on Lima and Kierszenbaum, 1985). 
Lactoferrin, Apoptosis and Tumour Proliferation 
The first published evidence on the role of apoptosis and 
lactoferrin secretion arose from studies on lactation and 
the involuting mammary tissue (Monks et al., 2002; Wang et 
al., 2005; Wilde et al., 1997). During lactation, there is 
a strong expression of lactoferrin mRNA expression on day 
1 of lactation, whereas a cDNA microarray analysis on the 
expression of genes during the involution of bovine 
mammary gland further revealed a decreased mRNA expression 
of the milk protein genes of β-, κ-casein, α-lactalbumin 
and β-lactoglobulin and a dramatic increase of the 
expression of lactoferrin 192 h post-milking (Singh et 
al., 2008; Wang et al., 2005). Therefore, as the 
involution of the mammary tissue is dominantly 
characterised by elevated levels of apoptosis, the 
associated increase in the levels of lactoferrin provided 
initial insights that link lactoferrin to apoptosis.  
In this study, it was revealed that lactoferrin is 
endogenously expressed and released by a variety of tumour 
types upon induction of apoptosis. More specifically, when 
BL2 cells were staurosporine-stimulated, an upregulation 
in lactoferrin expression was noted parallel to the 
increase in apoptosis levels. In contrast, BL2 cells 
transfected with the anti-apoptotic BCL2, failed to 
express lactoferrin to similar levels due to the lower 
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apoptosis rates. Lactoferrin expression was also found to 
be upregulated in MCF-7 cells and expressed de novo in 
Jurkat, BL2 and A549 cells, irrespective of the apoptosis-
inducing agent. Not only was apoptosis-related lactoferrin 
expression demonstrated at the transcriptional level, 
lactoferrin protein was also recovered from supernatants 
of cells undergoing apoptosis. This finding demonstrated 
that lactoferrin is actively expressed by several tumour 
types and highlighted the importance of apoptosis in 
tumour progression. In this way, lactoferrin can be used 
as a marker to histologically quantify apoptosis or to 
assess the progression rate of tumours. 
Indeed, several studies supported that in conditions like 
tumours that are characterised by distortions in the 
regulation of cell population, apoptosis plays a key role 
by regulating tumour progression and prognosis. For 
example, in breast carcinomas, high-grade tumours display 
more apoptosis (Lipponen et al., 1994; Mustonen et al., 
1997). Also, high-grade malignant non-Hodgkin’s lymphomas 
have a higher apoptotic index than low-grade lymphomas and 
this correlates to Bcl-2 expression, which is increased in 
low-grade lymphomas (Kiberu et al., 1996; Soini et al., 
1998a). In parallel, other studies have supported the role 
of lactoferrin as a growth factor. For example, 
lactoferrin induces the development of osteoblast cells by 
promoting their proliferation via low density lipoprotein 
receptor related protein-1 (LRP-1) signalling (Cornish et 
al., 2004; Grey et al., 2004). Also, in vivo, in mice in 
which lactoferrin (4 mg) had been administered 
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subcutaneously for 5 days, a marked fourfold increase in 
bone mass was noted (Cornish et al., 2004). In mammary 
cells, lactoferrin has been reported to interfere with 
retinoid signalling (Baumrucker et al., 2006b). The 
mitogenic effect of lactoferrin also extends to enterocyte 
formation, B and T lymphocyte expansion as well as 
macrophage development (Grey et al., 2006). In general, 
lactoferrin was suggested to be an important contributor 
in terms of organ formation and bone development, based on 
its high levels of expression in a foetus as well as in 
several tumours. Therefore, based on this study and 
previous published evidence, it can be speculated that the 
role of lactoferrin in tumours is at least two-fold, as it 
(i) prevents neutrophil infiltration and thus any arising 
cytostatic effects and (ii) promotes tumour cell 
proliferation. The latter is supported by results of this 
study, which indicated that blocking the activity of 
lactoferrin or knocking down its expression, also 
decreases the proliferation rate of the tumour cells in 
Burkitt’s lymphoma irrespective of whether they associate 
to EBV infection; however, the exact mode of lactoferrin 
recognition by proliferating cells is something till now 
not known.  
This effect was prominent by assessing the proliferation 
of cells cultured in the presence of monoclonal antibodies 
against lactoferrin as well as of cells that were shRNA-
transfected to knockdown lactoferrin expression. Such an 
effect on cell proliferation was accompanied by the 
observation that BL cells, in which lactoferrin has been 
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blocked via monoclonal antibodies, underwent apoptosis and 
an arrest at G1/S cell cycle checkpoint at a significantly 
higher rate than their control counterparts. Such a 
negative effect on cell cycle progression was also 
reported in other studies, in which lactoferrin was 
demonstrated to interfere with the cell cycle and induce a 
cell cycle arrest at the G1/S checkpoint by affecting cell 
cycle regulatory proteins such as cyclin E, p21 and p27 
Cdk inhibitory proteins that are associated with the Akt 
and MAPK pathways (Damiens et al., 1999; Xiao et al., 
2004; Zhou et al., 2008). It should be mentioned that the 
observed effect of lactoferrin on the cell cycle or on the 
levels of apoptosis was not evident when the proliferation 
of lactoferrin shRNA-transfected BL2 cells was assessed. 
Therefore, it could be proposed that the addition of the 
anti-lactoferrin antibody to BL cells induces cellular 
death via an antibody-dependent cytotoxicity. Moreover, 
the possibility that the use of antibody causes a rapid 
deprivation of lactoferrin in these cells, promoting their 
cellular death, shall not be excluded as the shRNA 
transfected ones were used to survive in a lactoferrin-
deficient environment. Also, in shRNA-transfected cells, 
lactoferrin was knocked down and not completely 
neutralised, and therefore, low levels of lactoferrin 
could have been present.  
Although depletion of endogenous lactoferrin by monoclonal 
antibodies resulted in an increase in the apoptosis levels 
of BL cells, lactoferrin per se was not found to induce or 
stimulate apoptosis. Indeed, BL cells that were cultured 
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in serum-free medium in the presence of lactoferrin 
underwent apoptosis at a similar rate as those cultured in 
the absence of lactoferrin. Moreover, staurosporine-
induced apoptotic BL cells displayed a similar level of 
apoptosis in the presence or absence of lactoferrin, 
showing in this way that lactoferrin does not promote the 
apoptosis program in Burkitt’s lymphoma. This finding 
comes in contrast to published evidence that reported that 
lactoferrin induced apoptosis in hepatic epithelial cells 
via an iron-dependent lysosomal death pathway in a process 
necessary for caspase-3 activation (Gorria et al., 2008). 
Recent evidence also suggested that the protease activity 
of lactoferrin may be instrumental in activating the 
caspase cascade, as endogenous lactoferrin has been 
reported to induce apoptosis through activation of 
caspase-3 (Gorria et al., 2008; Katunuma et al., 2006). 
Additionally, lactoferrin was demonstrated to promote 
apoptotic cell death in oral cancer cells by inducing 
cleavage of caspase-3 and poly (ADP-ribose) polymerase, 
phosphorylation of ERK1/2 and phosphorylation of cJun N-
terminal kinase/stress activated protein kinase (JNK/SAPK) 
(Sakai et al., 2005). Indeed, it was found that pre-
treatment of cells with a JNK/SAPK inhibitor reduced 
lactoferrin-induced apoptosis. This was also confirmed in 
subsequent studies in Jurkat T leukemias, to which 
lactoferrin- induced apoptosis via the regulation of c-
Jun-N-terminal kinase (JNK) activity and via the 
activation of caspase-9 and caspase-3 (Lee et al., 2009). 
However, how lactoferrin could sustain proliferation and 
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how its depletion can promote apoptosis could involve 
distinct signalling pathways -other than those reported so 
far- that could be caspase-dependent or independent 
differing among tumour types. For this reason, further 
investigation is required on the underlying molecular 
mechanisms.  
A possible mechanism of activity could be via the PPAR 
(peroxisome proliferator activated receptor) pathway, as 
PPARα was found to be a transcription factor for 
lactoferrin, while PPARβ/δ was demonstrated to inhibit 
leukocyte recruitment, expression of cell adhesion 
molecule (CAM) and chemokine release (Hasmall et al., 
2002; Piqueras et al., 2009). Therefore, it can be 
speculated that a PPAR-mediated mechanism seems able to 
link and regulate both activities of lactoferrin as a 
negative regulator of neutrophil migration and as a growth 
factor; however, it needs to be experimentally verified. 
Also, in the context of lactoferrin activity as a growth 
factor, it should be investigated whether the iron binding 
domain of lactoferrin or the iron saturation of 
lactoferrin regulate its growth factor activities, as iron 
and lactoferrin were previously reported to be essential 
for cell growth (Baumrucker et al., 2006a; Burnham, 1963).  
Additionally, in this study, initial insights were gained 
in terms of the mode of lactoferrin secretion by cells. So 
far, there is little published evidence on the manner that 
lactoferrin is released by neutrophils or mammary cells 
during lactation. In this study, it was demonstrated that 
309 
 
treatment of A549 cells with brefeldin A, which interferes 
with intracellular transport of newly synthesised 
proteins, resulted in inhibition of apoptosis-induced 
lactoferrin release, providing further evidence for the de 
novo synthesis and secretion of lactoferrin. Moreover, 
although it is clear that the secretory events inhibited 
by brefeldin A treatment (transport from the endoplasmic 
reticulum (ER) and Golgi network) are important for the 
release of lactoferrin from apoptotic cells, further work 
will be required to elucidate the details of this 
secretory process, including whether lactoferrin is 
transported directly from Golgi membranes for release from 
the cell surface. All these findings support the 
possibility of exocytosis as a mode of lactoferrin 
release.   
It can be suggested that other insights on the mode of 
lactoferrin release could be gained from the mode of 
annexin-1 release. Annexin-1 is also an inhibitor of 
neutrophil recruitment that is stored in gelatinase 
granules (Lominadze et al., 2005; Perretti and Flower, 
2004). Though the molecular mechanisms of annexin-1 
release are cell-specific, in macrophages, the ATP-binding 
cassette (ABC) transporter system was found to be 
responsible for annexin-1 release, while in neutrophils, 
annexin-1 becomes mobilised and relocated to the outer 
leaflet of the plasma membrane upon activation by 
chemoattractants (Perretti et al., 2000; Vong et al., 
2007; Wein et al., 2004). In pituary cells, 
phosphorylation at Ser27 of annexin-1 is enough to promote 
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its secretion (John et al., 2002; Porte et al., 1996; 
Solito et al., 2006). In this way, in the case of 
lactoferrin, the mode of its secretion might differ 
between neutrophils, where it is stored in granules, and 
apoptotic cells, by which it is de novo expressed. Also, 
lactoferrin release might occur as a stress-response; 
providing in this way an explanation why it is released at 
the early stages of apoptosis and thus rendering the 
involvement of the JNK/SAPK pathway more possible. 
Although this study failed to detect lactoferrin in 
apoptotic cells by immunohistochemical or 
immunofluorescent staining, as these approaches were not 
sensitive enough in detecting the low amount of expressed 
lactoferrin, it is anticipated that novel approaches or 
optimisation of the existing ones would allow more 
insights to be gained in terms of the mode of lactoferrin 
secretion.  
In general terms, the observation that lactoferrin 
released into the supernatants of apoptotic cells is able 
to inhibit the migration of neutrophils, demonstrates not 
only that physiological concentrations of lactoferrin are 
functional in mediating this effect but also that 
apoptotic cells are active in producing a factor that can 
potently suppress migration of neutrophils, the major 
subset of professional phagocytes among circulating 
leukocytes, to sites where homeostatic apoptosis rates are 
high. The anti-inflammatory role of lactoferrin has also 
been supported by the fact that the release of lactoferrin 
was found not to be linked to necrosis, which is 
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characterised by a highly inflammatory environment, but 
that it is expressed and actively released from cells as a 
consequence of activation of their apoptosis program.  
In summary, the results of this study have indicated that 
the overall apoptotic microenvironment of a tumour 
triggers the synthesis and release of lactoferrin. In 
addition, despite the fact that lactoferrin has been 
reported in other studies to exert apoptotic effects on 
cells, such as hepatocytes, mammary cells and others, 
something like that was not evident in this study using 
Burkitt’s lymphoma cells. Therefore, lactoferrin may have 
multiple properties in apoptosis: (a) regulating the 
initiation of the program, (b) influencing repair in the 
tissue microenvironment and (c) promoting the non-
phlogistic nature of the process; showing in this way that 
the endogenous production of lactoferrin is linked to the 
initiation of the apoptosis program, to its anti-




The involvement of lactoferrin in the regulation of 
neutrophil recruitment and BL cell proliferation enabled 
its characterisation as a molecule of the tumour 
immunosurveillance mechanism (Figure 50). Under 
physiological conditions, lactoferrin expression extends 
to nearly all tissues such as breast, stomach, pancreas, 
salivary gland, endometrium, spleen, prostate liver, blood 
and others (Siebert and Huang, 1997). Its expression 
becomes upregulated under specific normal conditions such 
as organ morphogenesis, lactation and involution of the 
mammary gland (Monks et al., 2002; Wilde et al., 1997). 
Based on the results of this study, the absence of 
neutrophils from these tissues could be attributed to the 
presence of lactoferrin.  
In the case of tumours, studies have reported enhanced 
lactoferrin expression in neoplastic bone tissues, in 
human sporadic renal cell carcinomas, in human 
astrocytomas, in colon carcinomas, in human breast cancer, 
in Hodgkin’s disease and Burkitt’s lymphoma (Brock et al., 
1994; Campbell et al., 1992; Hoffer et al., 1979; Ieni et 
al., 2009; Tuccari et al., 1999) and during the neoplastic 
transformation of the endometrium (Walmer et al., 1995) 
and of the endocervix (Giuffre et al., 2006). Especially, 
in the case of endocervix neoplasms, neoplastic formation 
correlates with downregulation of lactoferrin expression 
(Farley et al., 1997). Lactoferrin mRNA was also shown by 
RT-PCR analysis to be expressed by the promyelocytic 
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leukemia HL-60 cell line, T-lymphoblastic leukemia Jurkat 
cell line, breast tumour T41D cell line, Burkitt’s 
lymphoma Raji, colorectal adenocarcinoma SW490 and 
erythroleukemia K562 (Hoffer et al., 1979; Siebert and 
Huang, 1997). However, the role or how lactoferrin 
expression becomes regulated in tumour tissues requires 
further investigation. Moreover, based on the 
identification of the differential expression of the 
lactoferrin isoform, delta lactoferrin in tumour tissues, 
it cannot be excluded that inside a tumour cell, 
lactoferrin can be cleaved or alternatively spliced 
(Breton et al., 2004; Siebert and Huang, 1997). Another 
point that requires investigation is whether the 
glycosylation profile of lactoferrin or its iron 
saturation status might promote tumour progression (van 
Berkel et al., 1996). Also, whether there are polymorphic 
sites in the lactoferrin gene that account for these 
properties of lactoferrin shall also be examined.  
In general terms, although the exact activities of 
lactoferrin in relation to tumour biology are currently 
unclear, based on this study, it can be therefore 
suggested that due to its anti-inflammatory properties, 
lactoferrin is a protein that is manipulated by the tumour 
itself to regulate any possible anti-tumour immune 
responses by the host. For instance, lactoferrin 
expression might be altered or upregulated by tumour-
derived cytokines that are released to render 
hypofunctional the immunogenicity of the host organism. 
One example is IL-10, which is expressed by tumours, like 
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Burkitt’s lymphoma in this case, and was presented to be 
upregulated following administration of lactoferrin (Hwang 
et al., 2007). Lactoferrin could also account for B cell 
maturation by potentially upregulating factors such as B 
cell-activating factor (BAFF/BLyS)(Ogden et al., 2005), 
whereas the tight association of lactoferrin with the 
tumour regulatory protein IL-18 could also support the 
involvement of lactoferrin in tumour-promoting responses 
(Iigo et al., 2009; Iigo et al., 2004). Other point that 
could be examined is the association between lactoferrin 
and Bcl-2 expression, as alterations in Bcl-2 expression 
are linked to tumour establishment and progression. Also 
how lactoferrin expression can influence or be modulated 
by the hypoxic environment of some tumour regions is a 
point not known yet. 
Despite the fact that lactoferrin exerts no effect on 
monocyte migration, it might possibly induce TAM 
differentiation to M2 phenotype, affect their activation 
status as well as the rate of phagocytosis of engulfed 
apoptotic tumour cells. Indeed, the phagocytosis rate and 
the presence of apoptotic bodies in tumours, especially 
BL, are high and the presence of lactoferrin is very 
possible to affect these processes. Also, whether 
recruited monocytes or TAMs express lactoferrin is 
something that has not been examined yet. On a similar 
basis, the production of lactoferrin could account for the 
absence of neutrophils from the Burkitt’s lymphoma site. 
It can thus be predicted that in situ production of 
lactoferrin acts as a homeostatic mechanism to prevent the 
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cytostatic effects that the migrated neutrophils would 
exert. This prediction is supported by the observation 
that Burkitt’s lymphoma, in which high rate of apoptosis 
occurs, has been demonstrated to display in situ 
production of lactoferrin (Hoffer et al., 1979).  
Other functions that are still under investigation involve 
the efficiency of lactoferrin as a growth factor in 
association to its anti-tumour ability and the arising 
controversy on how its activities are interrelated. 
Indeed, there are studies that support lactoferrin as an 
anti-apoptotic molecule, as oral administration of 
lactoferrin in a mouse intestinal mucosa was demonstrated 
to inhibit carcinogenesis and metastasis (Iigo et al., 
2004), diminished head and neck squamous cell carcinomas 
in vivo (McKeown et al., 2006; Wolf et al., 2007; Xiao et 
al., 2004), prevented lung colonisation and experimental 
metastasis in a B16-F10 melanoma model (Bezault et al., 
1994) as well as azoxymethane (AOM)-induced rat colon 
tumour formation and aberrant crypt foci development 
(Sekine et al., 1997a; Sekine et al., 1997b; Tsuda et al., 
1998; Tsuda et al., 2000). In other words, since 
lactoferrin is actively synthesised and involved in tumour 
proliferation, a question that arises is how lactoferrin 
can exert an anti-tumour effect. This is a point that does 
not reject the results of this study, but instead it 
prompts particular attention in terms of the dose and the 
source of the administered lactoferrin. There are many 
variations in the mode of administration of lactoferrin, 
its purity, species’ specificity as well as differences in 
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the time of experimentation or even non-specific immune 
responses that are elicited by the glycan moieties of the 
protein. Another determinant is also differences in the 
production of native and recombinant lactoferrin. Purified 
lactoferrin usually arises following metal ion affinity 
chromatography or concanavalin A affinity chromatography 
and is in the iron-saturated form (Nuijens et al., 1996). 
However, unlike previous published literature that is 
based on the exogenous administration of lactoferrin, this 
study is the first to report that lactoferrin is an 
endogenously expressed factor by tumours that plays a role 
in their proliferation.  
In this way, based on the endogenous expression of 
lactoferrin, attempts shall be made in order to 
beneficially employ this molecule in tumour immunotherapy. 
Future experiments shall be focused on the knock-down of 
lactoferrin in tumour models in vivo and on the 
examination of whether this affects the recruitment of 
neutrophils in order to exert any cytostatic effects 
against tumour. Also, the level and type of tumour-
secreted cytokines are crucial on how tumour responds in 
the absence of lactoferrin and the type of mechanisms that 
are employed by the tumour to survive regression should be 
investigated. Additionally, the rate of proliferation and 
tumour apoptosis are two parameters that shall be 
examined. A useful tool to address all these questions 
would be the establishment of a valid lactoferrin knockout 
mouse model, which, in parallel, will provide useful 
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insights on the underlying molecular mechanism of 
lactoferrin activity.   
Therefore, based on the findings of this study, further 
research is required to unravel the exact molecular 
mechanisms that enable neutrophil anti-tumoural activity 
as well as the elaboration of molecules that tumour cells 
employ in order to prevent neutrophil recruitment. It is 
evident that the manipulation of mechanisms that induce 
neutrophil migration and their cytostatic responses can be 
very successful. Hopefully, lactoferrin is one of the 
molecules that can be therapeutically beneficial in this 
context. Although the existence of a tumour and the 
mechanisms that promote tumour immunosurveillance are too 
complex to prevent tumour regression, it is anticipated 
that lactoferrin, in combination with the existing anti-
tumour therapies would lead to a massive infiltration of 
neutrophils to the tumour stroma, decrease the rate of 
tumour proliferation and finally succeed in the total 
eradication of the tumour itself.  
In summary, given the multifunctional abilities of 
lactoferrin, the results of this study highlight the 
influence of apoptotic cells on multiple physiological 
processes, including cell growth, differentiation, innate 
and adaptive immune responses, as well as the pathological 
process of inflammatory and malignant diseases. Since 
lactoferrin has potent ability to inhibit neutrophil 
migration, it seems likely that in tumours in which 
neutrophils are absent, like Burkitt’s lymphoma, this 
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might act as an evading mechanism by the tumour in order 
to escape neutrophil infiltration and therefore, their 
cytotoxic effects. In this way, induction of neutrophil 
infiltration through inhibition of lactoferrin may lead to 
tumour destruction. On the contrary, in tumours in which 
neutrophils play a supportive role, such as gliomas, 
limitation of neutrophil infiltration through lactoferrin 
















Based on the results of this study, in a tumour site, 
endogenous lactoferrin (a) promotes BL cell proliferation, 
(b) is released from viable (?) and/or apoptotic tumour 
cells to inhibit neutrophil migration as a homeostatic 
mechanism to avoid the cytostatic effects of neutrophils. 
Also, based on de la Rosa et al. (2008), secreted 
lactoferrin chemoattracts monocytes that could later 
become differentiated to tumour-associated macrophages 
(TAMs), which have a symbiotic relationship with the 
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U6: U6 promoter; insert: shRNA-encoding insert sequence; 
cppt: central polypurine tract; hPGK: human 
phosphoglycerate kinase eukaryotic promoter; Puro: 
puromycin resistance gene for mammalian selection; 3’ LTR: 
3’ self inactivating long terminal repeat; f1 ori: E.coli 
f1 origin of replication; AmpR Prom: bacterial 
constitutive promoter for the ampicillin resistance gene; 
AmpR: ampicillin resistance gene for bacterial selection; 
pUC ori: pUC-based E.coli origin of replication; 5’ LTR: 
L’ long terminal repeat; ψ: ψ sequence - RNA packaging 




     1 TTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCGCAGGGACGCGGCTGCTCTGGG 
    61 CGTGGTTCCGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGCACATTCTTCACGTCCGTT 
   121 CGCAGCGTCACCCGGATCTTCGCCGCTACCCTTGTGGGCCCCCCGGCGACGCTTCCTGCT 
   181 CCGCCCCTAAGTCGGGAAGGTTCCTTGCGGTTCGCGGCGTGCCGGACGTGACAAACGGAA 
   241 GCCGCACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAGGGAGCAATGGCAGCGCGC 
                                                        M  A  A  R 
   301 CGACCGCGATGGGCTGTGGCCAATAGCGGCTGCTCAGCAGGGCGCGCCGAGAGCAGCGGC 
        R  P  R  W  A  V  A  N  S  G  C  S  A  G  R  A  E  S  S  G 
   361 CGGGAAGGGGCGGTGCGGGAGGCGGGGTGTGGGGCGGTAGTGTGGGCCCTGTTCCTGCCC 
        R  E  G  A  V  R  E  A  G  C  G  A  V  V  W  A  L  F  L  P 
   421 GCGCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCGGCAGTCGGCTCCCTCGTT 
        A  R  C  S  A  F  C  K  P  P  E  R  T  S  A  V  G  S  L  V 
   481 GACCGAATCACCGACCTCTCTCCCCAGGGGGATCCACCGGAGCTTACCATGACCGAGTAC 
        D  R  I  T  D  L  S  P  Q  G  D  P  P  E  L  T  M  T  E  Y 
   541 AAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCC 
        K  P  T  V  R  L  A  T  R  D  D  V  P  R  A  V  R  T  L  A 
   601 GCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCACATCGAG 
        A  A  F  A  D  Y  P  A  T  R  H  T  V  D  P  D  R  H  I  E 
   661 CGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTG 
        R  V  T  E  L  Q  E  L  F  L  T  R  V  G  L  D  I  G  K  V 
   721 TGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCG 
        W  V  A  D  D  G  A  A  V  A  V  W  T  T  P  E  S  V  E  A 
   781 GGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCC 
        G  A  V  F  A  E  I  G  P  R  M  A  E  L  S  G  S  R  L  A 
   841 GCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTC 
        A  Q  Q  Q  M  E  G  L  L  A  P  H  R  P  K  E  P  A  W  F 
   901 CTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTG 
        L  A  T  V  G  V  S  P  D  H  Q  G  K  G  L  G  S  A  V  V 
   961 CTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCG 
        L  P  G  V  E  A  A  E  R  A  G  V  P  A  F  L  E  T  S  A 
  1021 CCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTG 
        P  R  N  L  P  F  Y  E  R  L  G  F  T  V  T  A  D  V  E  V 
  1081 CCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCAC 
        P  E  G  P  R  T  W  C  M  T  R  K  P  G  A  * 
  1141 GACCCGCAGCGCCCGACCGAAAGGAGCGCACGACCCCATGCATCGGTACCTTTAAGACCA 
  1201 ATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAA 
  1261 GGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGG 
  1321 TTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 
  1381 CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT 
  1441 AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGTAGTTCA 
  1501 TGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATATCAGAGAGTGAGAGG 
  1561 AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACA 
  1621 AATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT 
  1681 TATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGC 
  1741 CCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCG 
  1801 AGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAG 
  1861 GGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTT 
  1921 ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCC 
  1981 CCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTT 
  2041 GCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT 
  2101 GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC 
  2161 TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG 
  2221 GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTA 
  2281 GGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTT 
  2341 GGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTAT 
  2401 CTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAA 
  2461 TGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTA 
  2521 GGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACAT 
  2581 TCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAA 
  2641 AGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTT 
  2701 TGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAG 
  2761 TTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGT 
  2821 TTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCG 
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  2881 GTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAG 
  2941 AATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTA 
  3001 AGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTG 
  3061 ACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTA 
  3121 ACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC 
  3181 ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTT 
  3241 ACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCA 
  3301 CTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAG 
  3361 CGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTA 
  3421 GTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAG 
  3481 ATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTT 
  3541 TAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGAT 
  3601 AATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTA 
  3661 GAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAA 
  3721 ACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTT 
  3781 TTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG 
  3841 CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTA 
  3901 ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCA 
  3961 AGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAG 
  4021 CCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAA 
  4081 AGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGA 
  4141 ACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC 
  4201 GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGC 
  4261 CTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTT 
  4321 GCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT 
  4381 GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAG 
  4441 GAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAA 
  4501 TGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAAT 
  4561 GTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATG 
  4621 TTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTAC 
  4681 GCCAAGCGCGCAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCTGCAAGCTTAATGT 
  4741 AGTCTTATGCAATACTCTTGTAGTCTTGCAACATGGTAACGATGAGTTAGCAACATGCCT 
  4801 TACAAGGAGAGAAAAAGCACCGTGCATGCCGATTGGTGGAAGTAAGGTGGTACGATCGTG 
  4861 CCTTATTAGGAAGGCAACAGACGGGTCTGACATGGATTGGACGAACCACTGAATTGCCGC 
  4921 ATTGCAGAGATATTGTATTTAAGTGCCTAGCTCGATACATAAACGGGTCTCTCTGGTTAG 
  4981 ACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAAT 
  5041 AAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACT 
  5101 AGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAG 
  5161 GGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGA 
  5221 AGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAG 
  5281 CGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAG 
  5341 ATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACA 
  5401 TATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAAC 
  5461 ATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGA 
  5521 AGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGA 
  5581 GATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAC 
  5641 CACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATT 
  5701 GGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA 
  5761 CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGT 
  5821 TCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGG 
  5881 TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA 
  5941 TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA 
  6001 GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCT 
  6061 CTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTC 
  6121 TGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA 
  6181 CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG 
  6241 AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC 
  6301 TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTT 
  6361 TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGA 
  6421 CCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAG 
  6481 AGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGATCACGAG 
  6541 ACTAGCCTCGAGCGGCCGCCCCCTTCACCGAGGGCCTATTTCCCATGATTCCTTCATATT 
  6601 TGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAA 
  6661 AGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTT 
  6721 TAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATT 
  6781 TCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGCGGTGCAGATAAAGGACAGT 
  6841 TCTCGAGAACTGTCCTTTATCTGCACCGTTTTTGATCTGTCAGCATCTGGGTCATTCATA 
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  6901 ATAATAATATCTGCATCATGTTTAATACCATATTCAAGCGGTATTTTTCATGCAGGATCA 
  6961 AATTCTGGATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGT 
  7021 AGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCA 








U6: U6 promoter; insert: shRNA-encoding insert sequence; cppt: 
central polypurine tract; hPGK: human phosphoglycerate kinase 
eukaryotic promoter; Puro: puromycin resistance gene for 
mammalian selection; 3’ LTR: 3’ self inactivating long 
terminal repeat; f1 ori: E.coli f1 origin of replication; AmpR 
Prom: bacterial constitutive promoter for the ampicillin 
resistance gene; AmpR: ampicillin resistance gene for 
bacterial selection; pUC ori: pUC-based E.coli origin of 
414 
 
replication; 5’ LTR: L’ long terminal repeat; ψ: ψ sequence - 




     1 TTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCGCAGGGACGCGGCTGCTCTGGG 
    61 CGTGGTTCCGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGCACATTCTTCACGTCCGTT 
   121 CGCAGCGTCACCCGGATCTTCGCCGCTACCCTTGTGGGCCCCCCGGCGACGCTTCCTGCT 
   181 CCGCCCCTAAGTCGGGAAGGTTCCTTGCGGTTCGCGGCGTGCCGGACGTGACAAACGGAA 
   241 GCCGCACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAGGGAGCAATGGCAGCGCGC 
                                                        M  A  A  R 
   301 CGACCGCGATGGGCTGTGGCCAATAGCGGCTGCTCAGCAGGGCGCGCCGAGAGCAGCGGC 
        R  P  R  W  A  V  A  N  S  G  C  S  A  G  R  A  E  S  S  G 
   361 CGGGAAGGGGCGGTGCGGGAGGCGGGGTGTGGGGCGGTAGTGTGGGCCCTGTTCCTGCCC 
        R  E  G  A  V  R  E  A  G  C  G  A  V  V  W  A  L  F  L  P 
   421 GCGCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCGGCAGTCGGCTCCCTCGTT 
        A  R  C  S  A  F  C  K  P  P  E  R  T  S  A  V  G  S  L  V 
   481 GACCGAATCACCGACCTCTCTCCCCAGGGGGATCCACCGGAGCTTACCATGACCGAGTAC 
        D  R  I  T  D  L  S  P  Q  G  D  P  P  E  L  T  M  T  E  Y 
   541 AAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCC 
        K  P  T  V  R  L  A  T  R  D  D  V  P  R  A  V  R  T  L  A 
   601 GCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCACATCGAG 
        A  A  F  A  D  Y  P  A  T  R  H  T  V  D  P  D  R  H  I  E 
   661 CGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTG 
        R  V  T  E  L  Q  E  L  F  L  T  R  V  G  L  D  I  G  K  V 
   721 TGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCG 
        W  V  A  D  D  G  A  A  V  A  V  W  T  T  P  E  S  V  E  A 
   781 GGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCC 
        G  A  V  F  A  E  I  G  P  R  M  A  E  L  S  G  S  R  L  A 
   841 GCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTC 
        A  Q  Q  Q  M  E  G  L  L  A  P  H  R  P  K  E  P  A  W  F 
   901 CTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTG 
        L  A  T  V  G  V  S  P  D  H  Q  G  K  G  L  G  S  A  V  V 
   961 CTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCG 
        L  P  G  V  E  A  A  E  R  A  G  V  P  A  F  L  E  T  S  A 
  1021 CCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTG 
        P  R  N  L  P  F  Y  E  R  L  G  F  T  V  T  A  D  V  E  V 
  1081 CCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCAC 
        P  E  G  P  R  T  W  C  M  T  R  K  P  G  A  * 
  1141 GACCCGCAGCGCCCGACCGAAAGGAGCGCACGACCCCATGCATCGGTACCTTTAAGACCA 
  1201 ATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAA 
  1261 GGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGG 
  1321 TTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 
  1381 CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT 
  1441 AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGTAGTTCA 
  1501 TGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATATCAGAGAGTGAGAGG 
  1561 AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACA 
  1621 AATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT 
  1681 TATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGC 
  1741 CCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCG 
  1801 AGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAG 
  1861 GGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTT 
  1921 ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCC 
  1981 CCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTT 
  2041 GCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT 
  2101 GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC 
  2161 TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG 
  2221 GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTA 
  2281 GGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTT 
  2341 GGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTAT 
  2401 CTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAA 
  2461 TGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTA 
  2521 GGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACAT 
  2581 TCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAA 
  2641 AGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTT 
  2701 TGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAG 
  2761 TTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGT 
  2821 TTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCG 
  2881 GTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAG 
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  2941 AATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTA 
  3001 AGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTG 
  3061 ACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTA 
  3121 ACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC 
  3181 ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTT 
  3241 ACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCA 
  3301 CTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAG 
  3361 CGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTA 
  3421 GTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAG 
  3481 ATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTT 
  3541 TAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGAT 
  3601 AATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTA 
  3661 GAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAA 
  3721 ACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTT 
  3781 TTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG 
  3841 CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTA 
  3901 ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCA 
  3961 AGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAG 
  4021 CCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAA 
  4081 AGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGA 
  4141 ACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC 
  4201 GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGC 
  4261 CTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTT 
  4321 GCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT 
  4381 GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAG 
  4441 GAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAA 
  4501 TGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAAT 
  4561 GTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATG 
  4621 TTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTAC 
  4681 GCCAAGCGCGCAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCTGCAAGCTTAATGT 
  4741 AGTCTTATGCAATACTCTTGTAGTCTTGCAACATGGTAACGATGAGTTAGCAACATGCCT 
  4801 TACAAGGAGAGAAAAAGCACCGTGCATGCCGATTGGTGGAAGTAAGGTGGTACGATCGTG 
  4861 CCTTATTAGGAAGGCAACAGACGGGTCTGACATGGATTGGACGAACCACTGAATTGCCGC 
  4921 ATTGCAGAGATATTGTATTTAAGTGCCTAGCTCGATACATAAACGGGTCTCTCTGGTTAG 
  4981 ACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAAT 
  5041 AAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACT 
  5101 AGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAG 
  5161 GGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGA 
  5221 AGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAG 
  5281 CGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAG 
  5341 ATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACA 
  5401 TATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAAC 
  5461 ATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGA 
  5521 AGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGA 
  5581 GATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAC 
  5641 CACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATT 
  5701 GGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA 
  5761 CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGT 
  5821 TCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGG 
  5881 TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA 
  5941 TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA 
  6001 GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCT 
  6061 CTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTC 
  6121 TGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA 
  6181 CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG 
  6241 AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC 
  6301 TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTT 
  6361 TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGA 
  6421 CCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAG 
  6481 AGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGATCACGAG 
  6541 ACTAGCCTCGAGCGGCCGCCCCCTTCACCGAGGGCCTATTTCCCATGATTCCTTCATATT 
  6601 TGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAA 
  6661 AGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTT 
  6721 TAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATT 
  6781 TCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGCCTGATCCTAACTGTGTGGA 
  6841 TCTCGAGATCCACACAGTTAGGATCAGGTTTTTGATCTGTCAGCATCTGGGTCATTCATA 
  6901 ATAATAATATCTGCATCATGTTTAATACCATATTCAAGCGGTATTTTTCATGCAGGATCA 
417 
 
  6961 AATTCTGGATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGT 
  7021 AGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCA 








U6: U6 promoter; insert: shRNA-encoding insert sequence; cppt: 
central polypurine tract; hPGK: human phosphoglycerate kinase 
eukaryotic promoter; Puro: puromycin resistance gene for 
mammalian selection; 3’ LTR: 3’ self inactivating long 
terminal repeat; f1 ori: E.coli f1 origin of replication; AmpR 
Prom: bacterial constitutive promoter for the ampicillin 
resistance gene; AmpR: ampicillin resistance gene for 
bacterial selection; pUC ori: pUC-based E.coli origin of 
419 
 
replication; 5’ LTR: L’ long terminal repeat; ψ: ψ sequence - 




     1 TTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCGCAGGGACGCGGCTGCTCTGGG 
    61 CGTGGTTCCGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGCACATTCTTCACGTCCGTT 
   121 CGCAGCGTCACCCGGATCTTCGCCGCTACCCTTGTGGGCCCCCCGGCGACGCTTCCTGCT 
   181 CCGCCCCTAAGTCGGGAAGGTTCCTTGCGGTTCGCGGCGTGCCGGACGTGACAAACGGAA 
   241 GCCGCACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAGGGAGCAATGGCAGCGCGC 
                                                        M  A  A  R 
   301 CGACCGCGATGGGCTGTGGCCAATAGCGGCTGCTCAGCAGGGCGCGCCGAGAGCAGCGGC 
        R  P  R  W  A  V  A  N  S  G  C  S  A  G  R  A  E  S  S  G 
   361 CGGGAAGGGGCGGTGCGGGAGGCGGGGTGTGGGGCGGTAGTGTGGGCCCTGTTCCTGCCC 
        R  E  G  A  V  R  E  A  G  C  G  A  V  V  W  A  L  F  L  P 
   421 GCGCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCGGCAGTCGGCTCCCTCGTT 
        A  R  C  S  A  F  C  K  P  P  E  R  T  S  A  V  G  S  L  V 
   481 GACCGAATCACCGACCTCTCTCCCCAGGGGGATCCACCGGAGCTTACCATGACCGAGTAC 
        D  R  I  T  D  L  S  P  Q  G  D  P  P  E  L  T  M  T  E  Y 
   541 AAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCC 
        K  P  T  V  R  L  A  T  R  D  D  V  P  R  A  V  R  T  L  A 
   601 GCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCACATCGAG 
        A  A  F  A  D  Y  P  A  T  R  H  T  V  D  P  D  R  H  I  E 
   661 CGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTG 
        R  V  T  E  L  Q  E  L  F  L  T  R  V  G  L  D  I  G  K  V 
   721 TGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCG 
        W  V  A  D  D  G  A  A  V  A  V  W  T  T  P  E  S  V  E  A 
   781 GGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCC 
        G  A  V  F  A  E  I  G  P  R  M  A  E  L  S  G  S  R  L  A 
   841 GCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTC 
        A  Q  Q  Q  M  E  G  L  L  A  P  H  R  P  K  E  P  A  W  F 
   901 CTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTG 
        L  A  T  V  G  V  S  P  D  H  Q  G  K  G  L  G  S  A  V  V 
   961 CTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCG 
        L  P  G  V  E  A  A  E  R  A  G  V  P  A  F  L  E  T  S  A 
  1021 CCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTG 
        P  R  N  L  P  F  Y  E  R  L  G  F  T  V  T  A  D  V  E  V 
  1081 CCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCAC 
        P  E  G  P  R  T  W  C  M  T  R  K  P  G  A  * 
  1141 GACCCGCAGCGCCCGACCGAAAGGAGCGCACGACCCCATGCATCGGTACCTTTAAGACCA 
  1201 ATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAA 
  1261 GGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGG 
  1321 TTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 
  1381 CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT 
  1441 AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGTAGTTCA 
  1501 TGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATATCAGAGAGTGAGAGG 
  1561 AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACA 
  1621 AATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT 
  1681 TATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGC 
  1741 CCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCG 
  1801 AGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAG 
  1861 GGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTT 
  1921 ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCC 
  1981 CCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTT 
  2041 GCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT 
  2101 GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC 
  2161 TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG 
  2221 GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTA 
  2281 GGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTT 
  2341 GGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTAT 
  2401 CTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAA 
  2461 TGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTA 
  2521 GGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACAT 
  2581 TCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAA 
  2641 AGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTT 
  2701 TGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAG 
  2761 TTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGT 
  2821 TTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCG 
  2881 GTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAG 
421 
 
  2941 AATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTA 
  3001 AGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTG 
  3061 ACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTA 
  3121 ACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC 
  3181 ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTT 
  3241 ACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCA 
  3301 CTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAG 
  3361 CGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTA 
  3421 GTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAG 
  3481 ATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTT 
  3541 TAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGAT 
  3601 AATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTA 
  3661 GAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAA 
  3721 ACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTT 
  3781 TTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG 
  3841 CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTA 
  3901 ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCA 
  3961 AGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAG 
  4021 CCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAA 
  4081 AGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGA 
  4141 ACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC 
  4201 GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGC 
  4261 CTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTT 
  4321 GCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT 
  4381 GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAG 
  4441 GAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAA 
  4501 TGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAAT 
  4561 GTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATG 
  4621 TTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTAC 
  4681 GCCAAGCGCGCAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCTGCAAGCTTAATGT 
  4741 AGTCTTATGCAATACTCTTGTAGTCTTGCAACATGGTAACGATGAGTTAGCAACATGCCT 
  4801 TACAAGGAGAGAAAAAGCACCGTGCATGCCGATTGGTGGAAGTAAGGTGGTACGATCGTG 
  4861 CCTTATTAGGAAGGCAACAGACGGGTCTGACATGGATTGGACGAACCACTGAATTGCCGC 
  4921 ATTGCAGAGATATTGTATTTAAGTGCCTAGCTCGATACATAAACGGGTCTCTCTGGTTAG 
  4981 ACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAAT 
  5041 AAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACT 
  5101 AGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAG 
  5161 GGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGA 
  5221 AGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAG 
  5281 CGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAG 
  5341 ATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACA 
  5401 TATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAAC 
  5461 ATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGA 
  5521 AGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGA 
  5581 GATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAC 
  5641 CACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATT 
  5701 GGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA 
  5761 CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGT 
  5821 TCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGG 
  5881 TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA 
  5941 TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA 
  6001 GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCT 
  6061 CTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTC 
  6121 TGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA 
  6181 CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG 
  6241 AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC 
  6301 TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTT 
  6361 TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGA 
  6421 CCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAG 
  6481 AGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGATCACGAG 
  6541 ACTAGCCTCGAGCGGCCGCCCCCTTCACCGAGGGCCTATTTCCCATGATTCCTTCATATT 
  6601 TGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAA 
  6661 AGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTT 
  6721 TAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATT 
  6781 TCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGGCAGGCATTACTAATCTGAA 
  6841 ACTCGAGTTTCAGATTAGTAATGCCTGCTTTTTGATCTGTCAGCATCTGGGTCATTCATA 
  6901 ATAATAATATCTGCATCATGTTTAATACCATATTCAAGCGGTATTTTTCATGCAGGATCA 
422 
 
  6961 AATTCTGGATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGT 
  7021 AGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCA 







U6: U6 promoter; insert: shRNA-encoding insert sequence; cppt: 
central polypurine tract; hPGK: human phosphoglycerate kinase 
eukaryotic promoter; Puro: puromycin resistance gene for 
mammalian selection; 3’ LTR: 3’ self inactivating long 
terminal repeat; f1 ori: E.coli f1 origin of replication; AmpR 
Prom: bacterial constitutive promoter for the ampicillin 
resistance gene; AmpR: ampicillin resistance gene for 
bacterial selection; pUC ori: pUC-based E.coli origin of 
replication; 5’ LTR: L’ long terminal repeat; ψ: ψ sequence - 






     1 TTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCGCAGGGACGCGGCTGCTCTGGG 
    61 CGTGGTTCCGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGCACATTCTTCACGTCCGTT 
   121 CGCAGCGTCACCCGGATCTTCGCCGCTACCCTTGTGGGCCCCCCGGCGACGCTTCCTGCT 
   181 CCGCCCCTAAGTCGGGAAGGTTCCTTGCGGTTCGCGGCGTGCCGGACGTGACAAACGGAA 
   241 GCCGCACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAGGGAGCAATGGCAGCGCGC 
                                                        M  A  A  R 
   301 CGACCGCGATGGGCTGTGGCCAATAGCGGCTGCTCAGCAGGGCGCGCCGAGAGCAGCGGC 
        R  P  R  W  A  V  A  N  S  G  C  S  A  G  R  A  E  S  S  G 
   361 CGGGAAGGGGCGGTGCGGGAGGCGGGGTGTGGGGCGGTAGTGTGGGCCCTGTTCCTGCCC 
        R  E  G  A  V  R  E  A  G  C  G  A  V  V  W  A  L  F  L  P 
   421 GCGCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCGGCAGTCGGCTCCCTCGTT 
        A  R  C  S  A  F  C  K  P  P  E  R  T  S  A  V  G  S  L  V 
   481 GACCGAATCACCGACCTCTCTCCCCAGGGGGATCCACCGGAGCTTACCATGACCGAGTAC 
        D  R  I  T  D  L  S  P  Q  G  D  P  P  E  L  T  M  T  E  Y 
   541 AAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCC 
        K  P  T  V  R  L  A  T  R  D  D  V  P  R  A  V  R  T  L  A 
   601 GCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCACATCGAG 
        A  A  F  A  D  Y  P  A  T  R  H  T  V  D  P  D  R  H  I  E 
   661 CGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTG 
        R  V  T  E  L  Q  E  L  F  L  T  R  V  G  L  D  I  G  K  V 
   721 TGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCG 
        W  V  A  D  D  G  A  A  V  A  V  W  T  T  P  E  S  V  E  A 
   781 GGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCC 
        G  A  V  F  A  E  I  G  P  R  M  A  E  L  S  G  S  R  L  A 
   841 GCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTC 
        A  Q  Q  Q  M  E  G  L  L  A  P  H  R  P  K  E  P  A  W  F 
   901 CTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTG 
        L  A  T  V  G  V  S  P  D  H  Q  G  K  G  L  G  S  A  V  V 
   961 CTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCG 
        L  P  G  V  E  A  A  E  R  A  G  V  P  A  F  L  E  T  S  A 
  1021 CCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTG 
        P  R  N  L  P  F  Y  E  R  L  G  F  T  V  T  A  D  V  E  V 
  1081 CCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCAC 
        P  E  G  P  R  T  W  C  M  T  R  K  P  G  A  * 
  1141 GACCCGCAGCGCCCGACCGAAAGGAGCGCACGACCCCATGCATCGGTACCTTTAAGACCA 
  1201 ATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAA 
  1261 GGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGG 
  1321 TTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 
  1381 CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT 
  1441 AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGTAGTTCA 
  1501 TGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATATCAGAGAGTGAGAGG 
  1561 AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACA 
  1621 AATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT 
  1681 TATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGC 
  1741 CCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCG 
  1801 AGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAG 
  1861 GGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTT 
  1921 ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCC 
  1981 CCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTT 
  2041 GCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT 
  2101 GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC 
  2161 TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG 
  2221 GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTA 
  2281 GGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTT 
  2341 GGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTAT 
  2401 CTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAA 
  2461 TGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTA 
  2521 GGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACAT 
  2581 TCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAA 
  2641 AGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTT 
  2701 TGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAG 
  2761 TTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGT 
  2821 TTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCG 
  2881 GTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAG 
426 
 
  2941 AATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTA 
  3001 AGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTG 
  3061 ACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTA 
  3121 ACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC 
  3181 ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTT 
  3241 ACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCA 
  3301 CTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAG 
  3361 CGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTA 
  3421 GTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAG 
  3481 ATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTT 
  3541 TAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGAT 
  3601 AATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTA 
  3661 GAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAA 
  3721 ACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTT 
  3781 TTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG 
  3841 CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTA 
  3901 ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCA 
  3961 AGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAG 
  4021 CCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAA 
  4081 AGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGA 
  4141 ACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC 
  4201 GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGC 
  4261 CTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTT 
  4321 GCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT 
  4381 GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAG 
  4441 GAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAA 
  4501 TGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAAT 
  4561 GTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATG 
  4621 TTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTAC 
  4681 GCCAAGCGCGCAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCTGCAAGCTTAATGT 
  4741 AGTCTTATGCAATACTCTTGTAGTCTTGCAACATGGTAACGATGAGTTAGCAACATGCCT 
  4801 TACAAGGAGAGAAAAAGCACCGTGCATGCCGATTGGTGGAAGTAAGGTGGTACGATCGTG 
  4861 CCTTATTAGGAAGGCAACAGACGGGTCTGACATGGATTGGACGAACCACTGAATTGCCGC 
  4921 ATTGCAGAGATATTGTATTTAAGTGCCTAGCTCGATACATAAACGGGTCTCTCTGGTTAG 
  4981 ACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAAT 
  5041 AAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACT 
  5101 AGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAG 
  5161 GGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGA 
  5221 AGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAG 
  5281 CGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAG 
  5341 ATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACA 
  5401 TATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAAC 
  5461 ATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGA 
  5521 AGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGA 
  5581 GATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAC 
  5641 CACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATT 
  5701 GGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA 
  5761 CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGT 
  5821 TCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGG 
  5881 TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA 
  5941 TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA 
  6001 GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCT 
  6061 CTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTC 
  6121 TGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA 
  6181 CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG 
  6241 AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC 
  6301 TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTT 
  6361 TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGA 
  6421 CCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAG 
  6481 AGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGATCACGAG 
  6541 ACTAGCCTCGAGCGGCCGCCCCCTTCACCGAGGGCCTATTTCCCATGATTCCTTCATATT 
  6601 TGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAA 
  6661 AGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTT 
  6721 TAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATT 
  6781 TCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGGCCATCCAGAACTTGAGGAA 
  6841 ACTCGAGTTTCCTCAAGTTCTGGATGGCTTTTTGATCTGTCAGCATCTGGGTCATTCATA 
  6901 ATAATAATATCTGCATCATGTTTAATACCATATTCAAGCGGTATTTTTCATGCAGGATCA 
427 
 
  6961 AATTCTGGATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGT 
  7021 AGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCA 









U6: U6 promoter; insert: shRNA-encoding insert sequence; cppt: 
central polypurine tract; hPGK: human phosphoglycerate kinase 
eukaryotic promoter; Puro: puromycin resistance gene for 
mammalian selection; 3’ LTR: 3’ self inactivating long 
terminal repeat; f1 ori: E.coli f1 origin of replication; AmpR 
Prom: bacterial constitutive promoter for the ampicillin 
resistance gene; AmpR: ampicillin resistance gene for 
bacterial selection; pUC ori: pUC-based E.coli origin of 
429 
 
replication; 5’ LTR: L’ long terminal repeat; ψ: ψ sequence - 




     1 TTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCGCAGGGACGCGGCTGCTCTGGG 
    61 CGTGGTTCCGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGCACATTCTTCACGTCCGTT 
   121 CGCAGCGTCACCCGGATCTTCGCCGCTACCCTTGTGGGCCCCCCGGCGACGCTTCCTGCT 
   181 CCGCCCCTAAGTCGGGAAGGTTCCTTGCGGTTCGCGGCGTGCCGGACGTGACAAACGGAA 
   241 GCCGCACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAGGGAGCAATGGCAGCGCGC 
                                                        M  A  A  R 
   301 CGACCGCGATGGGCTGTGGCCAATAGCGGCTGCTCAGCAGGGCGCGCCGAGAGCAGCGGC 
        R  P  R  W  A  V  A  N  S  G  C  S  A  G  R  A  E  S  S  G 
   361 CGGGAAGGGGCGGTGCGGGAGGCGGGGTGTGGGGCGGTAGTGTGGGCCCTGTTCCTGCCC 
        R  E  G  A  V  R  E  A  G  C  G  A  V  V  W  A  L  F  L  P 
   421 GCGCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCGGCAGTCGGCTCCCTCGTT 
        A  R  C  S  A  F  C  K  P  P  E  R  T  S  A  V  G  S  L  V 
   481 GACCGAATCACCGACCTCTCTCCCCAGGGGGATCCACCGGAGCTTACCATGACCGAGTAC 
        D  R  I  T  D  L  S  P  Q  G  D  P  P  E  L  T  M  T  E  Y 
   541 AAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCC 
        K  P  T  V  R  L  A  T  R  D  D  V  P  R  A  V  R  T  L  A 
   601 GCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCACATCGAG 
        A  A  F  A  D  Y  P  A  T  R  H  T  V  D  P  D  R  H  I  E 
   661 CGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTG 
        R  V  T  E  L  Q  E  L  F  L  T  R  V  G  L  D  I  G  K  V 
   721 TGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCG 
        W  V  A  D  D  G  A  A  V  A  V  W  T  T  P  E  S  V  E  A 
   781 GGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCC 
        G  A  V  F  A  E  I  G  P  R  M  A  E  L  S  G  S  R  L  A 
   841 GCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTC 
        A  Q  Q  Q  M  E  G  L  L  A  P  H  R  P  K  E  P  A  W  F 
   901 CTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTG 
        L  A  T  V  G  V  S  P  D  H  Q  G  K  G  L  G  S  A  V  V 
   961 CTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCG 
        L  P  G  V  E  A  A  E  R  A  G  V  P  A  F  L  E  T  S  A 
  1021 CCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTG 
        P  R  N  L  P  F  Y  E  R  L  G  F  T  V  T  A  D  V  E  V 
  1081 CCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCAC 
        P  E  G  P  R  T  W  C  M  T  R  K  P  G  A  * 
  1141 GACCCGCAGCGCCCGACCGAAAGGAGCGCACGACCCCATGCATCGGTACCTTTAAGACCA 
  1201 ATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAA 
  1261 GGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGG 
  1321 TTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 
  1381 CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT 
  1441 AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGTAGTTCA 
  1501 TGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATATCAGAGAGTGAGAGG 
  1561 AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACA 
  1621 AATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT 
  1681 TATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGC 
  1741 CCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCG 
  1801 AGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAG 
  1861 GGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTT 
  1921 ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCC 
  1981 CCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTT 
  2041 GCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT 
  2101 GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC 
  2161 TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG 
  2221 GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTA 
  2281 GGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTT 
  2341 GGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTAT 
  2401 CTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAA 
  2461 TGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTA 
  2521 GGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACAT 
  2581 TCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAA 
  2641 AGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTT 
  2701 TGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAG 
  2761 TTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGT 
  2821 TTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCG 
  2881 GTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAG 
431 
 
  2941 AATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTA 
  3001 AGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTG 
  3061 ACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTA 
  3121 ACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC 
  3181 ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTT 
  3241 ACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCA 
  3301 CTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAG 
  3361 CGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTA 
  3421 GTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAG 
  3481 ATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTT 
  3541 TAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGAT 
  3601 AATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTA 
  3661 GAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAA 
  3721 ACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTT 
  3781 TTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG 
  3841 CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTA 
  3901 ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCA 
  3961 AGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAG 
  4021 CCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAA 
  4081 AGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGA 
  4141 ACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC 
  4201 GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGC 
  4261 CTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTT 
  4321 GCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT 
  4381 GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAG 
  4441 GAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAA 
  4501 TGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAAT 
  4561 GTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATG 
  4621 TTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTAC 
  4681 GCCAAGCGCGCAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCTGCAAGCTTAATGT 
  4741 AGTCTTATGCAATACTCTTGTAGTCTTGCAACATGGTAACGATGAGTTAGCAACATGCCT 
  4801 TACAAGGAGAGAAAAAGCACCGTGCATGCCGATTGGTGGAAGTAAGGTGGTACGATCGTG 
  4861 CCTTATTAGGAAGGCAACAGACGGGTCTGACATGGATTGGACGAACCACTGAATTGCCGC 
  4921 ATTGCAGAGATATTGTATTTAAGTGCCTAGCTCGATACATAAACGGGTCTCTCTGGTTAG 
  4981 ACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAAT 
  5041 AAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACT 
  5101 AGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAG 
  5161 GGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGA 
  5221 AGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAG 
  5281 CGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAG 
  5341 ATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACA 
  5401 TATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAAC 
  5461 ATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGA 
  5521 AGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGA 
  5581 GATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAC 
  5641 CACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATT 
  5701 GGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA 
  5761 CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGT 
  5821 TCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGG 
  5881 TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA 
  5941 TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA 
  6001 GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCT 
  6061 CTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTC 
  6121 TGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA 
  6181 CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG 
  6241 AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC 
  6301 TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTT 
  6361 TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGA 
  6421 CCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAG 
  6481 AGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGATCACGAG 
  6541 ACTAGCCTCGAGCGGCCGCCCCCTTCACCGAGGGCCTATTTCCCATGATTCCTTCATATT 
  6601 TGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAA 
  6661 AGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTT 
  6721 TAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATT 
  6781 TCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGCCCTACAAACTGCGACCTGT 
  6841 ACTCGAGTACAGGTCGCAGTTTGTAGGGTTTTTGATCTGTCAGCATCTGGGTCATTCATA 
  6901 ATAATAATATCTGCATCATGTTTAATACCATATTCAAGCGGTATTTTTCATGCAGGATCA 
432 
 
  6961 AATTCTGGATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGT 
  7021 AGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCA 
  7081 AAATTTTCGGGTTTATTACAGGGACAGCAGAGATCCACTTTGGCCGCGGCTCGAGGGGG 
 
433 
 
 
 
